+

WO2014165075A1 - Antibacterial agents - Google Patents

Antibacterial agents Download PDF

Info

Publication number
WO2014165075A1
WO2014165075A1 PCT/US2014/024304 US2014024304W WO2014165075A1 WO 2014165075 A1 WO2014165075 A1 WO 2014165075A1 US 2014024304 W US2014024304 W US 2014024304W WO 2014165075 A1 WO2014165075 A1 WO 2014165075A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxobutan
benzamide
hydroxyamino
diyn
hydroxy
Prior art date
Application number
PCT/US2014/024304
Other languages
French (fr)
Inventor
Martin Sheringham Linsell
James Bradley Aggen
Paola Dozzo
Darin James Hildebrandt
Frederick Cohen
Ramesh Annasaheb KASAR
Timothy Robert Kane
Micah James Gliedt
Glenn A. Mcenroe
Original Assignee
Achaogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achaogen, Inc. filed Critical Achaogen, Inc.
Publication of WO2014165075A1 publication Critical patent/WO2014165075A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention pertains generally to treating infections caused by gram-negative bacteria. More specifically, the invention described herein pertains to treating gram-negative infections by inhibiting activity of UDP-3-0-(R-3-hydroxydecanoyi)- -acetylgiucosamine deacetylase (LpxC).
  • the present invention provides small molecule inhibitors of LpxC, pharmaceutical formulations containing such inhibitors, methods of treating patients with such pharmaceutical formulations, and methods of preparing such pharmaceutical formulations and inhibitors.
  • the invention described herein pertains to treating gram-negative infections by administering compounds capable of inhibiting activity of UDP-3-G-(j -3-hydroxydecanoyl)-/V- acetyiglucosamine deacetylase (LpxC), either alone or in combination with administering a second antibacterial compound.
  • UDP-3-G-(j -3-hydroxydecanoyl)-/V- acetyiglucosamine deacetylase (LpxC) either alone or in combination with administering a second antibacterial compound.
  • LpxC broad-spectrum antibacterial small molecules that comprise a new class of active bactericidal chemical entities that should encounter little, if any, naturally- occurring, target-related resistance.
  • LpxC the enzyme uridyldiphospho-3-0-(R- hydroxydecanoyl)-N-acetylglucosamine deacetylase
  • LpxC is present across all Gram-negative bacterial species of interest and is involved in the first committed step in outer membrane biosynthesis.
  • an object of this invention to provide compounds and combinations of such compounds for use in the preparation of nontoxic antibacteriais and other pharmaceuticals capable of inhibiting gram-negative bacterial infections.
  • the present invention provides novel compounds, pharmaceutical formulations including the compounds, methods of inhibiting UDP-3-0-( ?-3-hydroxydecanoyl)-/V- acetylglucosamine deacetylase (LpxC), and methods of treating gram-negative bacterial infections.
  • A is azetidinyl or pyrrolidiny!, wherein said azetidinyl or pyrrolidinyi is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted Ci-C 3 alkyl, halogen, cyano, -C ⁇ 0)R 4 , oxo, hydroxyl, -8(G) 2 R 4 , substituted or unsubstituted C 3 -C 6 heterocyclyl and substituted or unsubstituted C 4 -C 7 heterocyclylalkyl;
  • a and B together form a fused 5-9 membered bicyclic ring system, wherein A is azetidinyl or pyrrolidinyi and B is a C 3 -C 6 cyc!oa!kyi and wherein each of A and B is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted C C 3 alkyl, ha!ogen, cyano, -C(0)R 4 , oxo, hydroxy!, -S(0) 2 R4, substituted or unsubstituted C 3 -C 6 heterocyciyi and substituted or unsubstituted C4-C7 heterocyclylaiky!;
  • Q is O or NR, wherein R is hydrogen or an unsubstituted C r C 3 aikyl;
  • R, and R 2 independently are selected from the group consisting of hydrogen, substituted or unsubstituted C C 3 alkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted 4-8 membered heterocyciyi, and substituted or unsubstituted heteroaryl, or R-, and R 2 , together with the carbon atom to which they are attached, form an unsubstituted C 3 -C 6 cycloalkyl group or an unsubstituted 4-6 membered heterocyclic group:
  • R 3 is selected from the group consisting of hydrogen, substituted or unsubstituted C C 6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cyc!oaiky!alkyl, substituted or unsubstituted heterocyciyi, substituted or unsubstituted heterocyclylalky!, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyi;
  • each R 4 is independently hydrogen, substituted or unsubstituted C C 3 alkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl or NR 5 R 6 ;
  • each R 5 and R 6 is independently hydrogen or C 1 -C3 alkyl.
  • the present invention provides a pharmaceutical composition comprising a compound of Formula I, or or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, and a pharmaceutically acceptable carrier or diluent.
  • the present invention provides a pharmaceutical composition or formulation comprising an effective amount of an antibacterial compound of Formula I, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, and a pharmaceutically acceptable carrier or diluent.
  • the present invention provides a method of inhibiting a deacetylase enzyme in gram-negative bacteria, thereby affecting bacterial growth, comprising administering to a patient in need of such inhibition an LpxC-inhibitory compound of Formula I or a stereoisomer, pharmaceutically acceptable salt, or ester thereof.
  • the present invention provides a method of inhibiting LpxC, thereby modulating the virulence of a bacterial infection, comprising administering to a patient in need of such inhibition an LpxC-inhibitory compound of Formula 1 or a stereoisomer, pharmaceutically acceptable salt, or ester thereof.
  • the present invention provides a method for treating a patient having a bacterial infection comprising administering to the patient in need thereof an antibacterialiy effective amount of a compound of Formula I, or a stereoisomer,
  • the bacterial infection is a gram-negative bacterial infection
  • the patient is a mammal and in certain embodiments, a human.
  • the present invention provides a method of administering an antibacterialiy effective amount of a compound of Formula I or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, to a patient infected with a fermentative or non-fermentative gram-negative bacteria.
  • a fermentative or non-fermentative gram-negative bacteria examples include Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkhoideria cepacia, Aicaiigenes xyiosoxidans,
  • the present invention provides a method of administering an antibacterialiy effective amount of a compound of Formula I, or a stereoisomer,
  • bacteria examples include Enterobacteriaceae, such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis), Morganeila, Cedecea, Edwardsielia species and Escherichia coii.
  • Enterobacteriaceae such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis), Morganeila, Cedecea, Edwardsielia species and Escherichia coii.
  • the present invention provides novel compounds, methods for inhibiting LpxC in gram-negative bacteria, and novel methods for treating bacterial infections.
  • the compounds provided herein can be formulated into pharmaceutical formulations and medicaments that are useful in the methods of the invention.
  • the invention also provides for the use of the
  • the invention further provides compositions and methods for treating gram-negative infections by administering compounds capable of inhibiting activity of UDP ⁇ 3 ⁇ G-(R ⁇ 3 ⁇ hydroxydecanoyl)-/V-acetyiglucosamine deacetyiase (LpxC), either alone or in combination with administering a second antibacterial compound.
  • LpxC is an abbreviation that stands for UDP-3-0-(R-3-hydroxydecanoyl)-W- acetylgiucosamine deacetyiase.
  • Alkyi refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH 3 -), ethyl (CH 3 CH 2 -), n-propyl
  • Alkoxy refers to the group -O-a!ky!, wherein alky! is as defined herein. Alkoxy includes methoxy, etboxy, n-propoxy, isopropoxy, ⁇ -butoxy, i-butoxy, sec-butoxy, n-pentoxy, and the like.
  • Amino refers to the group -NH 2 .
  • Alkynyi refers to straight or branched monovalent hydrocarby! groups having from 2 to 6 carbon atoms and preferably 2 to 3 carbon atoms and having at least 1 and preferably from 1 to 2 sites of acetylenic ⁇ C ⁇ C- unsaturation. Examples of such a!kynyl groups include acetylenyl (-C ⁇ CH), and propargyl ( ⁇ CH 2 C ⁇ CH).
  • Carboxyl or “carboxy” refers to -CQOH or salts thereof.
  • Clarko or "nitri!e” refers to the group -CN.
  • Cyclonoalkyl refers to a monocyclic or po!ycyclic alky! group consisting , which may include fused or bridged ring systems, having from 3 to 13 carbon atoms.
  • Examples of cycloa!kyl groups include cyclopropy!, cyciobutyl, cyclopentyl, cyclooctyl, and the like.
  • Halo or “halogen” refers to fiuoro, chioro, bromo, and iodo and is typically fiuoro or chioro.
  • Heterocycle refers to a saturated or unsaturated monocyclic or polycyc!ic group, which may include fused or bridged ring systems, having from 3 to 15 ring atoms, including 1 to 4 hetero atoms. These ring atoms are selected from the group consisting of nitrogen, sulfur, or oxygen. In one implementation, the nitrogen and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, -S(O)-, or -S0 2 - moieties.
  • Niro refers to the group -NQ 2 .
  • Sulfony refers to the group -S0 2 -alkyi, -S0 2 -substituted alkyl, ⁇ S0 2 -alkenyl, -S0 2 -substituted alkenyl, wherein alkyl, substituted alkyl, aikenyi, substituted aikenyi, alkynyl, and substituted alkynyl are as defined herein.
  • Sulfonyl includes groups such as methyi-S0 2 -.
  • Thioacyl refers to the groups H-C(S)-, alkyl-C(S)-, substituted a!ky!-C(S)-, a!keny!-C(S)-, substituted aikenyi-C(S)-, a!kyny!-C(S)-, and substituted alkynyl-C(S)-, wherein alkyl, substituted alkyl, aikenyi, substituted alkenyl, alkynyl, and substituted alkynyl are as defined herein.
  • Alkylthio refers to the group -S-a!ky!, wherein alkyl is as defined herein.
  • sulfur may be oxidized to -S(O)-.
  • the sulfoxide may exist as one or more stereoisomers.
  • reference to a certain element such as hydrogen or H is meant to include all isotopes of that element.
  • a substituent group is defined to include hydrogen or H, if also includes deuterium and tritium.
  • the subject invention also includes isotopicaliy-labeied compounds of the present invention, that are structurally identical to those disclosed herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 8 0, 17 0, 3 ' P, 3 P, 35 S, 8 F and j6 Ci, respectively.
  • Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds and of said prodrugs that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
  • isotopicaliy labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H and '4 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • isotopicaliy labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out known or referenced procedures and by substituting a readily available isotopicaliy labeled reagent for a non-isotopicaily labeled reagent.
  • Stereoisomers refer to compounds that have same atomic connectivity but different atomic arrangement in space. Stereoisomers include cis-trans isomers, E and Z isomers, enantiomers, and diastereomers.
  • a person of ordinary skill in the art would recognize that other tautomeric ring atom arrangements are possible.
  • “Patient” refers to human and non-human animals, especially mammals.
  • “Pharmaceutically acceptable salt” refers to pharmaceutically acceptable salts of a compound, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraa!kyiammonium, and the like: and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, phosphate, sulfate and the like.
  • Pharmaceutically effective amount and “therapeuticaliy effective amount” refer to an amount of a compound sufficient to treat a specified disorder or disease or one or more of its symptoms and/or to prevent the occurrence of the disease or disorder.
  • antibacterial agent refers to agents that have either bactericidal or bacteriostatic activity.
  • inhibiting the growth indicates that the rate of increase in the numbers of a population of a particular bacterium is reduced.
  • the term includes situations in which the bacterial population increases but at a reduced rate, as well as situations where the growth of the population is stopped, as well as situations where the numbers of the bacteria in the population are reduced or the population even eliminated, if an enzyme activity assay is used to screen for inhibitors, one can make modifications in uptake/efflux, solubility, half-life, etc. to compounds in order to correlate enzyme inhibition with growth inhibition.
  • the activity of antibacterial agents is not necessarily limited to bacteria but may also encompass activity against parasites, virus, and fungi.
  • A is azetidinyi or pyrroiidinyi, wherein said azetidinyi or pyrroiidinyl is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted Ci-C 3 alkyl, halogen, cyano, -C(0)R 4 , oxo, hydroxyl, -S(0) 2 R4, substituted or unsubstituted C 3 -C 6 heterocyclyl and substituted or unsubstituted C 4 -C 7 heterocyclylalkyl;
  • B is absent, a CrC 2 aiky!ene or C 3 ⁇ C 6 cycloalkyl wherein said Ci-C 2 aikyiene or C 3 -C 6 cycioalkyl is unsubstituted or substituted with 1 or 2 groups seiected from substituted or unsubstituted C C 3 alkyi, halogen, cyano, -C(0)R 4 , oxo, hydroxy!, -S(0) 2 R4, substituted or unsubstituted C 3 -C 6 heterocyclyl and substituted or unsubstituted C4-C7 heterocyciyiaikyl;
  • a and B together form a fused 5-9 membered bicyclic ring system, wherein A is azetidinyi or pyrroiidinyi and B is a C 3 -C 3 cycloalkyl and wherein each of A and B is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted Ci-C 3 alkyi, halogen, cyano, -C(0)R 4 , oxo, hydroxy!, ---S(0) 2 R 4 , substituted or unsubstituted C 3 -C 6 heterocyc!y! and substituted or unsubstituted C4-C7 heterocyciyiaikyl;
  • Q is O or NR, wherein R is hydrogen or an unsubstituted d-C 3 alkyl
  • Ri and R 2 independently are seiected from the group consisting of hydrogen, substituted or unsubstituted Ci-C 3 alkyl, substituted or unsubstituted C 3 -C 6 cycioalkyl, substituted or unsubstituted 4-6 membered heterocyclyl, and substituted or unsubstituted heteroaryl, or R-. and R 2 , together with the carbon atom to which they are attached, form an unsubstituted C 3 -C 6 cycloaikyi group or an unsubstituted 4-8 membered heterocyclic group;
  • R 3 is selected from the group consisting of hydrogen, substituted or unsubstituted Ci-C 6 alkyi, substituted or unsubstituted cycloaikyi, substituted or unsubstituted cycloaikyla!ky!, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyi, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroaryla!ky!;
  • each R 4 is independently hydrogen, substituted or unsubstituted C C 3 alkyi, substituted or unsubstituted C 3 -C 6 cycloaikyi or NR S R 6 ;
  • each R 5 and R 6 is independently hydrogen or C C 3 alkyi.
  • R 3 is hydrogen or a substituted or unsubstituted C,-C 6 aikyl .
  • G is - ⁇ C-C ⁇ C-.
  • Q is NR, wherein R is hydrogen or unsubstituted Ci-C 3 aikyl. In certain embodiments where Q is NR, R is hydrogen. In certain embodiments, Q is O and R 3 is H. in certain embodiments both R 1 and R 2 are methyl.
  • B is absent, in other embdiments B is Ci ⁇ C 2 alky!ene. In still other embodiments B is C 3 -C 6 cycloaikyi.
  • A is unsubstituted azetidinyl. In other embodiments A is azetidinyl substituted with 1 or 2 groups selected from substituted or unsubstituted C C 3 aikyi, -C(0)R 4 , C 3 -C 6 heterocyclyl, hydroxy! and -S(0) 2 R 4 . In some embodiments A is azetidinyl substituted with substituted or unsubstituted Ci ⁇ C 3 aikyl. In other embodiments A is azetidinyl substituted with -C(0)R 4 . In certain embodiments where A is azetidinyl substituted with
  • R is hydrogen, in other embodiments where A is azetidinyl substituted with -C(0)R 4 , R is methyl. In certain embodiments where A is azetidinyl substituted with -C ⁇ 0)R 4 , R is Ci-C 3 aikyl substituted with hydroxy!, in certain embodiments where A is azetidinyl substituted with -C(0)R 4 , R 4 is Ci-C 3 aikyl substituted with amino. In certain embodiments where A is azetidinyl substituted with ⁇ C(0)R 4l R 4 is C; ⁇ C 3 a!ky! substituted with hydroxy!
  • A is azetidinyi substituted with -C(0)R 4
  • R 4 is C 3 -C 6 cycioa!ky!.
  • A is azetidinyi substituted with -C(0)R 4 and hydroxy!, !n
  • A is azetidinyi substituted with C 3 -C 6 heterocycly!.
  • A is azetidinyi substituted with hydroxyl.
  • A is azetidinyi substituted with -S(0) 2 R .
  • R is methyl
  • R 4 is NR 5 R 6 .
  • A is azetidinyi substituted with -S(0) 2 R 4 , where R 4 is NR 5 R 6 , R 5 and R 6 are both hydrogen.
  • R 4 is NR 5 R 6> R 5 is Ci ⁇ C 3 alky! and R 6 is hydrogen.
  • R 4 is NR 5 R 6 , R 5 is methyl and R 6 is hydrogen.
  • A is unsubstituted pyrrolidinyi.
  • A is pyrrolidinyi substituted with 1 or 2 groups selected from substituted or unsubstituted C,-C 3 alkyl, -C(0)R 4 , C 3 -C 6 heterocyclyl, hydroxyl and ⁇ 8(G) 2 R 4 .
  • A is pyrrolidinyi substituted with substituted or unsubstituted Ci ⁇ C 3 aiky!.
  • A is pyrrolidinyi substituted with substituted or unsubstituted C 3 -C 3 heterocyclyl.
  • A is pyrrolidinyi substituted with oxo.
  • A is pyrrolidinyi substituted with hydroxyl.
  • R 4 is hydrogen or methyl.
  • A is pyrrolidinyi substituted with 1 or 2 groups selected from substituted or unsubstituted C r C 3 alkyl, oxo, C 3 -C 6 heterocyclyl, hydroxy! and -S(0) 2 R 4 .
  • One aspect of the invention provides compounds selected from the group of: (S)-A-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!-4-(azetidin-3-ylbuta-1 ,3- diyny!benzamide (1 ); (S)-4-((1-acetyIazetidin-3-yI)buta-1 ,3-diyn-1-y!)-A/-(3-hydroxy-1 -(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (2a);
  • Another aspect of the invention provides compounds selected from the group of: (S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yi)-4-(azetidin-3-y!buta-1 l 3- diyny!benzamide (1 );
  • the compounds of Formula i are distinguished from previously known substances by a surprisingly low degree of binding to plasma proteins and can therefore provide a relatively high concentration of free, i.e. pharmacologically effective and available drug concentration, in order to achieve an antibacterial effect, the MIC for the target organism must be reached in vivo. Binding of the antibacterial agent to plasma proteins will decrease the available plasma concentration of the agent, making it more difficult to achieve a concentration at or above the MIC.
  • the compounds disclosed herein demonstrate decreased protein binding as compared to previously known substances, and therefore can more easily achieve a therapeutic concentration in the patient.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, and a pharmaceutically acceptable carrier or diluent.
  • the invention provides a method of inhibiting a deacetylase enzyme in a gram-negative bacteria, thereby affecting bacterial growth, comprising
  • the invention provides a method of inhibiting LpxC, thereby modulating the virulence of a bacteria! infection, comprising administering to a patient in need of such inhibition a compound of Formula or a stereoisomer, pharmaceutically acceptable salt, or ester thereof.
  • the IC 50 value of the compound is less than or equal to 10 ⁇ with respect to LpxC.
  • the !C 5 o value is less than or equal to 1 ⁇ , is less than or equal to 0.1 ⁇ , is less than or equal to 0.050 ⁇ , is less than or equal to 0.030 ⁇ , is less than or equal to 0.025 ⁇ , or is less than or equal to 0.010 ⁇ .
  • the invention provides a method for treating a patient having a gram-negative bacterial infection comprising administering to the patient in need thereof an antibacterially effective amount of a compound of Formula I or a stereoisomer, pharmaceutically acceptable salt, or ester thereof.
  • the invention provides a method of administering a
  • fermentative or non-fermentative gram-negative bacteria examples include Pseudomonas aeruginosa, Stenotrophomonas maltophila,
  • Francisce!iaceae e.g., Francisce!la tularensis
  • Neisseria species e.g., Francisce!la tularensis
  • the invention provides a method of administering an inhibitory amount of a compound described herein to gram-negative bacteria, such as Enterobacieriaceae which is selected from the group consisting of organisms such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis), Morganella, Cedecea, Edwardsiella species and Escherichia coli.
  • Enterobacieriaceae which is selected from the group consisting of organisms such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis), Morganella, Cedecea, Edwardsiella species and Escherichia coli.
  • the patient may be a mammal, and in some embodiments, a human.
  • Bacteria! infections susceptible to treatment according to the present invention include primary infections and co-infections caused by a species of bacteria and one or more additional infectious agents such as, for example, bacteria, virus, parasite and fungus.
  • Compounds of the invention can be used for treating conditions caused by the bacterial production of endotoxin and, in particular, by gram-negative bacteria and bacteria that use LpxC in the biosynthesis of !ipopolysaccharide (LPS) or endotoxin.
  • LPS !ipopolysaccharide
  • Compounds of the invention also are useful in treating conditions that are caused or exacerbated by the bacteria! production of lipid A and LPS or endotoxin, such as sepsis, septic shock, systemic inflammation, localized inflammation, chronic obstructive pulmonary disease (COPD) and acute exacerbations of chronic bronchitis (AECB).
  • treatment includes the administration of a compound of the invention, or a combination of compounds of the invention, optionally with a second agent wherein the second agent is a second antibacterial agent or a non-antibacterial agent.
  • non-antibacterial agents include antiendotoxins including endotoxin receptor- binding antibodies, endotoxin-binding antibodies, anti-CD14-binding protein antibodies, antilipopo!ysaccharide-binding protein antibodies and tyrosine kinase inhibitors.
  • compounds of the present invention may also be used with non-antibacterial agents administered via inhalation.
  • non-antibacterial agents used in this treatment include anti-inflammatory steroids, non-steroidal anti-inflammatory agents, bronchiodiiators, mucolytics, anti-asthma therapeutics and lung fluid surfactants, in particular, the non-antibacterial agent may be albuterol, salbuterol, budesonide, bec!omethasone, dexamethasone, nedocromi!,
  • Compounds of the invention can be used alone or in combination with a second antibacterial agent for the treatment of a serious or chronic respiratory tract infection including serious lung and nosocomial infections such as those caused by Enterobacter aerogenes, Enterobacter cloacae, Escherichia co/ , Klebsiella pneumoniae, Klebsiella oxytoca, Proteus rnirabiiis, Serratia marcescens, Stenotrophornonas ma!tophi!ia, Pseudornonas aeruginosa, Burkhoidena cepacia, Alcaligenes xylosoxidans, Fiavobacierium meningosepticum, Providencia siuartii and Citrobacter freundi, community lung infections such as those caused by Enterobacter aerogenes, Enterobacter cloacae, Escherichia co/ , Klebsiella pneumoniae, Klebsiella oxytoca, Proteus
  • Haemophilus Influenzae Legionella species, Moraxeila catarrhalis, Branhamella catarrhal, Enterobacter species, Klebsiella species, and Proteus species, infections caused by other bacterial species such as Neisseria species, Shigella species, Salmonella species, Helicobacter pylori, Vibrionaceae and Bordeteila species, as well as infections caused by a Brucella species, Francisetla tularensis and/or Yersinia Pestis.
  • compounds of the present invention When used for treating patients infected with gram-negative bacterial infections, compounds of the present invention can be used to sensitize gram-negative bacteria to the effects of a second agent.
  • the present invention provides novel combinations of compounds including a compound of Formula I or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, as well as methods for treating patients infected with gram-negative bacteria.
  • novel combinations provided herein can be formulated into pharmaceutical formulations and medicaments that are useful in the methods of the invention.
  • the invention also provides for the use of the novel combinations in preparing medicaments and pharmaceutical formulations, for use of the combinations in treating bacterial infections in a patient.
  • a second antibacterial agent is used in combination with a compound of Formula I, or stereoisomer or pharmaceutically acceptable salt thereof.
  • suitable second antibactierai agents include, but are not limited to, vancomycin, linezolid , azithromycin, imipenem, teicop!anin, daptomycin, clindamycin, rifampin, cefotaxime, gentamicin, novobiocin or telavancin.
  • the antibacterial agent is vancomycin, teicoplanin, rifampin, azithromycin, telavancin or novobiocin.
  • the antibacterial agent is vancomycin or rifampin
  • the antibacterial agent and/or the compound of Formula I, or stereoisomer or pharmaceutically acceptable salt thereof is administered at a sub-therapeutic dose, wherein a subtherapeutic dose is a dose that would be insufficient to treat bacterial infections, if administered alone.
  • Pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, formulated together with one or more pharmaceutically acceptable carriers or diluents.
  • the term "pharmaceutically acceptable carrier” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • materials that can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; saffiower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; aiginic acid; pyr
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenteraily (as by intravenous, intramuscular or subcutaneous injection), intracistemaily, intravaginaliy, intraperitonea!!y, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray, or a liquid aerosol or dry powder formulation for inhalation.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubiiizing agents and emu!sifiers such as ethyl alcohol, isopropyi alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, dimethyiformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as, for example, water or other solvents, solubii
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenteraliy acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, 1 % iidocaine, U.S. P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectabies.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • compositions for rectal or vaginal administration are preferably suppositories that can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules, in such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicaicium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethy!celluiose, alginates, gelatin, poiyvinyipyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as,
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentiaily, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the antibacterial compounds can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tabieting lubricants and other tableting aids such a magnesium stearate and microcrysta!!ine cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulations, ear drops, and the like areaiso contemplated as being within the scope of this invention.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • compositions of the invention may also be formulated for delivery as a liquid aerosol or inhalable dry powder.
  • Liquid aerosol formulations may be nebulized predominantly into particle sizes that can be delivered to the terminal and respiratory bronchioles where bacteria reside in patients with bronchial infections, such as chronic bronchitis and pneumonia.
  • Pathogenic bacteria are commonly present throughout airways down to bronchi, broncbioli and lung parenchema, particularly in terminal and respiratory bronchioles.
  • bacteria can also be present in alveoli.
  • Liquid aerosol and inhalabie dry powder formulations are preferably delivered throughout the endobronchial tree to the terminal bronchioles and eventually to the parenchymal tissue.
  • Aerosolized formulations of the invention may be delivered using an aerosol forming device, such as a jet, vibrating porous plate or ultrasonic nebulizer, preferably selected to allow the formation of a aerosol particles having with a mass medium average diameter predominantly between 1 to 5 ⁇ .
  • the formulation preferably has balanced osmolarity ionic strength and chloride concentration, and the smallest aerosoiizabie volume able to deliver effective dose of the compounds of the invention to the site of the infection.
  • the aerosolized formulation preferably does not impair negatively the functionality of the airways and does not cause undesirable side effects.
  • Aeroso!ization devices suitable for administration of aerosol formulations of the invention include, for example, jet, vibrating porous plate, ultrasonic nebulizers and energized dry powder inhalers, that are able to nebulize the formulation of the invention into aerosol particle size predominantly in the size range from 1 -5 pm. Predominantly in this application means that at least 70% but preferably more than 90% of all generated aerosol particles are 1 to 5 m range.
  • a jet nebulizer works by air pressure to break a liquid solution into aerosol droplets. Vibrating porous plate nebulizers work by using a sonic vacuum produced b a rapidly vibrating porous plate to extrude a solvent droplet through a porous plate.
  • An ultrasonic nebulizer works by a piezoelectric crystal that shears a liquid into small aerosol droplets.
  • suitable devices including, for example, AeroNeb and AeroDose vibrating porous plate nebulizers (AeroGen, inc., Sunnyvale, Calif.), Sidestream7 nebulizers (Medic-Aid Ltd., West Wales, England), Pari LC7 and Pari LC Siar7 jet nebulizers (Pari Respiratory Equipment, Inc., Richmond, Va.), and Aerosonic (DeViibisstechnik (Deutsch!and) GmbH, Heiden, Germany) and UltraAire7 (Omron Healthcare, inc., Vernon Hills, ill.) ultrasonic nebulizers.
  • Compounds of the invention may also be formulated for use as topical powders and sprays that can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propeilants such as chlorofluorohydrocarbons.
  • Transdermal patches have the added advantage of providing controi!ed delivery of a compound to the body.
  • dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • bacterial infections are treated or prevented in a patient such as a human or lower mammal by administering to the patient a therapeutically effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, in such amounts and for such time as is necessary to achieve the desired result.
  • a therapeutically effective amount of a compound of the invention is meant a sufficient amount of the compound to treat bacterial infections, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
  • the total daily dose of the compounds of this invention administered to a human or other mammal in single or in divided doses can be in amounts, for example, from 0.01 to 200 mg/kg body weight or more usually from 0.1 to 50 mg/kg body weight, in certain embodiments, the total daily dose administered to a human or other mammal is from 1.0 to 100 mg/kg body weight or from 5.0 to 25 mg/kg body weight.
  • Single dose compositions may contain such amounts or submultip!es thereof to make up the daily dose.
  • treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 15 g of the compound(s) of this invention per day in single or multiple doses, more usually, from 100 mg to 5 g, and even more usually from 250 mg to 1 g per day in single or multiple doses.
  • compositions for use in thepresent invention can be in the form of sterile, non-pyrogenic liquid solutions or suspensions, coated capsules, suppositories, lyophilized powders, transdermal patches or other forms known in the art.
  • a "kit” as used in the instant application includes a container for containing the pharmaceutical compositions and may also include divided containers such as a divided bottle or a divided foil packet.
  • the container can be in any conventional shape or form as known in the art that is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a resealabie bag (for example, to hold a "refill” of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule.
  • the container employed can depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in turn contained within a box.
  • Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff materia! is sealed against the plastic foil at the face of the foil that is opposite from the direction in which the recesses were formed.
  • the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet.
  • the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
  • the written memory aid is of the type containing information and/or instructions for the physician, pharmacist or other health care provider, or patient, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen that the tablets or capsules so specified should be ingested or a card that contains the same type of information.
  • a memory aid is a calendar printed on the card e.g., as follows "First Week, Monday, Tuesday,". . . etc . . . "Second Week, Monday, Tuesday, . . .” etc.
  • Other variations of memor aids will be readily apparent.
  • a “daily dose” can be a single tablet or capsule or several tablets or capsules to be taken on a given day.
  • a daily dose of one or more compositions of the kit can consist of one tablet or capsule while a daily dose of another one or more compositions of the kit can consist of several tablets or capsules.
  • kits of the present invention may also include, in addition to a compound of the present invention, one or more additional pharmaceutically active compounds.
  • the additional compound second antibacterial.
  • the additional compounds may be administered in the same dosage form as the compound of the present invention or in a different dosage form. Likewise, the additional compounds can be administered at the same time as the compound of the present invention or at different times.
  • compositions of the present compounds may also be used in combination with other known antibacterial agents of similar spectrum to (1 ) enhance treatment of severe gram- negative infections covered by the spectrum of this compound or (2) add coverage in severe infections in which multiple organisms are suspected in which another agent of a different spectrum may be required in addition to this compound.
  • Potential agents include members of the aminoglycosides, peniciiiins, cephalosporins, fluoroquinolones, macrolides, glycopeptides, lipopeptides and oxazolidsnones.
  • the treatment can involve administering a composition having both a compound of the present invention and a second antibacterial compound or
  • ACN Acetonitriie
  • DIBAL-H Diisobutyla!uminium hydride
  • DIPEA Diisopropylethylamine
  • DMAP 4-Dimethylaminopyridine
  • NMO N-methylmorphoiine N-oxide
  • PCC Pyridinium Chlorochromate
  • PE Petroleum Ether: Ethyl acetate
  • Mass spectrometry analysis was performed on one of three LCMS instruments: a Waters System. (Alliance HT HPLC and a icromass ZQ mass spectrometer; Column:
  • GCMS analysis was performed on a Hewlett Packard instrument (HP6890 Series gas chromatograph with a Mass Selective Detector 5973; injector volume: 1 ⁇ ; initial column temperature: 50° C; final column temperature: 250C; ramp time: 20 minutes; gas flow rate: 1 mL/min; column: 5% phenyl methyl siloxane, Model #HP 190915-443, dimensions: 30.0 mx25 mx0.25 m).
  • Nuclear magnetic resonance (NMR) analysis was performed with a Varian 300 MHz NMR (Palo Alto, Calif,), and a Varian Unity Enova 400 MHz NMR spectrometer (Palo Alto, Calif.).
  • the spectral reference was either TMS or the known chemical shift of the solvent.
  • Procedure 1 C ⁇ C coupling reaction using CuC!-Cadiot: Hydroxylamine hydrochloride (0.235 mmo!, 0.06 eq) and CuCI (0.08, 0.02 eq) were dissolved in 23% aqueous n-butylamine (1 mL) and the resulting solution was cooled to 0°C. A solution of the alkyne (4.3 mmol, 1.1 eq) in 23% aqueous n-buty!amine (2 mL) was then added.
  • Procedure 4A formation of srnine in reductive a snation to NH e: To a stirred solution of the amine (2.37 g, 7.20 mmoi) in DMF (14.39 mL) was added DIPEA (1.885 mL, 10.79 mmol) followed by formaldehyde (37% in water) (1.071 mL, 14.39 mmol) and the reaction was stirred for 2 hours. The excess aidehyde was quenched with n-butylamine (30% in water) (2.63 g, 10.79 mmol) and stirred for one hour. The reaction mixture was diluted with water, and iyophiiized to yield the desired imine.
  • Ethyny!trimethylsilane (82.4 g, 0.84 mol, 1.2 equiv) was added dropwise over 10 min under a nitrogen atmosphere to a solution of methyl 4-bromobenzoate (150 g, 0.7 mol 1.0 equiv), PdCI 2 (PPh 3 ) 2 (15 g, 0.021 mol, 0.03 equiv) and Cul (13 g, 0.068 mol, 0.1 equiv) in TEA (1.5 L). The reaction was stired at 90°C for 30 minutes, whereupon LCMS showed complete consumption of methyl 4-bromobenzoate. The reaction mixture was filtered and the filter cake was washed with EtOAc (5 x 500 mL).
  • reaction mixture was acidified with AcOH (8.54 pL, 0.149 mrnol) and purified by RPHPLC (1 ", 0.1 %TFA in water /ACN) to yield (S)-4-((1-(2-aminoacetyl)azetidin-3-yl)buta-1 ,3-diyn-1-yl)-W-(3- hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-yi)benzamide (0.0046 g, 0.01 1 mrnol, 52.4%).
  • Azetidin-3-ol hydrochloride (89.45 mg, 0.82 mmoi) was dissolved in MeOH (2 mL) and dipotassium carbonate (0.41 mL, 0.82 mmol) was added. The reaction was stirred at rt for 10 min.
  • Bacterial isolates were cultivated from -70° C. frozen stocks by overnight passages at 35 C in ambient air on Mue!er-Hinton agar (Beckton Dickinson, Franklin Lakes, NJ). Clinical isolates tested were obtained from various geographically diverse hospitals in the US and abroad (Focus Diagnostics, Herndon, VA and JMl, North Liberty, IA). Quality control strains were from the American Type Culture Collection (ATCC: Rockvbook, Md.).
  • MICs Minimum inhibitory Concentrations
  • CFU colony-forming units
  • A MlC's of 1.0 Mg/mL or less
  • AEC001 is E, Coii is ATCC 25922; APAE001 is Pseudomonas aeruginosa ATCC27853; It should be understood that the organic compounds according to the invention may exhibit the phenomenon of tautomerism. As the chemical structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the invention encompasses any tautomeric form of the drawn structure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antibacterial compounds of formula (I) are provided, as well as stereoisomers and pharmaceutically acceptable salts and esters thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

Description

ANTIBACTERIAL AGENTS
L CROSS-REFENCE TO RELATED APPLICATIONS
This application claims the benefit under 35 U.S.C. §1 19(e) of U.S. Provisional Patent Application No. 61/777,547, filed March 12, 2013. The foregoing application is incorporated herein by reference in its entirety.
II. STATEMENT OF GOVERNMENT INTEREST
This invention was made with government support under Contract HDTRA1 -07- C-0079 awarded by the United States Department of Defense. The government has certain rights in this invention.
Ill BACKGROUND
A. Field
This invention pertains generally to treating infections caused by gram-negative bacteria. More specifically, the invention described herein pertains to treating gram-negative infections by inhibiting activity of UDP-3-0-(R-3-hydroxydecanoyi)- -acetylgiucosamine deacetylase (LpxC). The present invention provides small molecule inhibitors of LpxC, pharmaceutical formulations containing such inhibitors, methods of treating patients with such pharmaceutical formulations, and methods of preparing such pharmaceutical formulations and inhibitors. The invention described herein pertains to treating gram-negative infections by administering compounds capable of inhibiting activity of UDP-3-G-(j -3-hydroxydecanoyl)-/V- acetyiglucosamine deacetylase (LpxC), either alone or in combination with administering a second antibacterial compound.
B, Introduction
Over the past several decades, the frequency of antimicrobial resistance and its association with serious infectious diseases have increased at alarming rates. The problem of antibacterial resistance is compounded by the existence of bacterial strains resistant to multiple antibacterials. Thus there is a need for new antibacterials, particularly antibacterials with novel mechanisms of action. A previously unexpioited but highly conserved target, LpxC, provides a new opportunity for developing broad-spectrum antibacterial small molecules that comprise a new class of active bactericidal chemical entities that should encounter little, if any, naturally- occurring, target-related resistance. LpxC (the enzyme uridyldiphospho-3-0-(R- hydroxydecanoyl)-N-acetylglucosamine deacetylase) is present across all Gram-negative bacterial species of interest and is involved in the first committed step in outer membrane biosynthesis. Thus LpxC Is essential for survival and presents an ideal target for antibiotic activity in Gram-negative bacterial species.
Researchers have identified some compounds with antibacterial activity that target lipid A biosynthesis. For example, Jackman et ai. (J. Biol. Chem., 2000, 275(15), 1 1002- 1 1009); Wyckoff et al. (Trends in Microbiology, 1998, 6(4), 154-159); U.S. Patent Application Publication No. 2001/0053555 (published 20 December 2001 , corresponding to International PCT Publication No. WO 98/18754, published 7 May 1998); International PCT Publication No. VVO 00/61 134 (published 19 October 2000); U.S. Patent Application Publication No.
2004/0229955 (published 18 November 2004); International PCT Publication No. VVO
2008/027466 (published 6 March 2008); International PCT Publication No, VVO 2008/105515 (published 4 September 2008); international PCT Publication No. WO 2008/154642 (published 18 December 2008); International PCT Publication No. WO 2009/158369 (published 30 December 2009); international PCT Publication No. WO 2010/017060 (published 1 1 February 2010); International PCT Publication No. WO 2010/024356 (published 4 March 2010);
International PCT Publication No. WO 2010/031750 (published 25 March 2010); international PCT Publication No. WO 2010/032147 (published 25 March 2010); International PCT
Publication No. WO 2010/100475 (published 10 September 2010); International PCT
Publication No. WO 2011/045703 (published 21 April 201 1 ); International PCT Publication No. WO 201 1/073845 (published 23 June 201 1 ); and International PCT Publication No. WO 201 1/132712 (published 27 October 2011 ) ail disclose compounds having antibacterial anti- LpxC activity. The commercial development of these LpxC inhibitors has been complicated by toxicity of these compounds in mammalian animals at concentrations at or near those required for antibacterial activity. The compounds presented herein are significantly better tolerated, more active and/or less protein-bound than other closely related compounds having anti-LpxC activity.
Although there have been advances in the field, there remains a need for LpxC inhibitors that have activity as bactericidal agents against gram-negative bacteria and have an acceptable efficacy and toxicity/tolerance profile. It is, accordingly, an object of this invention to provide compounds and combinations of such compounds for use in the preparation of nontoxic antibacteriais and other pharmaceuticals capable of inhibiting gram-negative bacterial infections.
IV, BRIEF SUGA Y OF THE INVENTION
The present invention provides novel compounds, pharmaceutical formulations including the compounds, methods of inhibiting UDP-3-0-( ?-3-hydroxydecanoyl)-/V- acetylglucosamine deacetylase (LpxC), and methods of treating gram-negative bacterial infections.
In one I:
Figure imgf000004_0001
and stereoisomers, pharmaceutically acceptable salts and esters thereof, wherein
A is azetidinyl or pyrrolidiny!, wherein said azetidinyl or pyrrolidinyi is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted Ci-C3 alkyl, halogen, cyano, -C{0)R4, oxo, hydroxyl, -8(G)2R4, substituted or unsubstituted C3-C6 heterocyclyl and substituted or unsubstituted C4-C7 heterocyclylalkyl;
B is absent, a Ci-C2 aikylene or C3-C6 cycloalkyi wherein said Ci-C2 alky!ene or C3-C6 cycioaikyl is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted C C3 alkyl, halogen, cyano, -C(0)R4, oxo, hydroxyl, --3(0)2ί¾, substituted or unsubstituted C3-C6 heterocyc!y! and substituted or unsubstituted C4-C7 heterocyclyla!ky!;
or A and B together form a fused 5-9 membered bicyclic ring system, wherein A is azetidinyl or pyrrolidinyi and B is a C3-C6 cyc!oa!kyi and wherein each of A and B is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted C C3 alkyl, ha!ogen, cyano, -C(0)R4, oxo, hydroxy!, -S(0)2R4, substituted or unsubstituted C3-C6 heterocyciyi and substituted or unsubstituted C4-C7 heterocyclylaiky!;
G is selected from the group consisting of -C≡C-, -CH=CH-C≡C~ -C≡C-CH=CH-, and ~ 0 ~ — o~o— >
Q is O or NR, wherein R is hydrogen or an unsubstituted CrC3 aikyl;
R, and R2 independently are selected from the group consisting of hydrogen, substituted or unsubstituted C C3 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 4-8 membered heterocyciyi, and substituted or unsubstituted heteroaryl, or R-, and R2, together with the carbon atom to which they are attached, form an unsubstituted C3-C6 cycloalkyl group or an unsubstituted 4-6 membered heterocyclic group:
R3 is selected from the group consisting of hydrogen, substituted or unsubstituted C C6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cyc!oaiky!alkyl, substituted or unsubstituted heterocyciyi, substituted or unsubstituted heterocyclylalky!, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyi;
each R4 is independently hydrogen, substituted or unsubstituted C C3 alkyl, substituted or unsubstituted C3-C6 cycloalkyl or NR5R6; and
each R5 and R6 is independently hydrogen or C1-C3 alkyl.
In another aspect, the present invention provides a pharmaceutical composition comprising a compound of Formula I, or or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, and a pharmaceutically acceptable carrier or diluent. In another aspect, the present invention provides a pharmaceutical composition or formulation comprising an effective amount of an antibacterial compound of Formula I, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, and a pharmaceutically acceptable carrier or diluent.
In another aspect, the present invention provides a method of inhibiting a deacetylase enzyme in gram-negative bacteria, thereby affecting bacterial growth, comprising administering to a patient in need of such inhibition an LpxC-inhibitory compound of Formula I or a stereoisomer, pharmaceutically acceptable salt, or ester thereof.
In another aspect, the present invention provides a method of inhibiting LpxC, thereby modulating the virulence of a bacterial infection, comprising administering to a patient in need of such inhibition an LpxC-inhibitory compound of Formula 1 or a stereoisomer, pharmaceutically acceptable salt, or ester thereof.
In another aspect, the present invention provides a method for treating a patient having a bacterial infection comprising administering to the patient in need thereof an antibacterialiy effective amount of a compound of Formula I, or a stereoisomer,
pharmaceutically acceptable salt, or ester thereof, in a more specific embodiment of the method of treatment, the bacterial infection is a gram-negative bacterial infection, in a further specific embodiment the patient is a mammal and in certain embodiments, a human.
In another aspect, the present invention provides a method of administering an antibacterialiy effective amount of a compound of Formula I or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, to a patient infected with a fermentative or non-fermentative gram-negative bacteria. Examples of such bacteria include Pseudomonas aeruginosa, Stenotrophomonas maltophila, Burkhoideria cepacia, Aicaiigenes xyiosoxidans,
Enterobacteriaceae, Haemophilus, Franciscellaceae (e.g., Franciscella tuiarensis) and
Neisseria species.
In another aspect, the present invention provides a method of administering an antibacterialiy effective amount of a compound of Formula I, or a stereoisomer,
pharmaceutically acceptable salt, or ester thereof, to a patient infected with gram-negative bacteria. Examples of such bacteria include Enterobacteriaceae, such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis), Morganeila, Cedecea, Edwardsielia species and Escherichia coii.
These and other aspects of the invention will be evident upon reference to the following detailed description.
V. DETAILED DESCRIPTION OF THE INVENTION
The present invention provides novel compounds, methods for inhibiting LpxC in gram-negative bacteria, and novel methods for treating bacterial infections. The compounds provided herein can be formulated into pharmaceutical formulations and medicaments that are useful in the methods of the invention. The invention also provides for the use of the
compounds in preparing medicaments and pharmaceutical formulations, for use of the compounds in inhibiting LpxC, and for use of the compounds in treating bacterial infections in a patient. The invention further provides compositions and methods for treating gram-negative infections by administering compounds capable of inhibiting activity of UDP~3~G-(R~3~ hydroxydecanoyl)-/V-acetyiglucosamine deacetyiase (LpxC), either alone or in combination with administering a second antibacterial compound.
A. Definitions
The following abbreviations and definitions are used throughout this application:
"LpxC" is an abbreviation that stands for UDP-3-0-(R-3-hydroxydecanoyl)-W- acetylgiucosamine deacetyiase.
As used herein, the following definitions shall apply unless otherwise indicated.
"Alkyi" refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH3-), ethyl (CH3CH2-), n-propyl
(CH3CH2CH2-), isopropyl ((CH3)2CH-), n-butyl (CH3CH2CH2CH2-), isobutyl ((CH3)2CHCH2-), sec- butyl ((CH3)(CH3CH2)CH-), i-but l ((CH3)3C-), n-pentyl (CH3CH2CH2CH2CH2-), and neopentyl ((CH3)3CCHr). "Alkoxy" refers to the group -O-a!ky!, wherein alky! is as defined herein. Alkoxy includes methoxy, etboxy, n-propoxy, isopropoxy, π-butoxy, i-butoxy, sec-butoxy, n-pentoxy, and the like.
"Amino" refers to the group -NH2.
"Alkenyl" refers to straight chain or branched hydrocarby! groups having from 2 to 6 carbon atoms and preferably 2 to 4 carbon atoms and having at least 1 and preferably from 1 to 2 sites of vinyl (>C=C<) unsaturation. Such groups are exemplified by viny!, ally!, and but-3-en-1-yl. Included within this term are the c/s and trans isomers or mixtures of these isomers.
"Alkynyi" refers to straight or branched monovalent hydrocarby! groups having from 2 to 6 carbon atoms and preferably 2 to 3 carbon atoms and having at least 1 and preferably from 1 to 2 sites of acetylenic ~C≡C- unsaturation. Examples of such a!kynyl groups include acetylenyl (-C≡CH), and propargyl (~CH2C≡CH).
"Carboxyl" or "carboxy" refers to -CQOH or salts thereof.
"Cvano" or "nitri!e" refers to the group -CN.
"Cvcioalkyl" refers to a monocyclic or po!ycyclic alky! group consisting , which may include fused or bridged ring systems, having from 3 to 13 carbon atoms. Examples of cycloa!kyl groups include cyclopropy!, cyciobutyl, cyclopentyl, cyclooctyl, and the like.
"Halo" or "halogen" refers to fiuoro, chioro, bromo, and iodo and is typically fiuoro or chioro.
"Hydroxy" or "hydroxyl" refers to the group -OH,
"Heterocycle," "heterocyclic," and "heterocyciyi" refer to a saturated or unsaturated monocyclic or polycyc!ic group, which may include fused or bridged ring systems, having from 3 to 15 ring atoms, including 1 to 4 hetero atoms. These ring atoms are selected from the group consisting of nitrogen, sulfur, or oxygen. In one implementation, the nitrogen and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, -S(O)-, or -S02- moieties.
"Nitro" refers to the group -NQ2.
"Oxo" refers to the atom (=0). "Substituted" refers to a group having one or more hydrogens replaced with substituents selected from the group consisting of alkoxy, acyi, acylamino, acyloxy, amino, aminocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyioxy, amidino, carboxyl ester, (carboxyl ester)amino, (carboxyi ester)oxy, cyano, halo, hydroxy, nitro, suifony!, thioacyl, and alkylthio, wherein said substituents are as defined herein, in certain substituted cyclic groups, "substituted" also refers to a group having one or more hydrogens replaced with an alkyl group or "substituted" refers a group having two hydrogens replaced with a single double bonded oxygen atom (an oxo group) or a single double bonded sulfur atom (thioxo). in some implementations, the substituted group has 1 to 3 of the aforementioned substituents. in other implementations, the substituted group has 1 to 2 of the aforementioned substituents
"Suifony!" refers to the group -S02-alkyi, -S02-substituted alkyl, ~S02-alkenyl, -S02-substituted alkenyl, wherein alkyl, substituted alkyl, aikenyi, substituted aikenyi, alkynyl, and substituted alkynyl are as defined herein. Sulfonyl includes groups such as methyi-S02-.
"Thioacyl" refers to the groups H-C(S)-, alkyl-C(S)-, substituted a!ky!-C(S)-, a!keny!-C(S)-, substituted aikenyi-C(S)-, a!kyny!-C(S)-, and substituted alkynyl-C(S)-, wherein alkyl, substituted alkyl, aikenyi, substituted alkenyl, alkynyl, and substituted alkynyl are as defined herein.
"Thioxo" refers to the atom (=S).
"Alkylthio" refers to the group -S-a!ky!, wherein alkyl is as defined herein. In other implementations, sulfur may be oxidized to -S(O)-. The sulfoxide may exist as one or more stereoisomers.
Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent "arylalkyloxycarbony!" refers to the group (ary!)-(alkyl)-0-C(0)-.
Generally, reference to a certain element such as hydrogen or H is meant to include all isotopes of that element. For example, if a substituent group is defined to include hydrogen or H, if also includes deuterium and tritium. The subject invention also includes isotopicaliy-labeied compounds of the present invention, that are structurally identical to those disclosed herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 80, 170, 3 ' P, 3 P, 35S, 8F and j6Ci, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds and of said prodrugs that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopicaliy labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and '4C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances, isotopicaliy labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out known or referenced procedures and by substituting a readily available isotopicaliy labeled reagent for a non-isotopicaily labeled reagent.
"Stereoisomer" and "stereoisomers" refer to compounds that have same atomic connectivity but different atomic arrangement in space. Stereoisomers include cis-trans isomers, E and Z isomers, enantiomers, and diastereomers.
"Tautomer" refers to alternate forms of a molecule that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of neteroary! groups containing a -N=C(H)-NH- ring atom arrangement, such as pyrazoies, imidazoles, benzimidazoles, triazoies, and tetrazoies. A person of ordinary skill in the art would recognize that other tautomeric ring atom arrangements are possible.
"Patient" refers to human and non-human animals, especially mammals. "Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts of a compound, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraa!kyiammonium, and the like: and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, phosphate, sulfate and the like.
" Pharmaceutically effective amount" and "therapeuticaliy effective amount" refer to an amount of a compound sufficient to treat a specified disorder or disease or one or more of its symptoms and/or to prevent the occurrence of the disease or disorder.
The term "antibacterial agent" refers to agents that have either bactericidal or bacteriostatic activity. The term "inhibiting the growth" indicates that the rate of increase in the numbers of a population of a particular bacterium is reduced. Thus, the term includes situations in which the bacterial population increases but at a reduced rate, as well as situations where the growth of the population is stopped, as well as situations where the numbers of the bacteria in the population are reduced or the population even eliminated, if an enzyme activity assay is used to screen for inhibitors, one can make modifications in uptake/efflux, solubility, half-life, etc. to compounds in order to correlate enzyme inhibition with growth inhibition. The activity of antibacterial agents is not necessarily limited to bacteria but may also encompass activity against parasites, virus, and fungi.
Unless the context requires otherwise, throughout the specification and claims which follow, the word "comprise" and variations thereof, such as, "comprises" and "comprising" are to be construed in an open, inclusive sense, that is, as "including, but not limited to".
Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment.
Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. 8, Compounds, Compositions and Use Thereof
in one I:
Figure imgf000012_0001
stereoisomer, pharmaceutically acceptable salt or ester thereof, wherein
A is azetidinyi or pyrroiidinyi, wherein said azetidinyi or pyrroiidinyl is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted Ci-C3 alkyl, halogen, cyano, -C(0)R4, oxo, hydroxyl, -S(0)2R4, substituted or unsubstituted C3-C6 heterocyclyl and substituted or unsubstituted C4-C7 heterocyclylalkyl;
B is absent, a CrC2 aiky!ene or C3~C6 cycloalkyl wherein said Ci-C2 aikyiene or C3-C6 cycioalkyl is unsubstituted or substituted with 1 or 2 groups seiected from substituted or unsubstituted C C3 alkyi, halogen, cyano, -C(0)R4, oxo, hydroxy!, -S(0)2R4, substituted or unsubstituted C3-C6 heterocyclyl and substituted or unsubstituted C4-C7 heterocyciyiaikyl;
or A and B together form a fused 5-9 membered bicyclic ring system, wherein A is azetidinyi or pyrroiidinyi and B is a C3-C3 cycloalkyl and wherein each of A and B is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted Ci-C3 alkyi, halogen, cyano, -C(0)R4, oxo, hydroxy!, ---S(0)2R4, substituted or unsubstituted C3-C6 heterocyc!y! and substituted or unsubstituted C4-C7 heterocyciyiaikyl;
G is selected from the group consisting of -C≡C-, -CH=CH-C≡C--, -C≡C-CH=CH-, and " 0 ~ ~~C -~ """ .
Q is O or NR, wherein R is hydrogen or an unsubstituted d-C3 alkyl;
Ri and R2 independently are seiected from the group consisting of hydrogen, substituted or unsubstituted Ci-C3 alkyl, substituted or unsubstituted C3-C6 cycioalkyl, substituted or unsubstituted 4-6 membered heterocyclyl, and substituted or unsubstituted heteroaryl, or R-. and R2, together with the carbon atom to which they are attached, form an unsubstituted C3-C6 cycloaikyi group or an unsubstituted 4-8 membered heterocyclic group;
R3 is selected from the group consisting of hydrogen, substituted or unsubstituted Ci-C6 alkyi, substituted or unsubstituted cycloaikyi, substituted or unsubstituted cycloaikyla!ky!, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyi, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroaryla!ky!;
each R4 is independently hydrogen, substituted or unsubstituted C C3 alkyi, substituted or unsubstituted C3-C6 cycloaikyi or NRSR6; and
each R5 and R6 is independently hydrogen or C C3 alkyi.
in certain embodiments, R3 is hydrogen or a substituted or unsubstituted C,-C6 aikyl .
In some embodiments G is - ≡C-C≡C-.
In some embodiments, Q is NR, wherein R is hydrogen or unsubstituted Ci-C3 aikyl. In certain embodiments where Q is NR, R is hydrogen. In certain embodiments, Q is O and R3 is H. in certain embodiments both R1 and R2 are methyl.
In certain embodiments B is absent, in other embdiments B is Ci~C2 alky!ene. In still other embodiments B is C3-C6 cycloaikyi.
In some embodiments A is unsubstituted azetidinyl. In other embodiments A is azetidinyl substituted with 1 or 2 groups selected from substituted or unsubstituted C C3 aikyi, -C(0)R4, C3-C6 heterocyclyl, hydroxy! and -S(0)2R4. In some embodiments A is azetidinyl substituted with substituted or unsubstituted Ci~C3 aikyl. In other embodiments A is azetidinyl substituted with -C(0)R4. In certain embodiments where A is azetidinyl substituted with
-C(0)R4, R is hydrogen, in other embodiments where A is azetidinyl substituted with -C(0)R4, R is methyl. In certain embodiments where A is azetidinyl substituted with -C{0)R4, R is Ci-C3 aikyl substituted with hydroxy!, in certain embodiments where A is azetidinyl substituted with -C(0)R4, R4 is Ci-C3 aikyl substituted with amino. In certain embodiments where A is azetidinyl substituted with ~C(0)R4l R4 is C;~C3 a!ky! substituted with hydroxy! and amino, in certain embodiments where A is azetidinyi substituted with -C(0)R4, R4 is C3-C6 cycioa!ky!. in certain embodiments A is azetidinyi substituted with -C(0)R4 and hydroxy!, !n certain embodiments A is azetidinyi substituted with C3-C6 heterocycly!. In certain embodiments A is azetidinyi substituted with hydroxyl. In certain embodiments A is azetidinyi substituted with -S(0)2R . In certain embodiments where A is azetidinyi substituted with -S(0)2R4, R is methyl, in certain other embodiments where A is azetidinyi substituted with -8(G)2R4, R4 is NR5R6. In certain
embodiments where A is azetidinyi substituted with -S(0)2R4, where R4 is NR5R6, R5 and R6 are both hydrogen. In certain embodiments where A is azetidinyi substituted with -S(0)2R,:, where R4 is NR5R6> R5 is Ci~C3 alky! and R6 is hydrogen. In certain embodiments where A is azetidinyi substituted with ~S(0)2R , where R4 is NR5R6, R5 is methyl and R6 is hydrogen.
In some embodiments A is unsubstituted pyrrolidinyi. in other embodiments A is pyrrolidinyi substituted with 1 or 2 groups selected from substituted or unsubstituted C,-C3 alkyl, -C(0)R4, C3-C6 heterocyclyl, hydroxyl and ~8(G)2R4. in some embodiments A is pyrrolidinyi substituted with substituted or unsubstituted Ci~C3 aiky!. In some embodiments A is pyrrolidinyi substituted with substituted or unsubstituted C3-C3 heterocyclyl. In some embodiments A is pyrrolidinyi substituted with oxo. In some embodiments A is pyrrolidinyi substituted with hydroxyl.
In certain embodiments G is -CH=CH--C≡C- and A is azetidinyi substituted with 1 or 2 groups selected from substituted or unsubstituted C;~C3 alkyl, -C(G)R4, C3-C6
heterocyclyl, hydroxyl and -S(0)2R4. In certain embodiments where G is -CH=CH-C≡C- A is azetidinyi substituted with -C(0)R4 or -S{0)2R . In certain embodiments where G is -CH=CB- C≡C- and A is azetidinyi substituted with -C(0)R4 or -S(0)2R4, R4 is hydrogen or methyl. In certain embodiments A is pyrrolidinyi substituted with 1 or 2 groups selected from substituted or unsubstituted CrC3 alkyl, oxo, C3-C6 heterocyclyl, hydroxy! and -S(0)2R4.
One aspect of the invention provides compounds selected from the group of: (S)-A-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-(azetidin-3-ylbuta-1 ,3- diyny!)benzamide (1 ); (S)-4-((1-acetyIazetidin-3-yI)buta-1 ,3-diyn-1-y!)-A/-(3-hydroxy-1 -(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (2a);
(S)-4-((azetidin-3-y!)buta-1 ,3-diyn-1-y!)-A/-(3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide (2b);
(S)-4-((1-formylazetidin-3-yl)buta-1 ,3-diyn-1-yl)-A/-(3-hydroxy-1-(hydroxyamino)-3-methy!-1- oxobutan-2-yl)benzamide (3);
(S)-4-((1-(2-aminoacety!)azetidin-3-yl)buta-1 ,3-diyn-1-yl)-W-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yi)benzamide (4);
4-({1-(2-amino-3-hydroxypropanoyi)azetidin-3-yl)buia-1 ,3-diyn-1-yi)-A -((S)-3-hydroxy-1- (hydroxyamino)-3-methy!-1-oxobutan-2-y!)benzamide (5);
(S)-A/-(3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((1-(2-hydroxyethyl)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (6);
(S)-A/-(3-hydroxy-1-(hydroxyamino)-3-meihyi-1-oxobuian-2-y!)-4-((1-methyiazetidin-3-yi)buta- 1 ,3-diyn-1-y!)benzamide (7);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyI-1-oxobutan-2-y!)-4-((1-(oxeian-3-yi)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (8);
A/-{(S)-3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-yl)-4-(5-((2/?,3S)-3- hydroxypyrroiidin-2-y!)periia-1 ,3-diyn-1-y!)benzamide (9);
(S)-4-((1-acetyiazetidin-3-yi)buta-1 l3-diyny!)-A/-(3-amino-1-(hydroxyamino)-3-methy!-1- oxobutan-2-yl)benzamide 2,2,2-trif!uoroacetate (10);
(S)-3-((4-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobuian-2-ylcarbamoyl)phenyl)buta-1 ,3- diyny!)-A/-methylazetidine-1-carboxamide (1 1 );
(S)-3-((4-(3-amino-1-(hydroxyamino)-3-meihyl-1-oxobuian-2-ylcarbamoyl)phenyl)buta-1 l3- diyny!)azetidine-1-carboxamide (12);
(S)-4-((1-acety!azetidin-3-y!)buta-1 ,3-diynyi)-W-(3-(dimethyiamino)-1-(hydroxyamino)-3-met 1-oxobutan-2-y!)benzamide (13);
(S)-A/-(3-amino-1-{hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-{(1-(2-hydroxyacetyl)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (14);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-(2-hydroxyethyi)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (15);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-formylazetidin-3-yl)buta-1 ,3- diyn-1-y!)benzamide (16);
(S)-4-((1-formylazetidin-3-yl)buta-1 ,3-diyn-1-yl)-A -(1-(hydroxyamino)-3-methyi-3-(methyiami 1-oxobutan-2-y!)benzamide (17);
(S)-4-((1-acety!azeiidin-3-yI)buia-1 ,3-diyn-1-y!)-A/-(1-(hydroxyamino)-3-methy!-3-(methylamino)^ 1-oxobutan-2-y!)benzamide (18);
(S)-4-((1-acetyi-3-hydroxyazetidin-3-y!)buta-1 ,3-diyn-1-yi)-A/-(3-amino-1-(hydroxyamino)-3- methyi-1-oxobutan-2-y!)benzamide (19);
W-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-y!)-4-((1-formy!azetidin-3-y!)buta-1 ,3-diyn- 1-y!)benzamide (20);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-{methy!sulfonyl)azetidin-3- yl)buta-1 ,3-diyn-1-yi)benzatnide (21 );
4-((1-formylazetidin-3-yl)buta-1 ,3-diyn-1-yl)-W-((2S,3/ )-1-(hydroxyamino)-3-(methyiamino)-1- oxobutan-2-yl)benzamide (22);
(S)-A/-(3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-y!)-4-((1-(oxetan-3-y!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (23);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-(5-(azetidin-3-yi)penta-1 ,3-diyr!- 1-y!)benzamide (24);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-(5-(1-formyiazetidin-3-yl)penta- 1 ,3-diyn-1-yl)benzamide (25);
(S,E)-A/-(3-amino-1-(hydroxyamino)-3-methyi-1-oxobutan-2-yi)-4-(4-(1-(methyisulfonyi)azetidi 3-yi)but-3-en-1 -yn-1 -yl)benzamide (26);
(S>E)-W-(3-amino-1-(hydroxyamino)-3-methyi-1-oxobutan-2-y!)-4-(4-(1-formylazetidin-3-yi)but^ en-1-yn-1-y!)benzamide (27);
(S!£)-4-(4-(1-acety!azetidin-3-y!)but-3-en-1-yn-1-yl)-A -(3-amino-1-(hydroxyamino)-3-met^ oxobutan-2-yl)benzamide (28);
(S!E)-4-(4-(1-acety!azetidin-3-y!)bui-3-en-1-yn-1-yl)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (29); W-((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-methy!-5-oxopyrrolidin-3- yl)buta-1 ,3-diynyi)benzamide (30);
A -((S)-3-amino-1-(hydroxyamino)-3-methy!-1-oxobutan-2-y!)-4-((1-(2- (hydroxymethy!)cyc!opropanecarbonyl)azetidin-3-y!)ethyny!)benzamide (31 );
A/-((S)-3-hydroxyamino)-3-methy!-1-oxobutan-2-yl)-4-((1-(oxetan-3-yl)pyrrolidiri-3-yl)buta-1 !3- diyn-1-yi)benzamide (32);
A/-((S)-3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-yl)-4-(((S)-1-(2- hydroxyethyl)pyrrolidin-3-yl)buta-1 ,3-diyn-1-y!)benzamide (33);
4-((1-(1-fluoropropan-2-yl)azetidin-3-yl)buta-1 l3-diyn-1-yl)-N-((S)-3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-y!)benzamide (34);
N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((3-(3-hydroxyazetidin-1- yl)cyciobutyl)buta-1 !3-dsyn-1-yl)benzamide (35);
N-((S)-3-hydroxy-1-(hydroxyamino)-3-meihyi-1-oxobutan-2-y!)-4-((3-((S)-3-hydroxypyrro!idin-1- yl)cyc!obutyl)buta-1 ,3-diyn-1-yI)benzamide (36);
N-((S)-3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-y!)-4-((3-((R)-3-hydroxypyrro!idin-1- yl)cyc!obutyl)buta-1 ,3-diyn-1-yl)benzamide (37);
4-((3-(3-fluoroazetidin-1-yl)cyclobutyl)buta-1 ,3-diyn-1-yi)-N-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yl)benzamide (38);
4-((1-(2-cyanoethyI)azeiidin-3-y!)buta-1 ,3-diyn-1-y!)-N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide(39);
4-((1-(2!2-difluoroethyl)azetidin-3-y!)buta-1 ,3-diyn-1-y!)-N-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yl)benzamide (40);
4-((1-(2-amino-2-oxoethyi)azetidin-3-yi)buta-1 ,3-diyn-1-yi)-N-(3-hydroxy-1-(hydroxyamino)-3- methy!-1-oxobutan-2-yl)benzamide (41 );
4-((3-(3-fluoropyrrolidin-1-y!)cyc!obutyl)buta-1 ,3-diyn-1-yl)-N-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yl)benzamide (42);
4-((3-(3!3-difluoroazeiidin-1-yl)cyclobutyl)buta-1 ,3-diyri-1-yl)-N-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-y!)benzamide (43); (S)-N-(3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-(6-(3-hydroxyazetidin-1- yl)hexa-1 ,3-diyn-1-yi)benzamide (44);
(S)-4-(6-(3-f!uoroazetidin-1-yl)hexa-1 ,3-diyn-1-yl)-N-(3-hydroxy-1-(hydroxyamino)-3-methy!-1- oxobutan-2-yl)benzamide (45);
(S)-4-(6-(3,3-dif!uoroazetidin-1-yl)hexa-1 ,3-diyn-1-yl)-N-(3-hydroxy-1-(hydroxyamino)-3-methy!- 1-oxobutan-2-y!)benzamide (48);
N-((S)-3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-y!)-4-(6-(3-hydroxypyrro!idin-1- yl)hexa-1 ,3-diyn-1-yl)benzamide (47);
4-(6-(3-fiuoropyrrolidin-1-y!)hexa-1 ,3-diyn-1-yl)-N-({S)-3-hydroxy-1-(hydroxyamino)-3-nriethyl-1- oxobutan-2-yl)benzamide (48);
(S^-ie-iS.S-difluoropyrroiidin-l-ylJhexa-l ^-diyn-l-y -N-iS-hydroxy-l-ihydroxyaminoJ-S-meihy!-
1- oxobutan-2-y!)benzamide (49);
(S)-4-(azetidin-3-yibuta-1 ,3-diyn-1-yl)-N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutari-2- yl)benzamide (50);
4-(azetidin-3-ylbuta-1 l3-diyn-1-y!)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2- yl)benzamide (51 );
4-({1-formylazetidin-3-yl)buta-1 ,3-diyn-1-yi)-N-((2S,3R)-3-hydroxy-1-(hydroxyarnino)-1- oxobutan-2-yl)benzamide (52);
4-((1-gIycyiazetidin-3-yl)buta-1 l3-diyn-1-y!)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobuian-
2- yl)benzamide (53);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-serylazetidin-3-yl)buta-1 ,3-diyn- 1-yl)benzamide (54);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-{2-hydroxyethy!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (55);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-methylazetidin-3-yl)buta-1 !3- diyn-1-yi)benzamide (56);
N-{(2S,3R)-3-hydroxy-1-(hydroxyarnino)-1-oxobutan-2-yl)-4-((1-(meihyisulfonyi)azeiidin-3- y!)buta-1 ,3-diyn-1-y!)benzamide (57); N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yI)-4-((1-(oxetan-3-y!)azetidin-3-y!)buta- 1 ,3-diyn-1-yl)benzamide (58);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(5-((2R,3S)-3-hydroxypyrro!idin-2- yl)penta-1 ,3-diyn-1-yl)benzamide (59);
(S)-3-((4-((3-hydroxy-1-(hydroxyamino)-3-meihyl-1-oxobuian-2-yl)carbamoyl)phenyl)buta-1 ,3- diyn-1-yi)-N-meihylazetidine-1-carboxamide (60);
3-((4-(((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)carbamoy!)pheny!)buta-1 ,3-diyn-1- yl)-N-methylazetidine-1-carboxamide (61 );
(S)-3-((4-{(3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)carbamoyl)phenyl)buta-1 ,3- diyn-1-y!)azeiidine-1-carboxamide (62);
3- ((4-(((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)carbamoy!)phenyi)buta-1 ,3-diyn-1- yl)azetidine-1-carboxamide (63);
(S)-N-(3-hydroxy-1-(hydroxyarnino)-3-meihyi-1-oxobutan-2-y!)-4-((1-(2-hydroxyacety!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (64);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-(2-hydroxyaceiy!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (65);
(S)-N-(3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-yi)-4-({1-(2-hydroxyethyl)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (66);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yI)-4-((1-(2-hydroxyethyi)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (67);
(S)-4-((1-acetyi-3-hydroxyazetidin-3-yl)buta-1 ,3-diyn-1-y!)-N-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yi)benzamide (68);
4- ((1-aceiyi-3-hydroxyazetidin-3-yl)buia-1 ,3-diyn-1-y!)-N-((2S,3R)-3-hydroxy-1-{hydroxyamino)- 1-oxobutan-2-y!)benzamide (69);
(S)-N-(3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-yl)-4-((1-(methylsu!fonyi)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (70);
N-{(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-(meihyisulfonyi)azeiidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (71 ); (S)-4-(5-(azetidin-3-y!)penta-1 ,3-diyn-1-yl)-N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (72);
4-(5-(azetidin-3-y!)penta-1 ,3-diyn-1-y!)-N-((2S!3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2- yl)benzamide (73);
(S)-4-(5-(1-formylazetidin-3-yl)penta-1 ,3-diyn-1-y!)-N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (74);
4-(5-(1-formylazetidin-3-y!)penta-1 !3-diyn-1-y!)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (75);
(S!E)-N-(3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yl)-4-(4-(1- (methylsuifony!)azetidin-3-yI)but-3-en-1-yn-1-y!)benzamide (76);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-y!)-4-((E)-4-(1-(methy!sulfony!)azetidin-3- yl)but-3-en-1-yn-1-yl)benzamide (77);
(SlE)-4-(4-(1-formylazetidin-3-yl)but-3-en-1-yn-1-y!)-N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (78);
4-((E)-4-(1-formylazetidin-3-yl)but-3-en-1-yn-1-y!)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (79);
N-{(S)-3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-yi)-4-((5-oxopyrrolidin-3-y!)buia-1 ,3- diyn-1-yl)benzamide (80);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yI)-4-((5-oxopyrrolidin-3-yl)buia-1 ,3-diyn- 1-yl)benzamide (81 );
N-((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((1-methyl-5-oxopyrro!idin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (82);
N-((2Sl3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-methy!-5-oxopyrro!idin-3-yl)buta- 1 ,3-diyn-1-yI)benzamide (83);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(((S)-1-(oxetan-3-yl)pyrrolidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (84);
N-{(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(((S)-1-(2-hydroxyethyl)pyrroiidir!-3- y!)buta-1 ,3-diyn-1-y!)benzamide (85); 4-((1-(1-fluoropropan-2-yl)azetidin-3-yi)buta-1 >3-diyn-1-yl)-N-((2S,3R)-3-hydroxy-1- (hydroxyamino)-1-oxobutan-2-y!)benzamide (88);
4-((1-(2!2-difluoroethyl)azetidin-3-y!)buta-1 ,3-diyn-1-y!)-N-((3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (87);
4-((1-(2-cyanoethyl)azeiidin-3-yi)buta-1 ,3-diyn-1-yi)-N-((3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (88);
4-((1-(2-amino-2-oxoethy!)azetidin-3-yi)buta-1 ,3-diyn-1-y!)-N-((3R)-3-hydroxy-1-(hydroxyamino)- 1-oxobutan-2-y!)benzamide (89);
N-{(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-((1-methyi-1 H-imidazol-4- yI)methyl)azetidin-3-y!)buta-1 ,3-diyn-1-yl)benzamide (90);
N-((3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-y!)-4-((3-(3-hydroxyazetidin-1- y cyciobuty buta-l ^-diyn-l-y benzamide (91 );
4-((3-(3-fluoroazetidiri-1-yl)cyclobutyl)buta-1 ,3-diyn-1-yi)-N-((3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (92);
N-((3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-y!)-4-((3-(3-hydroxypyrrolidin-1- yl)cyc!obutyl)buta-1 ,3-diyn-1-yl)benzamide (93);
4-((3-(3-fluoropyrrolidin-1-y!)cyc!obutyl)buta-1 ,3-diyn-1-yl)-N-{(3R)-3-hydroxy-1-(hydroxyamino)- 1-oxobutan-2-yi)benzatnide (94);
4-((3-(3!3-difluoroazetidin-1-yl)cyclobuty!)buta-1 ,3-diyn-1-yl)-N-((3R)-3-hydroxy-1- (hydroxyamino)-1-oxobutan-2-y!)benzamide (95);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(6-(3-hydroxyazetidin-1-yl)hexa-1 ,3- diyn-1-yi)benzamide (96);
4-(6-(3-f!uoroazeiidin-1-yl)hexa-1 ,3-diyn-1-yl)-N-({2S!3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (97);
4-(6-(3,3-dif!uoroazetidin-1-yl)hexa-1 ,3-diyn-1-yl)-N-((2S,3R)-3-hydroxy-1-(hydroxyarnino)-1- oxobutan-2-yl)benzamide (98);
N-{(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(6-(3-hydroxypyrrolidin-1-y!)hexa- 1 ,3-diyn-1-yl)benzamide (99); 4-(6-(3-fiuoropyrrolidin-1-y!)hexa-1 ,3-diyn-1-yi)-N-((2S!3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (100);
4-(6-(3,3-difiuoropyrroiidin-1-y!)hexa-1 ,3-diyn-1-yi)-N-((2S,3R)-3-hydroxy-1 -(hydroxyamino)-1- oxobutan-2-yl)benzamide (101 );
4-((1-(4l5-dimeihyi-4,5-dihydrooxazo!-2-yi)azetidin-3-yi)buta- 3-diyn-1-yl)-N-((2S,3R)-3- hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide (102);
4-((1-(4!5-dimethyl-4,5-dihydrooxazol-2-y!)azetidin-3-y!)buta-1 !3-diyn-1-y!)-N-((S)-3-hydroxy-1- (hydroxyamino)-3-methy!-1-oxobutan-2-y!)benzamide (103); and
(S)-N-(3-hydroxy-1-(hydroxyamino)-3-meihy!-1-oxobutan-2-yi)-4-((1-((1-methyl-1 H-imidazol-4- yI)methyl)azeiidin-3-yI)buta-1 ,3-diyn-1-yl)benzamide (104).
Another aspect of the invention provides compounds selected from the group of: (S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yi)-4-(azetidin-3-y!buta-1 l3- diyny!)benzamide (1 );
(S)-4-((1-acetylazetidin-3-yl)buta-1 ,3-diyn-1-y!)-A/-(3-hydroxy-1-(hydroxyamino)-3-methyI-1- oxobutan-2-yl)benzamide (2a);
(S)-4-((azetidin-3-yi)buta-1 ,3-diyn-1-y!)-A/-(3-hydroxy-1-{hydroxyamino)-3-methyi-1-oxobutan y!)benzamide (2b);
(S)-4-((1-formyIazetidin-3-yI)buta-1 ,3-diyn-1-yl)-W-(3-hydroxy-1-(hydroxyamino)-3-methy!-1- oxobutan-2-yl)benzamide (3);
(S)-4-((1-(2-aminoacetyi)azetidin-3-yl)buta-1 !3-diyn-1-yl)-W-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yi)benzamide (4);
4-((1-(2-amino-3-hydroxypropanoy!)azetidiri-3-yl)buta-1 ,3-diyri-1-y!)-W-((S)-3-hydroxy-1-
(hydroxyamino)-3-methy!-1-oxobutan-2-y!)benzamide (5);
(S)~A/~(3-hydroxy-1-(hydroxyamino)~3~m
yl)buta-1 ,3-diyn-1-y!)benzamide (6);
(S)-W-(3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxob
1 ,3-diyn-1-y!)benzamide (7); (S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-(oxetan-3-y!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (8);
A -((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yl)-4-(5-((2/:?,3S)-3- hydroxypyrroiidin-2-yi)penta-1 ,3-diyn-1-y!)benzamide (9);
(S)-4-((1-acety!azei!din-3-y!)buia-1 ,3-diynyi)-W-(3-amino-1-(hydroxyamino)-3-methyi-1- oxobutan-2-yl)benzamide 2,2,2-trif!uoroacetate (10);
(S)-3-((4-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-ylcarbamoyl)phenyl)buta-1 !3- diyny!)-A/-methylazetidine-1-carboxamide (1 1 );
(S)-3-((4-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobuiari-2-ylcarbamoyl)phenyl)buta-1 !3- diyny!)azetidine-1-carboxamide (12);
(S)-4-((1-acetyiazetidin-3-yi)buta-1 ,3-diyny!)-A/-(3-(dimethy!amino)-1-(hydroxyamino)-3-meth 1-oxobutan-2-y!)benzamide (13);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobuian-2-yi)-4-((1-{2-hydroxyacetyl)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (14);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyI-1-oxobutan-2-y!)-4-((1-(2-hydroxyethy!)azeiidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (15);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-formylazetidin-3-yl)buta-1 ,^ diyn-1-y!)benzamide (16);
(S)-4-((1-formyIazetidin-3-yI)buta-1 ,3-diyn-1-yl)-W-(1-(hydroxyamino)-3-methyi-3-(meihyiami 1-oxobutan-2-y!)benzamide (17);
(S)-4-((1-acetyiazetidin-3-yl)buta-1 ,3-diyn-1-y!)-A/-(1-(hydroxyamino)-3-methy!-3-(methylamin 1-oxobutan-2-y!)benzamide (18);
(S)-4-((1-acetyl-3-hydroxyazetidin-3-yi)buta-1 ,3-diyn-1-yl)-A-(3-amino-1-(hydroxyamino)-3- methy!-1-oxobutan-2-yi)benzamide (19);
A/-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-y!)-4-((1-formy!azetidin-3-y!)buta-1 ,3-diyn- 1-yl)benzamide (20);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-(methyisulfonyl)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (21 ); 4-((1-formylazetidin-3-yl)buia-1 ,3-diyn-1-yI)-W-((2Sl3R)-1-(hydroxyamino)-3-(methy!ami oxobutan-2-yl)benzamide (22);
(S)-A/-(3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((1-(oxetan-3-y!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (23);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yi)-4-(5-(azetidin-3-yl)penta-1 ,3-diyn- 1-yl)benzamide (24);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methy!-1-oxobutan-2-y!)-4-(5-(1-formy!azetidin-3-yl)penta- 1 ,3-diyn-1-yl)benzamide (25);
(S,£)-A/-(3-amino-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-(4-{1-(methy!sulfony!)azetidi
3- y!)but-3-en-1-yn-1-yI)benzamide (26);
(S,£)-A/-(3-amino-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-(4-(1-formylazetidin-3-y!)but-3- en-1-yn-1-y!)benzamide (27);
(S,£)-4-(4-(1-ace1y!azeiidin-3-y!)bui-3-en-1-yn-1-yl)-W-{3-amino-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (28);
(SlE)-4-(4-(1-acety!azetidin-3-y!)but-3-en-1-yn-1-yl)-W-(3-amino-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (29);
A/-{(S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-methyi-5-oxopyrrolidin-3- yl)buta-1 ,3-diynyi)benzamide (30);
A/-((S)-3-amino-1-(hydroxyamino)-3-methy!-1-oxobutan-2-y!)-4-((1-(2- (hydroxymethy!)cyc!opropanecarbonyl)azetidin-3-y!)ethyny!)benzamide (31 );
A -((S)-3-hydroxyamino)-3-methy!-1-oxobutan-2-yl)-4-((1-(oxetan-3-yl)pyrrolidin-3-yl)buta-1 !3- diyn-1-yi)benzamide (32);
A/-((S)-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((S)-1-(2- hydroxyethyl)pyrrolidin-3-yI)buta-1 ,3-diyn-1-y!)benzamide (33);
4- ((1-(1-fluoropropan-2-yl)azetidin-3-yl)buta-1 ,3-diyn-1-yl)-N-((S)-3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yi)benzamide (34);
N-{3-hydroxy-1-{hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((3-(3-hydroxyazetidin-1- yI)cyc!obutyl)buta-1 ,3-diyn-1-yl)benzamide (35); N-((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((3-((S)-3-hydroxypyrroiidin yl)cyciobutyl)buta-1 ,3-diyn-1-yi)benzamide (36);
N-((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((3-((R)-3-hydroxypyrro!idin-1- yl)cyciobutyl)buta-1 ,3-diyn-1-yi)benzamide (37);
4-((3-(3-fluoroazetidin-1-yl)cyclobutyl)buta-1 ,3-diyn-1-yi)-N-(3-hydroxy-1-(hydroxyamino)-3- methy!-1-oxobutan-2-yl)benzamide (38); and
4-((1-(2-cyanoethyl)azetidin-3-yi)buta-1 ,3-diyn-1-y!)-N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide{39).
Compounds of the present invention can be readily synthesized using the methods described herein, or other methods, that are we!i known in the art. For example, the synthesis of hydroxamic acids or similar scaffolds having a wide variety of substituents are comprehensively reviewed in Kline, T., et a!., "Potent, novel in vitro inhibitors of the
Pseudomonas aeruginosa deacetyiase LpxC" J. Med Chem. 2002, 45(14), 31 12-29; U.S. Patent No. 5,925,659; Pirrung, M. C, et a!., "A Convenient Procedure for the Preparation of Amino Acid Hydroxamates from Esters" J. Org. Chem. 1995, 60, 8084-8085; Nhu, K., et a!., "A New and Efficient Solid Phase Synthesis of Hydroxamic Acids" J. Org. Chem. 1997, 62, 7088-7089; international PCT Publication No. W098/18754; Mellor, S. L, et al., "N-Fmoc-aminoxy-2- chlortrityl Polystyrene Resin: A Facile Solid-phase Methodology for the Synthesis of Hydroxamic Acids" Tetrahedron Lett. 1997, 38, 331 1-3314; Khan, S. I., et a!., "A Facile and Convenient Solid-phase Procedure for Synthesizing Nucleoside Hydroxamic Acids" Terahedron. Lett. 1998, 39, 8031-8034; Zhang, Y., et a!., "Design, Combinatorial Chemical Synthesis, and in vitro Characterization of Novel Urea Based Gelatinase inhibitors" Bioorg. Med. Chem. Lett. 1999, 9, 2823-2826; Ito, Y., et al., "Synthetic Reactions by Complex Catalysts. XXXI, A Novel and Versatile Method of Heterocycle Synthesis" J. Am Chem. Soc. 1973, 95, 4447-4448; Ito, Y., et a!., "Synthetic Reactions by Complex Catalysts XXXV" Syn. Commun. 1974, 4, 97-103; Witte, H., et al., "Cyclische imidsaurester aus Nitriien und Aminoalkoholen" Liebigs Ann. Chem. 1974, 996-1009; Pattenden, G., et al., "Naturally Occurring Linear Fused Thiazoline-Thiazole
Containing Metabolites: Total Synthesis of (-) Didehydromirabazole A, a Cytotoxic Alkaloid from Blue-Green Algae" J. Chem. Soc. Perkin Trans 1993, 1 , 1629-1636; Boyce, R. J., et al., "Total Synthesis of Thiangazo!e, A Novel Naturally Occurring HiV-1 Inhibitor from Polyangium sp." Tetrahedron 1995, 51 , 7321-7330; Galeotti, N., et a!., "Synthesis of Peptidyl Aldehydes from Thiazoiines" Tetrahedron. Lett. 1997, 38, 2459-2462; Charette, A. B., et a!., "Mild Method for the Synthesis of Thiazoiines from Secondary and Tertiary Amides" J. Org. Chem. 1998, 83, 908- 909; Bergeron, R. J., et a!., "Effects of C-4 Stereochemistry and C-4' Hydroxyiation on the Iron Clearing Efficienc and Toxicity of Desferrithiocin Analogues" J. Med, Chem. 1999, 42, 2432- 2440; Raman, P., et a!., "Titanium (IV)-mediated Tandem Deprotection-cyc!odehydration of Protected Cysteine N-Amides: Biomimetic Synthesis of Thiazoline- and Thiazole-containing Heterocycies" Org. Lett 2000, 2, 3289-3292; Fernandez, X., et al., "Novel Synthesis of 2- Thioazo!ines" Tetrahedron Lett. 2000, 41 , 3381-3384; and Wipf, P., et a!., "C. Thiolysis of Oxazolinenes: A New, Selective Method for the Direct Conversion of Peptide Oxazolines into Thiazoiines" Tetrahedron Lett. 1995, 36, 6395-6398, which are incorporated herein by reference.
The compounds of Formula i are distinguished from previously known substances by a surprisingly low degree of binding to plasma proteins and can therefore provide a relatively high concentration of free, i.e. pharmacologically effective and available drug concentration, in order to achieve an antibacterial effect, the MIC for the target organism must be reached in vivo. Binding of the antibacterial agent to plasma proteins will decrease the available plasma concentration of the agent, making it more difficult to achieve a concentration at or above the MIC. The compounds disclosed herein demonstrate decreased protein binding as compared to previously known substances, and therefore can more easily achieve a therapeutic concentration in the patient.
in another aspect, the present invention provides a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, and a pharmaceutically acceptable carrier or diluent.
In another aspect, the invention provides a method of inhibiting a deacetylase enzyme in a gram-negative bacteria, thereby affecting bacterial growth, comprising
administering to a patient in need of such inhibition a compound of Formula I or a stereoisomer, pharmaceutically acceptable salt, or ester thereof. In another aspect, the invention provides a method of inhibiting LpxC, thereby modulating the virulence of a bacteria! infection, comprising administering to a patient in need of such inhibition a compound of Formula or a stereoisomer, pharmaceutically acceptable salt, or ester thereof. In certain embodiments of the method of inhibiting LpxC using a compound of the present invention, the IC50 value of the compound is less than or equal to 10 μΜ with respect to LpxC. in other embodiments, the !C5o value is less than or equal to 1 μΜ, is less than or equal to 0.1 μΜ, is less than or equal to 0.050 μ , is less than or equal to 0.030 μΜ, is less than or equal to 0.025 μ , or is less than or equal to 0.010 μΜ.
In another aspect, the invention provides a method for treating a patient having a gram-negative bacterial infection comprising administering to the patient in need thereof an antibacterially effective amount of a compound of Formula I or a stereoisomer, pharmaceutically acceptable salt, or ester thereof.
In another aspect, the invention provides a method of administering a
therapeutically effective amount of a compound of Formula I or a stereoisomer,
pharmaceutically acceptable salt, or ester thereof, to a patient infected with a fermentative or non-fermentative gram-negative bacteria. Examples of fermentative or non-fermentative gram- negative bacteria include Pseudomonas aeruginosa, Stenotrophomonas maltophila,
Burkholderia cepacia, Alcaiigenes xyiosoxidans, Enterobacteriaceae, Haemophilus,
Francisce!iaceae (e.g., Francisce!la tularensis) and Neisseria species.
In another aspect, the invention provides a method of administering an inhibitory amount of a compound described herein to gram-negative bacteria, such as Enterobacieriaceae which is selected from the group consisting of organisms such as Serratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia (e.g., Yersinia pestis), Morganella, Cedecea, Edwardsiella species and Escherichia coli.
In certain embodiments, the patient may be a mammal, and in some embodiments, a human.
Bacteria! infections susceptible to treatment according to the present invention include primary infections and co-infections caused by a species of bacteria and one or more additional infectious agents such as, for example, bacteria, virus, parasite and fungus. Compounds of the invention can be used for treating conditions caused by the bacterial production of endotoxin and, in particular, by gram-negative bacteria and bacteria that use LpxC in the biosynthesis of !ipopolysaccharide (LPS) or endotoxin.
Compounds of the invention also are useful in treating conditions that are caused or exacerbated by the bacteria! production of lipid A and LPS or endotoxin, such as sepsis, septic shock, systemic inflammation, localized inflammation, chronic obstructive pulmonary disease (COPD) and acute exacerbations of chronic bronchitis (AECB). For these conditions, treatment includes the administration of a compound of the invention, or a combination of compounds of the invention, optionally with a second agent wherein the second agent is a second antibacterial agent or a non-antibacterial agent.
For sepsis, septic shock, systemic inflammation, localized inflammation, chronic obstructive pulmonary disease (COPD) and acute exacerbations of chronic bronchitis (AECB), representative non-antibacterial agents include antiendotoxins including endotoxin receptor- binding antibodies, endotoxin-binding antibodies, anti-CD14-binding protein antibodies, antilipopo!ysaccharide-binding protein antibodies and tyrosine kinase inhibitors.
In treatment of serious or chronic respiratory tract infections, compounds of the present invention may also be used with non-antibacterial agents administered via inhalation. Representative non-antibacterial agents used in this treatment include anti-inflammatory steroids, non-steroidal anti-inflammatory agents, bronchiodiiators, mucolytics, anti-asthma therapeutics and lung fluid surfactants, in particular, the non-antibacterial agent may be albuterol, salbuterol, budesonide, bec!omethasone, dexamethasone, nedocromi!,
beclomethasone, fluticasone, fluniso!ide, triamcinolone, ibuprofin, rofecoxib, naproxen, celecoxib, nedocromil, ipratropium, metaproterenol, pirbuteroi, saimeterol, formoterol, indacatero!, bronchiodiiators, mucolytics, calfactant, beractant, poractant alfa, surfaxin or pu!mozyme (also called domase alfa).
Compounds of the invention can be used alone or in combination with a second antibacterial agent for the treatment of a serious or chronic respiratory tract infection including serious lung and nosocomial infections such as those caused by Enterobacter aerogenes, Enterobacter cloacae, Escherichia co/ , Klebsiella pneumoniae, Klebsiella oxytoca, Proteus rnirabiiis, Serratia marcescens, Stenotrophornonas ma!tophi!ia, Pseudornonas aeruginosa, Burkhoidena cepacia, Alcaligenes xylosoxidans, Fiavobacierium meningosepticum, Providencia siuartii and Citrobacter freundi, community lung infections such as those caused by
Haemophilus Influenzae, Legionella species, Moraxeila catarrhalis, Branhamella catarrhal, Enterobacter species, Klebsiella species, and Proteus species, infections caused by other bacterial species such as Neisseria species, Shigella species, Salmonella species, Helicobacter pylori, Vibrionaceae and Bordeteila species, as well as infections caused by a Brucella species, Francisetla tularensis and/or Yersinia Pestis.
When used for treating patients infected with gram-negative bacterial infections, compounds of the present invention can be used to sensitize gram-negative bacteria to the effects of a second agent.
The present invention provides novel combinations of compounds including a compound of Formula I or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, as well as methods for treating patients infected with gram-negative bacteria. The novel combinations provided herein can be formulated into pharmaceutical formulations and medicaments that are useful in the methods of the invention. The invention also provides for the use of the novel combinations in preparing medicaments and pharmaceutical formulations, for use of the combinations in treating bacterial infections in a patient.
In one embodiment, a second antibacterial agent is used in combination with a compound of Formula I, or stereoisomer or pharmaceutically acceptable salt thereof. Examples of suitable second antibactierai agents include, but are not limited to, vancomycin, linezolid , azithromycin, imipenem, teicop!anin, daptomycin, clindamycin, rifampin, cefotaxime, gentamicin, novobiocin or telavancin. in one such embodiment, the antibacterial agent is vancomycin, teicoplanin, rifampin, azithromycin, telavancin or novobiocin. Most preferably, the antibacterial agent is vancomycin or rifampin, in some embodiments of the invention, the antibacterial agent and/or the compound of Formula I, or stereoisomer or pharmaceutically acceptable salt thereof, is administered at a sub-therapeutic dose, wherein a subtherapeutic dose is a dose that would be insufficient to treat bacterial infections, if administered alone. Pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, formulated together with one or more pharmaceutically acceptable carriers or diluents. As used herein, the term "pharmaceutically acceptable carrier" means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials that can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; saffiower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; aiginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium iauryi sulfate and magnesium sfearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formuiaior. The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenteraily (as by intravenous, intramuscular or subcutaneous injection), intracistemaily, intravaginaliy, intraperitonea!!y, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray, or a liquid aerosol or dry powder formulation for inhalation.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubiiizing agents and emu!sifiers such as ethyl alcohol, isopropyi alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, dimethyiformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenteraliy acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, 1 % iidocaine, U.S. P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. in addition, fatty acids such as oleic acid are used in the preparation of injectabies.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenteraliy administered drug form may be accomplished by dissolving or suspending the drug in an oil vehicle, injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-poiygiycoiide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poiy(orthoesters) and poly(anhydrides). Depot injectable formulations may also be prepared by entrapping the drug in liposomes or microemuisions that are compatible with body tissues. Compositions for rectal or vaginal administration are preferably suppositories that can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules, in such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicaicium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethy!celluiose, alginates, gelatin, poiyvinyipyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, acetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium iauryi sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentiaily, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The antibacterial compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tabieting lubricants and other tableting aids such a magnesium stearate and microcrysta!!ine cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulations, ear drops, and the like areaiso contemplated as being within the scope of this invention.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Compositions of the invention may also be formulated for delivery as a liquid aerosol or inhalable dry powder. Liquid aerosol formulations may be nebulized predominantly into particle sizes that can be delivered to the terminal and respiratory bronchioles where bacteria reside in patients with bronchial infections, such as chronic bronchitis and pneumonia. Pathogenic bacteria are commonly present throughout airways down to bronchi, broncbioli and lung parenchema, particularly in terminal and respiratory bronchioles. During exacerbation of infection, bacteria can also be present in alveoli. Liquid aerosol and inhalabie dry powder formulations are preferably delivered throughout the endobronchial tree to the terminal bronchioles and eventually to the parenchymal tissue.
Aerosolized formulations of the invention may be delivered using an aerosol forming device, such as a jet, vibrating porous plate or ultrasonic nebulizer, preferably selected to allow the formation of a aerosol particles having with a mass medium average diameter predominantly between 1 to 5 μπι. Further, the formulation preferably has balanced osmolarity ionic strength and chloride concentration, and the smallest aerosoiizabie volume able to deliver effective dose of the compounds of the invention to the site of the infection. Additionally, the aerosolized formulation preferably does not impair negatively the functionality of the airways and does not cause undesirable side effects.
Aeroso!ization devices suitable for administration of aerosol formulations of the invention include, for example, jet, vibrating porous plate, ultrasonic nebulizers and energized dry powder inhalers, that are able to nebulize the formulation of the invention into aerosol particle size predominantly in the size range from 1 -5 pm. Predominantly in this application means that at least 70% but preferably more than 90% of all generated aerosol particles are 1 to 5 m range. A jet nebulizer works by air pressure to break a liquid solution into aerosol droplets. Vibrating porous plate nebulizers work by using a sonic vacuum produced b a rapidly vibrating porous plate to extrude a solvent droplet through a porous plate. An ultrasonic nebulizer works by a piezoelectric crystal that shears a liquid into small aerosol droplets. A variety of suitable devices are available, including, for example, AeroNeb and AeroDose vibrating porous plate nebulizers (AeroGen, inc., Sunnyvale, Calif.), Sidestream7 nebulizers (Medic-Aid Ltd., West Sussex, England), Pari LC7 and Pari LC Siar7 jet nebulizers (Pari Respiratory Equipment, Inc., Richmond, Va.), and Aerosonic (DeViibiss Medizinische Produkte (Deutsch!and) GmbH, Heiden, Germany) and UltraAire7 (Omron Healthcare, inc., Vernon Hills, ill.) ultrasonic nebulizers. Compounds of the invention may also be formulated for use as topical powders and sprays that can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propeilants such as chlorofluorohydrocarbons.
Transdermal patches have the added advantage of providing controi!ed delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
According to the methods of treatment of the present invention, bacterial infections are treated or prevented in a patient such as a human or lower mammal by administering to the patient a therapeutically effective amount of a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, in such amounts and for such time as is necessary to achieve the desired result. By a "therapeutically effective amount" of a compound of the invention is meant a sufficient amount of the compound to treat bacterial infections, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
The total daily dose of the compounds of this invention administered to a human or other mammal in single or in divided doses can be in amounts, for example, from 0.01 to 200 mg/kg body weight or more usually from 0.1 to 50 mg/kg body weight, in certain embodiments, the total daily dose administered to a human or other mammal is from 1.0 to 100 mg/kg body weight or from 5.0 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultip!es thereof to make up the daily dose. In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 15 g of the compound(s) of this invention per day in single or multiple doses, more usually, from 100 mg to 5 g, and even more usually from 250 mg to 1 g per day in single or multiple doses.
Methods of formulation are well known in the art and are disclosed, for example, in Remington: The Science and Practice of Pharmacy, Mack Publishing Company, Easton, Pa., 19th Edition (1995). Pharmaceutical compositions for use in thepresent invention can be in the form of sterile, non-pyrogenic liquid solutions or suspensions, coated capsules, suppositories, lyophilized powders, transdermal patches or other forms known in the art.
A "kit" as used in the instant application includes a container for containing the pharmaceutical compositions and may also include divided containers such as a divided bottle or a divided foil packet. The container can be in any conventional shape or form as known in the art that is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a resealabie bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. The container employed can depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in turn contained within a box.
An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff materia! is sealed against the plastic foil at the face of the foil that is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
It maybe desirable to provide a written memory aid, where the written memory aid is of the type containing information and/or instructions for the physician, pharmacist or other health care provider, or patient, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen that the tablets or capsules so specified should be ingested or a card that contains the same type of information. Another example of such a memory aid is a calendar printed on the card e.g., as follows "First Week, Monday, Tuesday,". . . etc . . . "Second Week, Monday, Tuesday, . . ." etc. Other variations of memor aids will be readily apparent. A "daily dose" can be a single tablet or capsule or several tablets or capsules to be taken on a given day. When the kit contains separate compositions, a daily dose of one or more compositions of the kit can consist of one tablet or capsule while a daily dose of another one or more compositions of the kit can consist of several tablets or capsules.
Another specific embodiment of a kit is a dispenser designed to dispense the daily doses one at a time in the order of their intended use. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter, that indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal that, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken. The kits of the present invention may also include, in addition to a compound of the present invention, one or more additional pharmaceutically active compounds. For example, the additional compound second antibacterial. The additional compounds may be administered in the same dosage form as the compound of the present invention or in a different dosage form. Likewise, the additional compounds can be administered at the same time as the compound of the present invention or at different times.
Compositions of the present compounds may also be used in combination with other known antibacterial agents of similar spectrum to (1 ) enhance treatment of severe gram- negative infections covered by the spectrum of this compound or (2) add coverage in severe infections in which multiple organisms are suspected in which another agent of a different spectrum may be required in addition to this compound. Potential agents include members of the aminoglycosides, peniciiiins, cephalosporins, fluoroquinolones, macrolides, glycopeptides, lipopeptides and oxazolidsnones. The treatment can involve administering a composition having both a compound of the present invention and a second antibacterial compound or
administration of a compound of the present inventive compounds followed by or preceded by administration of a second antibacterial agent.
The foregoing may be better understood by reference to the following examples, that are presented for illustration and not to limit the scope of the inventive concepts.
VI. EXAMPLES
A. Compound synthesis
The following are abbreviations used in the examples:
ACN: Acetonitriie
AcOH: Acetic acid
aq: Aqueous
BOC: tert-butoxycarbonyl
DCM: Dichloromethane
DIBAL-H: Diisobutyla!uminium hydride
DIPEA: Diisopropylethylamine DMAP: 4-Dimethylaminopyridine
DMF: N,N-Dimethylformamide
DMSO: Dimethyl sulfoxide
EA: Ethyl acetate
Et20: Diethy!ether
HATU: 2-(1 H-7-Azabenzotriazol-1-yi)-1 !1 ,3,3-tetramethyl uronium
hexafluorophosphate Methanaminium
HOBt: N-Hydroxybenzotriazoie
I PA: Isopropy! alcohol
-CPBA: meia-Chloroperoxybenzoic acid
MTBE: Methyl tert-butyl ether
NBS N-Bromosuccinimide
NMO: N-methylmorphoiine N-oxide
PCC: Pyridinium Chlorochromate
PE: Petroleum Ether
PE:EA: Petroleum Ether: Ethyl acetate
RP HPLC: Reverse phase high performance liquid chromatography
TBAF: Tetra-n-buty!ammonium fluoride
TEA: Triethyiamine
TFA: Trifluoroacetic acid
THF: Tetrah drofuran
TLC: Thin layer chromatography
Referring to the examples that follow, compounds of the present invention were characterized by high performance liquid chromatography (HPLC) using a Waters Millenium chromatography system with a 2690 Separation Module (Miiford, MA) or an Agilent 1 100 series chromatography system (Santa Clara, CA). The analytical columns were Phenomenex Luna C18(2) reversed phase, 10pm, 100 A, axia packed, 2, 0x50mm and the preparative columns were Phenomenex Luna C18(2) reversed phase, 10pm, 100 A, axia packed, 21.2x250 or 50x250mm. A gradient eiution was used, typically starting with 100% water and progressing to 100% acetonitriie over a varying lengths of time All solvents contained 0.1 % acetic acid (AcOH). Compounds were detected by ultraviolet light (UV) absorption at either 220 or 254 nm. in some instances, purity was assessed by thin layer chromatography (TLC) using glass or plastic backed silica gel plates, such as, for example, Baker-Flex Silica Gel 1 B2-F flexible sheets. TLC results were readily detected visually under ultraviolet light, or by employing well known iodine vapor and other various staining techniques
Mass spectrometry analysis was performed on one of three LCMS instruments: a Waters System. (Alliance HT HPLC and a icromass ZQ mass spectrometer; Column:
Eclipse XDB-C-18, 2.1 x50 mm; solvent system: 5-95% (or 35-95%, or 65-95% or 95-95%) acetonitriie in water with 0.05%TFA; flow rate 0.8 mL/min; molecular weight range 500-1500; cone Voltage 20 V; column temperature 40° C.) or a Hewlett Packard System (Series 1 100 HPLC; Column: Eclipse XDB-C18, 2.1 x50 mm; solvent system: 1-95% acetonitriie in water with 0.05% TFA; flow rate 0.4 mL/min; molecular weight range 150-850; cone Voltage 50 V; column temperature 30° C). or an Agilent System (Series 1 100 HPLC; Column: Waters Sunfire C18 reversed phase, 2.5 m, 100 A, 2.1x50mm; solvent system: 1-95% acetonitriie in water with 0.1 % TFA; flow rate 0.5 mL/min; molecular weight range 150-1500; cone Voltage 70 V; column temperature 35° C).
GCMS analysis was performed on a Hewlett Packard instrument (HP6890 Series gas chromatograph with a Mass Selective Detector 5973; injector volume: 1 μί; initial column temperature: 50° C; final column temperature: 250C; ramp time: 20 minutes; gas flow rate: 1 mL/min; column: 5% phenyl methyl siloxane, Model #HP 190915-443, dimensions: 30.0 mx25 mx0.25 m).
Nuclear magnetic resonance (NMR) analysis was performed with a Varian 300 MHz NMR (Palo Alto, Calif,), and a Varian Unity Enova 400 MHz NMR spectrometer (Palo Alto, Calif.). The spectral reference was either TMS or the known chemical shift of the solvent. Some compound samples were run at elevated temperatures (e.g. 75° C.) to promote increased sample solubility. Procedure 1 (C~C coupling reaction using CuC!-Cadiot): Hydroxylamine hydrochloride (0.235 mmo!, 0.06 eq) and CuCI (0.08, 0.02 eq) were dissolved in 23% aqueous n-butylamine (1 mL) and the resulting solution was cooled to 0°C. A solution of the alkyne (4.3 mmol, 1.1 eq) in 23% aqueous n-buty!amine (2 mL) was then added. The bromo-aikyne (3.92 mmo!) and hydroxylamine hydrochloride (0.235 mmoi, 0.06 eq) were dissolved in 23% aqueous n-butylamine (2 mL) and THF (3 mL), and they were slowly added to the reaction mixture. The reaction was stirred for 1 hr, followed by quenching with EtOAc and water. The organic layer was separated and washed with brine, dried over Na2S04, filtered and concentrated under reduced pressure to yield the desired coupled product.
Procedure 2 (Boc deprotection using TFA): To the Boc-protected compound (3.39 mmoi) at 0°C was added a TFA:DCM solution (9 mL, 2: 1 ) and the reaction was stirred for 1 hour. The reaction was concentrated under reduced pressure to yield a crude residue, which was azeotroped with I PA twice to yield the desired deprotected product.
Procedure 3 (Hydroxa ate formation): To a stirring solution of the ester (3.38 mmol) in IPA (4 mL) at 0°C was slowly added 50% aqueous hydroxylamine (40 eq), and the reaction was stirred overnight. The reaction was quenched with AcOH (0.121 mo!, 20 eq) or until the pH is 6. The volatiies were removed under reduced pressure, and the resulting solution was purified by RP HPLC.
Procedure 4A (formation of srnine in reductive a snation to NH e): To a stirred solution of the amine (2.37 g, 7.20 mmoi) in DMF (14.39 mL) was added DIPEA (1.885 mL, 10.79 mmol) followed by formaldehyde (37% in water) (1.071 mL, 14.39 mmol) and the reaction was stirred for 2 hours. The excess aidehyde was quenched with n-butylamine (30% in water) (2.63 g, 10.79 mmol) and stirred for one hour. The reaction mixture was diluted with water, and iyophiiized to yield the desired imine.
Procedure 4B (reduction to amine in reductive amination to NHMe): To a stirring solution of the imine (3.96 g, 1 1.60 mmoi) in THF (23.17 mL) and MeOH (2.439 mL) was added acetic acid (1.328 mL, 23.20 mmol) followed by sodium cyanoborohydride (10.94 g, 174 mmol) and the reaction was stirred for 1 hour. The reaction mixture was diluted with wafer (7 mL) and concentrated under reduced pressure to yield the amine. {S)-meihyl! 2-(4-{bromoethyn S)ben2:amido)-3-{(terf~butoxycarbony1)amino)- 3-methy!buianoaie {!NT-1}:
Figure imgf000042_0001
Ethyny!trimethylsilane (82.4 g, 0.84 mol, 1.2 equiv) was added dropwise over 10 min under a nitrogen atmosphere to a solution of methyl 4-bromobenzoate (150 g, 0.7 mol 1.0 equiv), PdCI2 (PPh3)2 (15 g, 0.021 mol, 0.03 equiv) and Cul (13 g, 0.068 mol, 0.1 equiv) in TEA (1.5 L). The reaction was stired at 90°C for 30 minutes, whereupon LCMS showed complete consumption of methyl 4-bromobenzoate. The reaction mixture was filtered and the filter cake was washed with EtOAc (5 x 500 mL). The filtrate was concentrated under reduced pressure to give a residue, which was distilled under reduced pressure to yield methyl 4-({trimethylsilyl) ethynyi) benzoate (!NT-1.2) as an off-white solid (156 g, 96%).
To a solution of methyl 4-((trimethylsiIyI) ethynyi) benzoate (156 g, 0.67 mol, 1.0 equiv) in methanol (800 mL) was added dropwise KOH/methanol (18 g/250 mL) keeping the temperature below 10°C, the mixture was allowed to warm to room temperature for 5 min. The reaction mixture was neutralized with 2 HCI. The reaction suspension was filtered to collect methyl 4-ethynyibenzoate (!NT-1 ,3) as a white solid (97 g, 90%). MS: m/z calcd for Ci0H8Q2 160.0, found [M+H]* 161.
Figure imgf000042_0002
To a solution of methyl 4-ethynylbenzoate (50 g, 0.3125 mol, 1.0 equiv) in acetone (750 mL) was added AgN03 (5 g, 29.7 mmol 0.095 equiv) and the reaction mixture was stirred for 1 hr. NBS (61.2 g, 0.344 mol, 1.1 equiv) was added and the reaction mixture was stirred at room temperature for 20 hr, filtered and concentrated under reduced pressure. The residue was diluted in EA, and washed with iced 20% H2S04. The EA layer was washed with water and brine, dried (Na2S04), and filtered. The filtrate was concentrated under reduced pressure to give a residue, which was recrystallized from MeOH (1 mL/4 g) to yield methyl 4- (bromoethynyl) benzoate (INT-1.4) as an off-yei!ow solid (67 g, 90%). 'H NMR (400 MHz, CDCI3) δ 7.98 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.8 Hz, 2H), 3.92 (s, 3H).
To a solution of methyl 4-(bromoethynyl) benzoate (67 g, 280 mmol, 1.0 equiv) in CH3OH/THF/H20=5/5/1 (1 100 mL) was added NaOH (44.84 g, 4.0 equiv) and the reaction mixture was stirred at 25°C for 3 hr. The volati!es were removed under reduced pressure and the resulting solution was neutralized with 1 N HCi to pH 3-5. 4~(bromoethynyl) benzoic acid (iNT-1.5) was collected by filtration. The filter cake was washed with water, and dried in an oven at 50°C for 5 hr (61g, 96%).
Figure imgf000043_0001
(S)-methyl 2-amino-3-(iert-butoxycarbonylamino)-3-methylbutanoate oxalate (9.34 g, 27.8 mmol) (synthesized as described in WO 2008/154642 at pages 240-6) was suspended in ethyl acetate (80 mL) and water (80 mL). While cooling in an ice bath, potassium carbonate (7.67 g, 55.5 mmol) was added and the reaction was stirred for 10 min. The aqueous layer was separated and extracted with ethyl acetate (2 x 75 mL) and the combined organic extracts were dried over sodium sulfate, and concentrated under reduced pressure to give a clear oil. To a stirring solution of 4-(bromoethynyl)benzoic acid (5.68 g, 25.2 mmol) in D F (45 mL) at 0°C was added a solution of (S)-methyl 2-amino-3-(fert-butoxycarbonylamino)-3- methyibutanoate in DMF (40 mL), followed by HATU (1 1.52 g, 30.3 mmol) and A -ethy!-W- isopropylpropan-2-amine (13.19 mL, 76 mmol) and the reaction was stirred for two hours with warming to room temperature. The reaction mixture was poured into water (300 mL) and was extracted with ethyl acetate (3 x 200 mL), The combined extracts were washed with saturated NaCI, dried over sodium sulfate and concentrated under reduced pressure to yield a crude, which was purified by flash chromatography (silica ge!/20-60% EtOAc/Hexanes) to yield the desired product, (S)-methyl 2-(4-(biOmoethynyl)benzamido)-3-((te/f-butoxycarbonyi)amino)-3- methylbutanoate {INT-1), (9.24g) as a white foam: TLC ethyl acetate/hexanes 1 : 1 Rf 0.5; MS: m/z calcd for CaoHzsBr^Os 452.09, found [M-Boc+H 353.1.
Figure imgf000044_0001
ΜΊ-2 was generated from !M!T-1 according to Procedure 2,
{S)-methy! 3~({ferf-butoxycarbonyI)amino)~2~(4-iodobenzam!do)-3~ methy!butanoate (f T-3):
Figure imgf000044_0002
Figure imgf000044_0003
Figure imgf000045_0001
To a stirring solution of iodobenzoic acid (8.62 g, 34.8 mmol) in acetonitrile (69.5 mL) was added HATU (26.4 g, 69.5 mmol), followed by TEA (4.84 mL, 34.8 mmol). INT-1 ,6 (1 1.69 g, 34.8 mmol) was then added and the reaction was stirred for 1 hr. Additional TEA (1 eq) was added and the reaction was stirred for 2.5 hr. The mixture was concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/10- 50% EtOAc in hexanes) to yield \HJ-Z (1 1 .7 g, 70.7%).
Bestmann reagent:
Figure imgf000045_0002
To a solution of dimethyl 2-oxopropyiphosphonate (65.3 g, 331 mmol) in acetonitrile (150 mL) at 0°C was added K2C03 (45.8 g, 331 mmol) followed by the dropwise addition of 4-methy!benzenesulfony! azide (50 g, 300 mmol) and the reaction mixture was stirred overnight. It was diluted with EA (500 mL), washed with water (3 x 300 mL), brine (3 x 100 mL), dried (Na2S04), and filtered. The filtrate was concentrated under reduced pressure to a residue, which was dissolved in Et20 (300 mL) and recrystailized with DCM and PE to remove 4-methylbenzenesulfonamide as a white solid byproduct several times. The remaining solution was concentrated under reduced pressure to give the Bestmann reagent as a yellow oil (43 g, 75%). H NMR (400 MHz, CDC!3) δ 2.28 (s, 3 H), 3.85 (d, J = 8.0 Hz, 6 H). G. Roth, B. Liepoid, S. u!!er and H. J. Bestmann, Synthesis 2004, 1 , 59-62.
1. {S}-N-(3-8mino-1-(hydroxyaminQ}~3-methyi-1-Qxobutan-2^!)-4- (azetidin-S-y!tuta-l^-diynyljbenzamide (1)
Figure imgf000046_0001
ferf-butyl 3-(hydroxymethyl)a∑etidine-1 -carboxy!ate (1.2)
Figure imgf000046_0002
To a stirring solution of BH THF (285 mL) at -78°C was added 1-(ferf- butoxycarbony!)azetidine-3-carboxy!ic acid (22.53 g, 1 12 mmol) in portions under a N2 atmosphere, and the reaction was stirred for 30 min. The reaction was then warmed to rt and stirred for 2 hr. The reaction mixture was poured into ice (500 mL), and extracted with EA (3 x 300 mL). The combined organic layers were washed with brine (3 x 100 mL), dried (Na2S04), and filtered. The filtrate was concentrated under reduced pressure to yield compound 1.2 as clear oil (20.9 g, 100%). MS: rn/z calcd for C9H17N03 187.1 , found [M-H] 186.1. ferf-butyl 3-formyl!azet!dme-1-carb0xy!ate (1.3) Reagent MW Eqiv. Mmo! Amount
Compound 1.2 187.24 1.0 1 12 20,96 g
!BX 280.02 2.0 224 62.69 g
EA 500 mL
To a stirring solution of ferf-butyi 3-(hydroxymethyl)azetidine-1-carboxylate (20.96 g, 1 12 mmoi) in EA (500 mL) was added IBX (62.69 g, 224 mmoi) and the reaction was refluxed overnight. The reaction was cooled to rt, PE (500 mL) was added and the reaction mixture was filtered. The filtrate was concentrated under reduced pressure to give compound 1.3 as yellow oii product (20.56 g, 99%). H NMR (400 MHz, CDCI3) δ 1.44 (s, 9 H), 3.32-3.40 (m, 1 H), 4.07-4.14 (m, 4 H), 9.85 (d, J = 2.0 Hz, 3 H). ierf-buty S-eihyny azetsdme-l -earboxyJaie (1.4)
Figure imgf000047_0001
Figure imgf000047_0002
To a stirring solution of aldehyde 1.3 (5 g, 27 mmoi) in MeOH (70 mL) at 0°C was added the Bestmann reagent (6 g, 31.2 mmoi), followed by potassium carbonate (14.92 g, 108 mmoi) and the reaction was stirred for 3 hr. The reaction mixture was then diluted with EtOAc (150 mL), filtered and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica ge!/ 0-100% EtOAc in hexanes) to yield compound 1.4 (4.6 g, 94%). Ή NMR (400 MHz, DMSO-d6) δ 1.34 (s, 9 H), 3.22-3,23 (m, 1 H), 3.34-3.39 (m, 1 H), 3.68 (t, J = 6.8, 2 H), 4.04 (t, J = 8.4 Hz, 2 H).
3-{{4-(3~ammo-1 -methoxy-3-methy!-1 -oxobutan-2-y carbamoy!)pheny!)buta- :etsdine-1-carboxy§aie 2,2,2-tnfiuoroac
Figure imgf000048_0001
Figure imgf000048_0002
To a stirring solution of SNT-1 (12,5 g, 27.6 mrnol) in DCM (70 mL) was added TFA (80 mL) and the reaction was stirred for 10 min. The mixture was concentrated under reduced pressure from DCM (150 mL) twice to yield which was dissolved in THF (25 ml).
TEA (33.3 mL) was added followed by a solution of compound 1.4 (5 g, 27.6 mrnol) in THF (75 mL) and PdC!2(PPh3)2 (0.48 g) and Cul (0,26 g), and the reaction was heated to 75°C for 20 min. The reaction mixture was cooled to 0°C, filtered and washed with THF. The filtrate was concentrated under reduced pressure to give a crude, which was purified by RP HPLC (6", 0.1 % TFA in water/ACN) to yield compound 1.5 (6.5 g, 42%). MS: m/z calcd for sHai NaQs 435.23, found [IVHHf 454.2.
(S)~methyl 3-amino~2-{4-(azet!dsn~3~y!buta~1 ,3~dsynyI)ben amido)-3-rnethyibutanoate bss{2,2,2-trif!uoroacetate) (1.6)
Figure imgf000049_0001
To a stirring solution of compound 1.5 (250 mg, 0.44 mmol) in DCM (2 mL) was added TFA (2 mL) and the reaction was stirred for 5 min. Reaction was concentrated under reduced pressure from DCM twice to yield compound 1.6 (370 mg), which was carried through to the next step without further purification. MS: rn/z calcd for C20H23 3O3 353.17, found [M+H 354.1 .
{S)-/^-(3~amsno-1 -(hydroxyamino)~3~m
diyny!)benzamide (1)
To a stirring solution of compound 1.6 (370 mg) in I PA (1 mL) was added hydroxylamine (50% aq, 1 mL) and the reaction was stirred at 0°C overnight. The reaction mixture was acidified with TFA, diluted with water, and purified by RP HPLC (1 ", 0.1 % TFA in water/ACN) to yield compound 1 (86 mg, 21 .6%). MS: rn/z calcd for C19H22N4O3 354.17, found [M+H]+ 355.1. 4-{{1-(terf~butoxycarbony!)azet!dsn~3~y!)buta~1 ,3-diyn~1-y!)benzo!C acid (2.1)
Figure imgf000050_0001
Figure imgf000050_0002
To a stirring solution of compound 1.4 (10.1 1 g, 55.8 mmo!) in 30% aqueous n- butylamine (29.6 ml) at 0°C were added copper chloride (0.1 10 g, 1.1 16 mmol) and
hydroxy!amine hydrochloride (0.233 g, 3.35 mmol). In a separate flask, to a stirring solution of
4-(bromoethyny!)benzoic acid (12,55 g, 55.8 mmol) in 30% aqueous n-butylamine (63.4 ml) was added hydroxylamine hydrochloride (0.233 g, 3.35 mmol) and this solution was then added dropwise to the solution containing compoud 1.4, and the reaction was stirred for 1 hr. The reaction mixture was diluted with MeTHF (400 mL), and acidified to pH 1 with concentrated HCi.
The resulting solution was filtered through Celite, and the layers were separated. The aqueous layer was extracted with MeTHF (200 mL), and the combined organic layers were washed with 2M HCI (2 x 20 mL), water (200 mL), brine (200 mL), dried over Na2SC>4, filtered, and concentrated under reduced pressure to yield compound 2.1 as a white solid (16.6 g, 91 %), which was carried through to the next step without further purification. MS: m/z caicd for C19H19N04 325.13, found [M+Na]+ 348.2,
4-{a2etid!n-3-yibuta-1 ,3-d!yn-1-yi)ben2:o!C add (2,2)
Figure imgf000051_0001
To a stirring solution of compound 2.1 (3 g, 9.22 mmol) in DCM (30.7 ml) was added TFA (61.5 ml) and the reaction was stirred for 1 hr. The reaction was azeotroped with DCM (3 x 75 mL) and then concentrated under reduced pressure to yield compound 2.2 as a white solid, which was carried through to the next step without further purification. MS: m/z calcd for Ci4Hii 02 225.1 , found [M+Hf 226.0.
4~((1~acetyla∑etidin~3~yf)buta-1,3~d!yn~1~yf)benzoic acid (2,3)
Figure imgf000051_0002
Figure imgf000051_0003
To a stirring solution of compound 2.2 (2 g, 8.88 mmol) in water (22.2 mL) and dioxane (22.2 mL) were added Ac20 (1.089 ml, 1 1.54 mmol) and NMO (1.30 mi, 10.21 mmol) and the reaction was stirred for 18 hr. The reaction was filtered and washed with water:dioxane (1 : 1 , 2 x 30 mL). The solids were then dried under reduced pressure to yield compound 2.3 a white solid, which was carried through to the next step without further purification.
{5)-methy 2-{4-C(1-aceiy!a;£etidin-^
methy!butarsoate (2.4)
Figure imgf000052_0001
Figure imgf000052_0002
To a stirring solution of methyl 2-amino-3-hydroxy-3-methylbutanoate (2.4, synthesized as described in WO 2008/154642 at page 247 ei seq) (2.065 g, 14.03 mmol) in
DMF (76 mL) was added K2C03 (5.82 g, 42.1 mmol) and the reaction was stirred for 1 hr. Then compound 2.3 (2.5 g, 9.35 mmol) and DI PEA (2.45 mi, 14.03 mmol) were added, followed by
HATU (3.91 g, 10.29 mmoi) and the reaction was stirred for 3 hr. The reaction was diluted with ethyl acetate, washed with 1 M citric acid, aHC03 and brine, dried over a2S04< filtered, and concentrated under reduced pressure to yield compound 2.5 (2.18 g, 58.8%) as a brown oil. MS: m/z calcd for C22H24N2Os 396,2, found [M+H]+ 397.2. (S)-4-{(1 -acetyl! a£etidin-3-y!)buta-1 ,3~dsyn-1 -y!)- /-{3-hydrox -1 -(hydroxyamsno)-3-methy!- 1 -oxobutan-2-yi}benzamide (2a) and (S)-4-((azetidin-3-yl)buta-1 ,3-diyn-1 -yl)-Af-(3-hydroxy- 1 -(hydroxyamsno)-3-methyM -oxobutan-2-yi)benz:am!de (2b)
Figure imgf000053_0001
To a stirring solution of compound 2,5 (3 g, 7.57 mmoi) in IPA (32.5 mL) was added hydroxy!amine (50% solution in water, 30.0 mL, 454 mmol) and the reaction was stirred for 18 hr. The reaction mixture was then concentrated under reduced pressure to a thick oil, which was diluted with AcOH (70 mL) and purified by RP HPLC (6", 0.1 % AcOH in water/ACN) to yield compound 2a (0.35 g, 1 1.2%) MS: m/z calcd for C21 H23 3O5 397.16, found [M+H 398.3 and 2b (0.51 g) MS: m/z calcd for C19H21 N3O4 355.15, found [M+Hf 356.3
3. (S)-4-{{1 ormy!azeiidin-3-y!)buta-1,3-diyn-1-y!)-N-{3-hydroxy-1- (hydroxya ino}-3- ethyS-1-Qxobutan-2-yi}benzamide (3)
Figure imgf000053_0002
Figure imgf000054_0001
To a stirring solution of compound 2b (536 mg, 1.14 mmol) in DMF (4 ml) at 0°C was added DIPEA (0.24 ml, 1.37 mmol), followed by 2,2,2-trifluoroethyi formate (0.1 1 ml, 114 mmol), and the reaction was stirred for 75 min. The reaction mixture was acidified with AcOH (0.098 ml, 1.71 mmol) and purified by RP HPLC (2", 0.1 % AcOH in ACN/water) to yield (S)-4- ((1-formyiazetidin-3-yi)buta-1 !3-diyn-1-y1)-W-(3-hydroxy-1-(hydroxyamjno)-3-methyi-1-oxobutan- 2-yi)benzamide (412.6 mg, 1.08 mmol, 94%). MS: m/z caicd for C> >-N ,Ob 383.1 , found [M+H]+ 384.1.
4, {S ^l-^-aminoacety azetidin-S-y buia-l S-diyn-l-y -N-fS- hydrQxy-1-(hydroxyamino}-3-methy!-1-oxobiitan-2-y!}benzamide (4)
(S)-(9H-fluoren-9-y m© hyl (2-{3-{{4-({3-hydroxy-1 -{hydroxyamino)-3-meihyl-1 -oxobutan-2- yl)carbamoyl)phenyl)buta-1 ,3-d!y'"i-
Figure imgf000054_0002
-yl)-2-oxoeihy!)carbamaie (4.1)
Figure imgf000054_0003
Figure imgf000055_0001
To a stirring solution of 2-((({9H-fluoren-9-yl)methoxy)carbonyl)amino)acetic acid (6.97 mg, 0.023 mrnol) and HATU (8.10 mg, 0.021 mrnol) in DMF (0.2 mL) was added DiPEA (9.30 μΙ_, 0.053 mrnol), and the resulting solution was added to compound 2b (10 mg, 0.021 mrnol), and the reaction was stirred overnight. The crude solution containing 4.1 was carried through to the next step. MS: m/z calcd for C36H34N4O7 634.24, found [M+H]+ 635.4.
(S)-4-((1 -{2-aminoaeety!}azet!d!n~3~ l}buta~1 ,3-diyn-1 -yl}-A ~(3~hydroxy-1 -(hydroxyamino)- 3-rnethyI-1 -oxobutan-2-yl!)benzamide (4)
Figure imgf000055_0002
To a stirring solution of compound 4.1 (13.52 mg, 0.021 mrnol) in DMF (0.2 mL) was added piperidine (10.52 pL, 0.107 mrnol) and the reaction was stirred for 30 min. The reaction mixture was acidified with AcOH (8.54 pL, 0.149 mrnol) and purified by RPHPLC (1 ", 0.1 %TFA in water /ACN) to yield (S)-4-((1-(2-aminoacetyl)azetidin-3-yl)buta-1 ,3-diyn-1-yl)-W-(3- hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-yi)benzamide (0.0046 g, 0.01 1 mrnol, 52.4%). MS: m/z calcd for C21 H24N4O5 412.2, found [M+H]+ 413.3. 5. 4-{(1~{2~amino~3~hydmxypropanoy!)azetidiii~3~y!)buta-1,3~diyii~1~y!)- N~({S}~3~hydroxy~1-(hydroxyamsno}-3-methyM~oxobutan~2^!}ben {5} teri-butyl-(3-hydroxy-1 -(3-((4-(((S)-3-hydroxy-1 -(hydroxyamino)-3-methy 1 -oxobistan-2- yi)carbamoy!)phenyI)buta-1 ,3~diyn~1 ~yf)a∑etidin~1 ~yI)-1 -oxopropan~2~yf)carbarnate (5.1)
Figure imgf000056_0001
Figure imgf000056_0002
To a stirring solution of 2-((iert-butoxycarbony!)amino)-3-hydroxypropanoic acid (17.34 mg, 0.084 mmo!) and HATU (32.1 mg, 0.084 mmoi) in DCM (0.2 mL) was added DIPEA (0.025 ml, 0.146 mmoi) and the resulting solution was added to compound 2b (19.5 mg, 0.047 mmoi) and the reaction was stirred for 45 min. Additional HATU, Boc-Ser and DIPEA (half the original amounts) in DMF (0.075 mL) were added and the reaction was stirred for another 45 min. Piperidine (0.023 ml, 0.235 mmo!) was added followed by 40% methylamine (100 μί). Solvent evaporation under reduced pressure gave compound 5.1 , which was carried through to the next step without further purification. MS: m/z calcd for C27H34 4O8 542.2, found [M+Na]+ 565.3. 4~{{1-(2-ammo-3-hydrQxypropanoy^a;^
(hydroxyamino)-3-methyi-1-oxobutan-2-y!)benz:amide (5)
Figure imgf000057_0001
To a stirring solution of compound 5.1 (47 mg, 0.047 mmol) in DCM (0.2 mL) was added TFA (0.20 mL) and the reaction was stirred for 30 min. The reaction mixture was concentrated under reduced pressure, and purified by RP HPLC (1 " column, 0.1 % TFA in water/ACN) to yield 4-((1-(2-amino-3-hydroxypropanoyl)azetidin-3-y!)buta-1 ,3-diyn-1 -yl)-A -((S)- 3-hydroxy-1-(hydroxyarnino)-3-methyl-1-oxobutan-2-y!)benzamide (0.0072 g, 0.013 mmol, 27.7%). MS: m/z caicd for C22H26N406 442.2, found [M+H]+ 443.3.
6. {S)~N~{3~hydroxy~1~(hydroxyamino)~3~methyi-1-oxobutan-2~yl)~4~{{1~ {2~hydroxyethy!}azetidsn~3~yl}buta~1,3~diyn~1~yl}benza sde (6)
Figure imgf000057_0002
Figure imgf000057_0003
Figure imgf000058_0001
To a stirring solution of compound 2b (27.7 mg, 0.067 mmo!) in THF (0.2 mL) was added DIPEA (10.48 pL, 0.060 mmol) foiiowed by methanol (0.1 mL). Next, 2-({tert~ butyldimethylsilyl)oxy)acetaldehyde (0.038 ml, 0.200 mmol) was added foiiowed by sodium triacetoxyborohydride and the reaction was stirred for 20 min. Methanol (0.3 mL) was added followed by water (0.3 mL) and TFA (0.3 mL, 3.89 mmol) and the reaction was stirred for 90 min. The reaction mixture was concentrated under reduced pressure, diluted with water and DMF (0.1 mL) and purified by RP HPLC (0.1 % TFA in water/ACN) to yield (S)-/V-(3~hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((1-(2-hydroxyethyl)azetidin-3-yi)buta- yhbenzamide (1 1.6 mg, 0.023 mmol, 33.8%). MS: m/z caicd for C21 H25 305 399.2, found [M+H]+ 400.2.
7. {S)~N~(3~hydmxy-1-(hydroxya !no)~3~ ethyl-1'Oxobutan'2^!)~4~{{1- methyiazet!din-3-y!)buta- 1,3-diyn- 1 -y!)benza ide {7}
Figure imgf000058_0002
Figure imgf000059_0001
To a stirring solution of compound 2b (22.7 mg, 0.055 mmol) in THF (0.2 mL) was added DIPEA (8.59 μΙ_, 0.049 mmol) followed by MeOH (0.1 ml), formaldehyde (0.012 ml, 0.164 mmol) and molecular sieves. After 5 min sodium triacetoxyborohydride (57.9 mg, 0.273 mmol) was added and the reaction was stirred for 25 min. The reaction mixture was concentrated under reduced pressure to give a residue, which was dissolved in water, acidified with AcOH and purified by RP HPLC (1 ", 0.1 % TFA in ACN/water) to yield (S)-A/-(3-hydroxy-1- (hydroxyam!no)-3-methyl-1-oxobutarv2-yl)-4-((1-methyiazetidin-3-yl)buta-1 l3-diyn-1- yl)benzamide (6, 1 mg, 0.013 mmol, 23.1 %). MS: m z calcd for C20H23N3O4 369,2, found [M+H]+ 370.2.
8, {S)-N-{3-amsno-1-{hydroxyamino}-3-methyl-1-Qxobutan-2-yi}-4-((1- (oxetan~3~yl}azetidin~3~yl}biita~1,3~diyn~1~y!}benzamide (8)
Figure imgf000060_0001
{S)-methy! 2-{4-{a∞iidin-3-y!buia-1 ,3-diyn-1 -y )ben^amido)~3~{(ferf- butoxycarbony am5no)-3-methy!butanoaie (8.2)
Figure imgf000060_0002
To a stirring solution of compound 1.4 (2 g, 11.04 mmol) in DCM (20 mL) at 0°C was added TFA (20 mL) and the reaction was warmed to rt and stirred for 1 hr. The reaction mixture was concentrated under reduced pressure to yield compound 8.1 , which was carried through to the next step. Coupling of compound 8.1 to !NT-1 was carried out according to procedure 1 to yield compound 8,2, which was carried through to the next step. MS: m/z calcd for C25H3iN305 453.2, found [M+Hf 454.3.
(5)-i¥-(3-amino-1-(hydr0xyam!no)-3-me^^
yi)buia~1 ,3-diyn-l -yi)benzamide (8)
Figure imgf000061_0001
To a stirring solution of (S)-methyl 2-{4-(azetidin-3-yibuta-1 !3-diyn-1- yI)benzamido)-3-((tert-butoxycarbony!)amino)-3-methyIbutanoate (3 g, 6.61 mmol) in MeOH (20 mL) was added oxetan-3-one (0.6 g, 8,33 mmol) followed by sodium cyanoborohydrate (0.523 g, 8.33 mmol) and the reaction was stirred. Additional NaCNBH3 (200 mg), and oxetan-3-one (100 g) were added and the reaction was stirred for 18 hr. Excess MeOH was removed under reduced pressure, water (20 mL) was added and the reaction was extracted with EA (2 x 200 mL). The combined organic layers were dried over Na2S04 and concentrated under reduced pressure to yield compound 8.3 (3.8 g) (MS: m/z calcd for C28H35 306 509.2, found [M+Hf 510.3), which was dissolved in DCM (20 mL) and TFA (6.2 mL) and stirred for 2 hr. Solvent removal under reduced pressure gave compound 8.4 as a TFA salt, which was neutralized with aqueous saturated K2C03 (pH 9) and extracted with EA (3 x 100 mL), dried over Na2S0 , filtered and concentrated under reduced pressure to yield compound 8.4 (3.2 g) MS: m/z calcd for C23H27 3O4 409.2, found [M+Hj+ 410.2). To a stirring solution of compound 8.4 in I PA (10 mL) was added hydroxylamine (50% aq, 17 mL) and the reaction was stirred until deemed complete by LCMS. IPA was removed under reduced pressure, and the mixture was acidified with AcOH and purified by RP HPLC (2" column, 0.1 % AcOH in water/ACN) to yield (S)-/V-(3- amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yi)-4-((1-(oxetan-3-yl)azetidin-3-yi)buta-1 ,3- diyn-1-yl)benzamide (70.2 mg, 0.136 mmoi, 12.8 %). MS: m/z calcd for C22H26 404 410.2, found [M+H]+ 41 1.3.
9. N-((S)-3-hydroxy-1-(hydroxya ino)-3- ethyl-1-oxohutan-2-y!)-4-(5-
{ ( 2R, 3S}-3-hydrQxypyrrQiidin-2-y!)penta- 1, 3-d iyn- 1 -y!jbenzamide ( 9}
(S)~methyl 2-(4~{bromoethynyI)ben amido)-3-hydroxy~3~methylbutanoate (9.1)
Figure imgf000062_0001
Figure imgf000062_0002
To a stirring solution of (f?)-methyi 2-amino-3-hydroxy-3-methylbutanoate, HCi
(2.441 g , 13.29 mmol) in ACN (25 mL) was added INT-1.5 (3 g, 13.33 mmol) followed by TEA
(5.56 mL, 39.9 mmol). HATU (6.06 g, 15.95 mmol) was added portionwise over 20 minutes, and the reaction was stirred for 3 hours. The reaction was concentrated under reduced pressure to a residue, which was diluted with ethyl acetate (30 mL), and solids were removed by filtration. The filtrate was washed with 1 M citric acid (2 x 30 mL), saturated aqueous θΗΟΟ
(4 x 30 mL), 1 M NaOH (30 mL), and brine (30 mL). The organic layer was concentrated under reduced pressure to yield compound 9,1 (4.49 g, 95%) as a brown solid, which was carried through to the next step without further purification. MS: m/z calcd for C15H16BrN0 353.03 & 355.02, found [M+H]+ 354.0 & 356.0. eth S (3S)-3-hydroxy-L-pro!inate hydrochloride (9.3)
Figure imgf000063_0001
To a stirring solution of acetyl chloride (7.6 mL, 1 10 mmol) in methanol (70 mL) at 0°C was added (3S)-3-hydroxy-L-pro!ine (9.2, 10.0 g, 76.3 mmol) and the reaction was warmed to ambient temperature and was then heated at 65 °C for 6 hr. The reaction was cooled to ambient temperature and was diluted with ether (150 mL) and a white precipitate formed. The white precipitate was collected by filtration and the solids were washed with Et20 (2 x 25 mL) and dried overnight under reduced pressure to afford compound 9.3 (12.6 g, 91 %) as a white soiid. 1H NMR (400 MHz, DMSO-d6) δϋ 0.87 (br. s., 2 H), 5.93 (br. s., 1 H), 4.50 (br. s. , 1 H), 4.18 (d, J = 2.07 Hz, 1 H), 3.77 (s, 3 H), 3.35 (m, 2 H), 1 .94 (m, 2 H).
1 ~terf~buiyi 2~methy! (2$, SSJ-S-hydroxypyrrolidine-i ^-dicarboxyiate (9.4) r-'\ !siaHCO, r-
^~~~ HCI Bo¾0 HCr ""{
9.3 8.4
To a stirring solution of methyl (3S)-3-hydroxy-L-pro!inate hydrochloride (9.3, 12.62 g, 69.4 mmoi) in tetrahydrofu an (500 mL) and water (20 mL) at 0°C was added sodium bicarbonate (14.6 g, 0.174 mol) followed by the dropwise addition of a solution of di-feri- buty!dicarbonate (22.7 g, 0.104 rno!) in tetrahydrofuran (75 mL), and the reaction was stirred at ambient temperature overnight. The reaction was concentrated under reduced pressure and the resulting aqueous layer was extracted with ethyl acetate (3 x 50 mL), The combined organic layers were washed with H20 and brine, dried over MgS04, filtered and concentrated under reduced pressure to afford a crude product, which was purified by flash chromatography (silica gel/ 0 to 30% ethyl acetate in DC ) to yield compound 9.4 (16.6 g, 97%). H NMR (400 MHz, CDCIs) 50 4.48 {m, 1 H), 4.31 (ss 0,40 H, CH), 4.19 (s, 0.60 H,CH), 3.76 (s, 3 H), 3.64 (m, 2 H), 2.16 (m, 1 H), 2.12 (m, 1 H), 1.93 (m, 1 H), 1.49 (s, 4 H), 1.43 (s, 5 H).
1 -terf-Butyl 2-methy! {2S,3S)~3~{[ferf-butyl(d!methyf)siIyi]oxy}pyrro dine-1 ,2~dicarboxy!ate (9.5)
HCT ~i imidazois TBSO* ^
^O e DMF ^^~QUe
9.4 9.5
To a stirring solution of 1 -tert-Butyl 2-methy! (2S,3S)-3-hydroxypyrroiidine-1 ,2~ dicarboxylate (9.4, 16.6 g, 67.7 mmoi) in DMF (100 mL) was added 1 H-lmidazoie (6.91 g, 102 mmoi) followed by ferf-buty!dimethylsilyl chloride (12.2 g, 81.2 mmoi) and the reaction was stirred for 2.5 hr. Additional 1 H-imidazoie (1.4 g, 20.0 mmoi) and ferf-butyldimethyisilyl chloride (1.5 g, 10.0 mmoi) were added and the reaction was stirred for an additional hour and then quenched by the addition of water. The organic product was extracted with diethyl ether (2 x 200 mL) and the combined organic layers were washed with water (2 x 100 mL), saturated sodium bicarbonate (1 x 100 rnL), and brine (1 x 100 mL) and then dried over gS04. The filtered product was concentrated under reduced pressure to afford a clear oil, which was purified by flash chromatography (silica gel/ 0-10% ethyl acetate in hexanes) to yield 9.5 (23.4 g, 96%). 1 H NMR (400 MHz, CDCI3) δ 4.25 (m, 1 H), 4.08 (s, 0.4 H), 3.94 (d, J = 2.28 Hz, 0.6 H), 3.64 (s, 1 H, CH3), 3.63 (s, 2 H, CH3), 3.46 (m, 2 H), 1 .91 (m, 1 H), 1 .71 (m, 1 H), 1 .37 (s, 4 H), 1.31 (s, 5 H, t-Bu rotamer), 0.78 (s, 9 H), -0.01 (s, 3 H), -0.02 (s, 3 H).
carboxylaie (9.6)
Figure imgf000065_0001
stirring solution of terf-butyl 2-methyl (2S,ZS)-3-{[tert butyl(dimethyi)siiyl3oxy}pyrrolidine-1 ,2-dicarboxylate (9.5, 23.4 g, 65.1 mmoi) in tetrahydrofuran (400 rnL) at 0°C was added in portions lithium tetrahydroborate (2.13 g, 97.6 mmoi) and the reaction was stirred with warming to rt for 18 nr. The reaction was concentrated under reduced pressure to give a residue, which was partitioned between 0.1 M aqueous HCI (150 mL) and ice/water (300 mL). 1 M HCI was added until the pH was slightly acidic and the two layers separated. The aqueous layer was extracted with chloroform and the combined organic layers were washed with water (200 mL), brine (200 mL), dried over MgS0 , filtered and concentrated under reduced pressure to give an oil, which was purified by flash chromatography (silica gei/0- 30% ethyl acetate in hexanes) to yield alcohol 9.6 (20.7 g, 96%). ' H NMR (400 MHz, CDCI3) ϋδϋ 4.24 (m, 1 H)« 3.92 <m« 1 H), 3.85 (m, 2 H): 3,53 (br. s. : 1 H). 3.46 (i J = 8.60 Hz, 1 H), 3.27 (m, 1 H), 1.85 (m, 1 H), 1 .69 (m, 1 H), 1.39 (s, 9 H), 0.80 (s, 9 H), -0.00 (s, 3 H), -0.01 (s, 3
H). teri-Buty! (2S,3S}-3-{[teri-butyKdsmeihyi)sHy oxy}-2-formyipyrro!idine-1 -carboxySate (9.7) NBoc Swarn. NBoc
TBSO TBSO ΐ
A 500-mL round bottom flask equipped with a thermometer and addition funnel under an atmosphere of nitrogen was charged with CH2Ci2 (930 mL) and cooled to -78 °C . Oxa!y! chloride (10.6 mL, 0.125 mol) was added followed by the dropwise addition of dimethyl sulfoxide (17.7 mL, 0.250 moi) and the reaction was stirred for 10 minutes. A solution of tert- Butyi (2 3S)-3-{[lerf-butyi(dimethy!)s!iyi]oxy}-2-(hydroxymethyi)pyrrolidine-1-carboxyiate (9.6, 20.7 g, 62.5 mmol) in CH CI2 (200 mL) was added dropwise and the reaction was stirred for 20 minutes. Triethylamine (34.8 mL, 0.250 mol) was added and the reaction mixture was stirred for 1 nr. The reaction was quenched with wafer and the product was extracted with CH2CI2 (3 x 200 mL). The combined organic layers were washed with water (2 x 50 mL) and brine (2 x 50 mL), dried over MgS04, filtered and concentrated under reduced pressure to afford a crude, which was purified by flash chromatography (silica gel/ 0-30% ethyl acetate in hexanes) to yield 9.7 (17.7 g, 86%). Ή NMR (400 MHz, CDCI3) Οδ 9.49 (s, 0.4 H), 9.39 (d, J = 2.70 Hz, 0.6 H), 4.29 (m, 1 H), 4.05 (s, 0.4 H), 3.84 (t, J = 2.70 Hz, 0.6 H), 3.50 (m, 2 H), 1.80 (m, 2 H), 1.39 (m, 4 H), 1.34 (s, 5 H), 0.80 (s, 9 H), 0.01 (s, 3 H), -0.00 (s, 3 H). ierf-Buty! (2/?,3S)-3-hydroxy-2-(2-oxoeihy pyrro!id!ne-1 -carboxylate (9.9)
Figure imgf000066_0001
To a stirring solution of (methoxymethyl)triphenylphos-phonium chloride (46.0 g, 0.134 moi) in tetrahydrofuran (400 mL) at 0 °C was added in portions potassium ferf-butoxide (13.9 g, 0.124 mol) and the reaction was warmed to ambient temperature and stirred for 2 hr. The reaction was cooled to 0°C and a solution of terf-butyl (2S,3S)-3-{[ierf- butyl(dimethyl)siiyl3oxy}-2-formylpyrroiidine-1-carboxylate (9.7, 17.7 g, 53.7 mmol) in tetrahydrofuran (200 mL) was added dropwise over 20 min and the reaction mixture was stirred overnight . The reaction was quenched by pouring into ice-water and the organic product was extracted with ethyl acetate (2 x 150 mL). The combined organic layers were washed with brine, dried over MgS0 , filtered and concentrated under reduced pressure to afford a crude, which was purified by flash chromatography (silica gel/ 0-15% ethyl acetate in hexanes) to yield 9.8. To a stirring solution of enol ether 9.8 in acetonitriie (200 mL) was added 5% aqueous TFA (100 mL) and the reaction was stirred for 2 hours. The reaction was quenched by the addition of saturated aqueous sodium bicarbonate (200 mL). The volatsles were removed under reduced pressure and the product was extracted with ethyl acetate (3 x 10GmL). The combined organic layers were washed with wafer (150 ml) and brine (150 mL), dried over MgS04, filtered and concentrated under reduced pressure to afford a crude, which was purified by flash chromatography (silica gei/0-30% ethyl acetate in hexanes) to yield compound 9.9 (7.1 1 g, 58%) 1 H NMR (400 MHz, CDCi3)G δ 9.72 is, 1 H)« 4.06 (m, 1 H), 4.01 (m, 1 H , 3.52 (m, 1 H), 3.33 (m, 1 H), 3.01 (d, J = 18.45 Hz, 0.5 H), 2.79 (d, J = 18.87 Hz, 0.5 H), 2.37 (m, 1 H), 2.10 (br. s. , 1 H), 1 .96 (m, 1 H), 183 (m, 1 H), 1 .38 (s, 9 H). ferf-Butyl (2 3S)-3-hydroxy-2-prop-2-yn-1 -y pyrrolidine-1 -carboxyiaie (9.10)
Figure imgf000067_0001
To a stirring solution of dimethyl 2-oxopropylphosphon-ate (6.0 mL, 43 mmol) in acetonitriie (30 mL) at 0°C was added potassium carbonate (12 g, 86 mmo!) and the reaction was stirred for 5 minutes. A solution of 4-methyibenzenesuifony! azide (8.5 g, 43 mmol) in acetonitriie (20 mL) was added dropwise over 10 min and the reaction was warmed to room temperature and allowed to stir for 2 hr. The reaction was cooled in a water bath and a solution of ferf-butyl (2R, 3S)-3-hydroxy-2-(2-oxoethyl)pyrrolidine-1 -carboxylate (9.9, 6.60 g, 28.8 mmol) in CH3OH (500 mL) was added dropwise over 20 min, and the reaction was stirred overnight. The reaction was quenched by the addition of water, voiatiies were removed under reduced pressure and the reaction mixture was partitioned between ethyl acetate (150 mL) and water (100 mL). The product was extracted with ethyl acetate (2 x 100 mL) and the combined organic layers were washed with water and brine, dried over MgS04, filtered and concentrated under reduced pressure to afford a crude, which was purified by flash chromatography (0-20% ethyl acetate in CH2CI2) to yield compound 9,10 (5.6 g, 86%). H N R (400 MHz, CDCi3) δ 4,40 (br. s„ 1 H), 3.76 (m, 1 H), 3.57 (m, 1 H), 3.44 (m, 1 H), 2.75 (d, J = 16.59 Hz, 1 H), 2.64 (d, J = 17.00 Hz, 1 H), 2.24 (m, 1 H), 2.15 (m, 1 H), 2.02 (m, 1 H), 1 ,88 (m, 1 H), 1 .75 (m, 1 H), 1 .47 (s, 9 H).
{2 ,3S)~terf~butyi 3~hydroxy~2~fS-{4-(((S)-3-hydroxy~1 ~meihoxy-3-rnethyl-1 -oxobutan-2- y^carbamoy!lpheny^penta^^-diyn-l -yllpyrroydine-l -carboxySate (9.11)
Figure imgf000068_0001
Figure imgf000068_0002
To a stirring solution of hydroxylamine hydrochloride (2.68 mg, 0.039 mmol) and copper chloride (1.27 mg, 0.013 mmol) in 23% n-buty!amine/water (0.6 mL) at 0°C was added a solution of (2f?,3SHerf-butyl 3-hydroxy-2-(prop-2-yn-1-y!)pyrro!idine-1-carboxy!ate (0.15 g, 0.675 mmol) in 23% n-butylamine/water (1.2 mL), followed by a solution containing (S)-methyl 2-(4-(bromoethynyi)benzamido)-3-hydroxy-3-methy!butanoate (0.2 g, 0.565 mmol) and hydroxylamine hydrochloride (2.68 mg, 0.039 mmol) in MeOH (1 mL) and 23% n- butylamine/water (0.6 mL), and the reaction was stirred for 1.5 hr at 0°C. The reaction mixture was partioned between EtOAc and water/brine (1 : 1 ). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to yield compound 9.11 (313 mg, 98%) as a green foam, which was carried through to the next step without further purification. MS: m/z calcd for C27H34N207 498.2, found [M-s-H]4 499.3.
(21?, 3 SHeri-b uiy 3 -h yd roxy-2 -{5 -( ^
oxobutan-2-y!)carbamoyI)phenyf)penta-2,4~diyn~1 ~yI)pyrro!idine-1 -carboxy!ate (9.12)
Figure imgf000069_0001
To a stirring solution of compound 9.11 (313 mg, 0.628 mmol) in I PA (2 mL) at 0°C was added 50% hydroxylamine in water (2.074 ml, 31.4 mmol) and the reaction was stirred at 5-10°C overnight. The IPA was removed under reduced pressure and the product was extracted with MeTHF. The organic layer was washed with 1 M citric acid (2 x) and brine, then dried over sodium sulfate, filtered and concentrated under reduced pressure to yield compound 9.12 (494 mg) as a yellow oil, which was carried through to the next step without further purification. MS: m/z calcd for C26H33N3G7 499.2, found [M-Boc+H]* 400.2.
M-{{S}-3*ydroxy-1 hydroxyamino}»3»methyi-1 -oxobuian-2-y!}»4-(5-{(2 ?s3S)-3- hydroxypyrroHdin-2-yl)penta-1,3~diyn-1-y!)benzamide (9)
Figure imgf000070_0001
To a stirring solution of compound 9.12 (494 mg, 0,628 mmol) in DCM (1 mL) was added TFA (1 mL) and the reaction was stirred for 1 hr. The reaction was concentrated under reduced pressure to give a crude, which was dissolved in water and purified by RP HPLC (2", 0,1%TFA in water/ACN) to yield A/-((S)-3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2- yI)-4-(5-((2 ?,3S)-3-hydroxypyrro!idin-2-y!)penta-1>3-diyn-1-yl)benzamide (42.5 rng, 0.082 mmoi, 13,0%). MS: m/z calcd for C21H25N3O5399.2, found [M+Hf 400.3,
10. {S)-4-((1-aGety!azetidsn-3-y!)buta-1,3-dsyny!)-N-{3-amino-1- (hydmxyairssno}-3- ethyl~1~oxobutan~2~yl}benza ide ^,Ζ-ί ίίυοίθθθθίθίθ (10)
{S)-?eff -but l 3^(4-{3-{{(9H-f!uoren-9-y!)methoxy}carbonyiamino)-1-rnethoxy-3-rneihyl-1- oxobutan-2-yicarbamoy!)phenyS)buta-1,3-diyny!)a.:et!d!ne-1-carboxy!ate (10,1)
Figure imgf000070_0002
Figure imgf000070_0003
Reactant W Eq Moles Sample Mass Vol d
(mmol) (rug) (mL) (g/ml)
D!PEA 129,24 3.3 1.249 161 0.218 0.74
To a stirring solution of compound 1.6 (220 mg, 0.38 mmol) in MeOH (2 mL) was added D!PEA (0.22 mL) and the reaction was cooled in an Ice/acetone bath. Boc-ONB (95 mg, 0.34 mmol) was added and the reaction was stirred for 2 hr. Additional Boc-ONB (7 mg) was added and the reaction was stirred for 15 min. Fmoc-OSu (166 mg, 0.49 mmol) was added and the reaction was stirred overnight. Additional Fmoc-OSu (17 mg) was added and the reaction was stirred for 2 days. N,N-dimeihylaminopropyiamine (40 μί) was added and the reaction was stirred for 5 min at rt. The reaction mixture was partitioned between EtOAc and 1 M citric acid, and the organic layer was washed with 1 M citric acid, saturated sodium bicarbonate, brine, dried over magnesium suifate, and concentrated under reduced pressure to yield compound 10.1 (340 mg), which was carried through to the next step without further purification. MS: m/z calcd for C40H41 N3O7 675.29, found [M+H]4' 676.3.
CS)-methy!-3-CCC9H-fluoren-9-y!}meth^
d5ynyi)benzam!do)-3-methy§buianoate 2,2,2-irifSuoroacetate (10,2}
Figure imgf000071_0001
To a stirring solution of compound 10.1 (340 mg, 0.50 mmol) in DCM (4 mL) was added TFA (4 mL) and the reaction was stirred at rt for 10 min. The reaction was concentrated under reduced pressure from DCM twice to give a residue, which was lyophilized from water/ACN to yield compound 10.2 (305 mg, 88%), which was carried through to the next step without further purification. CS)-methy 2~C4~{f1 -aceiy!azet! !^
methy!butanoate 2,2,2-tnf!uoroaeetate (10.3)
Figure imgf000072_0001
To a stirring solution of compound 10.2 (280 mg, 0.41 mmo!) in pyridine (0.7 mL) was added acetic anhydride (0.1 mL) and the reaction was stirred for 30 min. eOH (5 mL) was added and the reaction was stirred for 30 min. Pyrrolidine (1 mL) was added and the reaction was stirred for 3.5 hr. The reaction mixture was acidified with TFA and purified by RP HPLC (2" column, 0.1 % TFA in water/ACN) to yield compound 10.3 (190 mg). MS: m/z calcd for C22H25N3O4 395.18, found [M+H]' 396.2.
(§)-4-{{1 -acetyl! as3iidin-3-y!)buta-1 ,3-dsyny!)- f-f3-arriino-1 -(hydroxyamino)-3-methy1-1- oxobutan-2-yi)benzamide 2,2,2-trifiuoroacetate (10)
Figure imgf000072_0002
To a stirring solution of compound 10.3 (3.5 g, 6.87 mmol) in IPA (10 mL) at 0°C was added hydroxylamine (50% aq., 2 mL) and the reaction was stirred at 5-10°C overnight. The reaction mixture was acidified with TFA, diluted with water and purified by RP HPLC (2", 0.1 % TFA in water/ACN) to yield compound 10. MS: m/z calcd for C21 H24N4O4 396.18, found [M+H]+ 397.2.
11. (S 3-({4~(3~amino~1~{hydroKyamino)~3~methyi-1~oxobutan~2~ ylGarbamoyl)phenyi)buta-1,3~d!ynyl)~N-methyiamtid!ne-1-GarbOKamide (11) (S)-methy1-3-{{(9H-f!uoren-9-y!)meihoxy)carbony!aniino)~3~niethy!-2-f4-{{1 - (meihy!carbamoyS)azeiidin-3-y!)buia-1 ,3-d!yny!)benz:amido)buianoaie (11.1 )
Figure imgf000073_0001
Figure imgf000073_0003
To a stirring solution of compound 10.2 (10 mg, 0.014 mmol) in pyridine (100 pL was added methylcarbamic chloride (13.6 mg, 0.145 mmol) and the reaction was stirred for 1 hr. MeOH (500 pL) was added and the reaction was stirred overnight. The reaction mixture was partitioned between 1 M citric acid and ethyl acetate. The organics were washed with saturated sodium bicarbonate, brine, dried over magnesium sulfate and concentrated under reduced pressure to yield compound 11.1 , which was carried through to the next step without further purification. MS: m/z calcd for C37H38 4G6 632.26, found [M+H 633.3.
(S)-3-((4-(3-amino-1 ^hydroxyam5no)-3-methy 1 -oxobuian-2-y!carbamoy!)pheny buta-1 s3- dsynyS)-iV-!Tiethy^a2eisdsne-1 -carboxa!Ti!de (11)
Figure imgf000073_0002
To a stirring solution of compound 11.1 (10 mg, 0.016 mmol) in I PA (300 μ!_) was added hydroxy!amine (50% aqueous, 300 pL) and the reaction was stirred at 0°C for 4 hr. Pyrrolidine (50 μϋ was added and the reaction was stirred for 3 hr at 0°C and at 5-10°C overnight. The reaction mixture was acidifed with TFA, diluted with MeOH and purified by RP HPLC (1 " column, 0.1 % TFA in water/ACN) to yield compound 11. MS: m/z calcd for C21 H25N5O4 41 1.2, found [M+Hf 412.2.
12. (8)-3-({4-(3~amino-1-(hydrQxyarrsinQ)~3~rrsethy!-1~oxobutan~2~ y!carbamoy!)pheny1)buta-1,3~diyny!)azetidine~1-carboxa ide (12)
(S)-methy! 3-({{9H-fiuoren-9-yi)meihoxy)carbonyiam!no}-2-(4-{{1 -carbamoyla-eetidin-3- y buta-1 ,3~diynyl)ben∑amido)-3-methylbutanoate (12.1)
Figure imgf000074_0001
Figure imgf000074_0002
To a stirring solution of compound 10.2 (10 mg, 0.014 mmol) in THF (100 μ[_) was added DIPEA (10 μ[_, 0.058 mmol) followed by isocyanatotrimethy!si!ane (19.27 μΐ_, 0.145 mmol) and the reaction was stirred for 1 hr. MeOH (500 pL) was added and the reaction was stirred overnight. The reaction mixture was partitioned between 1 M citric acid and ethyl acetate. The organics were washed with saturated sodium bicarbonate, brine, dried over magnesium sulfate and concentrated under reduced pressure to yield compound 12.1 , which was carried through to the next step without further purification. MS: rn/z calcd for C36H34 406 618.25, found [M+H]* 619.3. (S)-3-{(4~{3-aniino~1 ~{hydroxya mo)-3-meth !-1 -oxobutan-2- diyny a etidine-l-carboxamsde (12)
Figure imgf000075_0001
To a stirring solution of compound 12.1 (10 mg, 0.016 mmol) in IPA (300 μ!_) was added hydroxylamine (50% aqueous, 300 μ[_) and the reaction was stirred at 0°C for 4 hr. Pyrrolidine (50 pL) was added and the reaction was stirred for 3 hr at 0°C and at 5-10°C overnight. The reaction was acidified with TFA, diluted with MeOH and purified by RP HPLC (1 " column, 0.1 % TFA in water/ACN) to yield compound 12. MS: m/z calcd for C20H23N5O4 397.2, found [M+H]+ 398.2.
13. (S)-4~({1-acetyiazet!dsn~3^l)buta-1,3-dsynyl)~N-(3-(dime {hydrQxyaminQ)-3-methyi-1-QXQbiitan-2-yl}benzamide (13)
Figure imgf000075_0002
Figure imgf000075_0003
Figure imgf000076_0001
To a stirring solution of compound 10 (300 mg, 0.59 mmol) in D F (3 mL) was added paraformaldehyde (176 mg, 5.88 mmol) followed by DIPEA (0.20 mL, 1.17 mmol) and the reaction was stirred for 6 hr. Sodium cyanoborohydride (1 1 1 mg, 1.76 mmol) was added, followed by methanol (3 mL) and then acetic acid (0.1 mL) and the reaction was stirred overnight. Additional sodium cyanoborohydride (1 10 mg) and TFA (91 L) were added and the reaction was stirred for 3 days. Additional sodium cyanoborohydride and TFA were added and the reaction was stirred for 2 days. The mixture was purified by RP HPLC (2" column, 0.1 % TFA in water/ACN) to yield compound 13 (262 mg, 81 %). MS: m/z calcd for C23H28 404 424.2, found [M+H]4' 425.2.
14. (S)'N-(3-amsnO'1-(hydroxyam ao}~3~methy!~1~oxobutan~2^!}-4~{(1^ hydroxyacety!)azetidin-3-y!)but8--1!3-c!iyn-1-yl)benzamidle {14}
Figure imgf000076_0002
Figure imgf000076_0003
Reactant MW Eq Moles Sample Mass Vol Density
(rnfTioi) (mg) (ul) (g/rrsl)
Compound 1 354.403 1 ,000 1.806 640
DIPEA 129.243 .2 0.361 46.7 63.1 0.74
Acetoxyacetyl 136.534 .7 1 ,264 173 136 1.27 chloride
25 wt%Sodium 31.034 2.5 4,52 976 1027 .95 methoxide
AcOH 60.052 5 9.03 542 517 1.049
To a stirring solution of compound 1 (640 mg, 1.81 mmol) in DMF (4.5 mL) and water ( 100 pL) at 0°C was added DIPEA (63 μ!_) followed by acetoxyacetyl chloride (136 μΙ_, 1.26 mmol) and the reaction was stirred for 45 min. Sodium methoxide (25% in MeOH, 1 mL) was added and the reaction was stirred for 2 days. The reaction mixture was acidified with AcOH (517 pL), diluted with water and purified by RP HPLC (2", 0.1 % TFA in water/ACN) to yield compound 14 (185 mg, 25%). MS: m/z calcd for C 1 H24 4O5 412.2, found [M+H]+ 413.0.
15. (S)-N-(3-ammo-1-(hydroxyammo)-3-methyl-1-oxohutan-2^ hydroxyethyi)azetidin~3~y!)buta- 1, 3~diyn~1~y!)benzamide (15)
1 -{2-{(ierf-butyid5methyisi!y!)oxy)ethyi)-3-eihyny!a etidine (15.1)
Figure imgf000077_0001
Figure imgf000077_0002
Figure imgf000078_0001
To a stirring solution of compound 8.1 (800 mg, 9.86 mmol) in DMF (49 mL) was added 2-((trimethylsilyl)oxy)acetaldehyde (1.3 g, 9.86 mmol) and the reaction was stirred for 2 hr. Sodium cyano borohydride (620 mg, 9.86 mmol) was added and the progress of the reaction was monitored by LCMS. The reaction was partitioned between water and EtOAc, the organic layer was washed with water (3 x ) and brine (2 x), concentrated under reduced pressure to give a crude, which was purified by RP HPLC (0.1 % AcOH water and ACN) to yield compound 15,1 (61 mg). MS: m/z calcd for C10H19NOSi 239.2, found [M+H]+ 240.1.
{S)-methy! 3-{(teri-butoxycarbony1)am!no)-2-{4-({1-(2-{{ferf- buiy!dimethySsi!yi)oxy)eihy!)azetidin-3-y!)buia-1 ,3-diyn-1-y!)benzamido)-3- meihylbutanoate (15.2)
Figure imgf000078_0002
Figure imgf000078_0003
Figure imgf000079_0001
To a stirring solution of CuCI (16 mg) in 30% n-butylamine (1 : 1 THF:water, 240 μΙ_) was added hydroxylamine (50% aqueous, 18 μ!_) and the solution was cooled in an ice/MeOH bath. Next a solution of 3-ethynyl-1-(2-((trimethy!si!y!)oxy)ethyl)azetidine (57 mg, 0.24 mmol) in 30% n-buty!amine (1 : 1 THF:water, 540 μί) was added, followed by the dropwise addition (10 min) of a cold solution of INT-1 (108 mg, 0.24 mmol) and hydroxylamine (50% aqueous, 9 μ[_) in 30% n-butylamine (1 :1 THF: water, 595 μ!_), and the reacison was stirred overnight. The reaction mixture was diluted with EtOAc (20 mL), washed with 1 M citric acid (20 mL), saturated aqueous bicarbonate (20 mL), brine (2 x 10 mL), dried over Na2S04 and concentrated under reduced pressure to yield compound 15.2 (130 mg), which was carried through to the next step without further purification. MS: m/z calcd for C33H49 3O6S! 61 1.3, found [M+H]+ 612.5.
(S)-methyl 3-amino-2-{4-((1~{2~hydroxyethy ^
methyibutanoate (15.3)
Figure imgf000079_0002
To a stirring solution of compound 15.2 (130 mg, 0.21 mmo!) in DCM (660 μΙ_) was added TFA (2 mL) followed by water (383 pL) and the reaction was stirred for 2 hr. The reaction mixture was concentrated under reduced pressure, azeotroped with IPA (2 x 10 mL) to give an oil, which was diluted with saturated aqueous NaHC03 (1 mL) and water (200 L) and extracted with eTHF, The organic layer was dried over sodium sulfate and concentrated under reduced pressure to yield compound 15,3 as an oil. MS: m/z caicd for C22H27N3O4 397.2, found [M+H]+ 398.3.
{S)-^(3~am!no-1-(hydroxyamino)~3~methyl~1~oxobutan~2-yi)~4~(f1-{2- hydroxyeihyS)a^etsdin-3-yS)buta-1,3-diyn-1-yS)ben2:amide (15)
Figure imgf000080_0001
To a stirring solution of compound 15,3 (80 mg, 0.20 mmol) in IPA (750 μί) cooled in an ice/MeOH bath, was added cold hydroxylamine (50% aqueous, 247 pL) and the reaction was stirred overnight. Additional hydroxylamine (248 pL) was added and the reaction was stirred for 4 days. The reaction mixture was neutralized with AcOH (461 pL), IPA was removed under reduced pressure to give a crude, which was purified b RP HPLC (1 ", 0.1 % AcOH in water/ACN) to yield compound 15 (15 mg, 17.5%). MS: m/z caicd for C21 H26N4O4 398.2, found [M+H]+ 399.3.
16. (S)~N~{3~amino~1~{hydrQxyaminQ)-3-methy!-1"QXQbutari"2-y!)-4-((1~ formyiazetidin~3-yi)biita~1,3-diyn-1-yl)benzairiiide (18)
Figure imgf000080_0002
Figure imgf000081_0001
To a stirring solution of compound 1 (1.41 g, 3.40 mmol) in DMF (6.8 mL) and THF (6.8 mL) at 0°C was added 2,2,2-trifluoroethyl formate (536 mg, 4.19 mmol), followed by DIPEA (297 L, 1.70 mmol) and the reaction progress was followed by LCMS. Excess formate was quenched by N,N-Dimethy!-1 ,3-propanediamine (0.2 eq). After solvent evaporation under reduced pressure, the mixture was diluted with water (10 mL) and purified by RP HPLC (2", 0.1 % AcOH in water/ACN) to yield compound 16 (830 mg, 53.5%). MS: m/z calcd for C2oH22 404 382.2, found [M+H]+ 383.1.
17. {S)~4~{(14ormy!azetidin-3-y!)buta-1,3~d!yn-1^!)~N-(1^yd 3-methy!'3~{methy!a ino}-1-Qxobutan~2-y!)benza ide {17}
{S)"4-({1 -formy!a2etid!n~3~yl!)buta^
{meihyleneam5no)-1 -oxobutan-2-yi}benzamide (17.1)
Figure imgf000082_0001
Figure imgf000082_0002
A stirring soiution of compound 16 (1.3g, 3.12 mmol) in DMF (1 1 mL) and DiPEA (544 pL, 3.12 mmol) at 0°C was treated with 2,2,2-trifluoroetbyl formate (379 mg, 2.96 mmol). After 30 min the reaction was treated with formaldehyde (30% in water, 736 pL, 9.35mmol) and allowed to stir overnight at rt. The reaction mixture was quenched with n-butyiamine and the imine was purified by RP HPLC (2", 0.25 mM NH4OH in water/ACN) to yield compound 17.1 (500 mg, 41 %). MS: m/z. calcd for C2<H22N404 394.2, found [M+H]+ 395.1.
(S)-4-({1 -formylazetidin-3-y§)kuta-1 ,3-diyn-l -yi)-W-(1 -{hydroxyamsno)-3-methy -3- {methylamino)~1 ~oxobutan~2~yl)benzamsde (1?)
A stirring slurry of 17.1 (500 mg, 1.27 mmol) in DMF (9 mL) was treated with NaCNBH.3 (380 mg, 6.07 mmol) at room temperature for 2hr. The reaction was then heated at 30°C for 14 hr with the progress of the reaction monitored by LCMS. The reaction solution was purified by RP HPLC (0.1 % TFA in water/ACN) to yield compound 17 (397 mg, 79%). MS: m/z calcd for Ο^Η,, ,Ο. 396.2, found [M+H]+ 397.1
18. (S)-4-({1-acetyiazet!din-3-y!)buta-1 ,3-diyn-l -y!)-N-(1-{hydroxyamino)- 3-methy!-3-{methyiamino}-1-oxotutan-2-yi)benza !de (18)
Figure imgf000082_0003
Reactant MW Eq Moles Sample Vol Molarity Density %
(mmo!) Mass (ul) (molar) (g/rni) Wt
(mg) (%)
(S)-4-((1 -acety!azetidin-3- 396.440 1 .000 2.510 995
yl)buta-1 ,3-diyn-1 -yl)-/V-(3- amino-1 -(hydroxyamino)-3- methy!-1 -oxobutan-2- yl)benzamide
Formaldehyde 30.026 24.62 61 .8 5014 4600 1 .09 37
Sodium cyanoborohydride 39.853 40 100 6309
To a stirring solution of compund 16 (995 mg, 2.51 mmol) in THF (4.6 mL) was added formaldehyde (37% aqueous, 4.6 mL) and the reaction was stirred for 90 min. Cone. NH OH (20 mL) was added and the reaction was concentrated under reduced pressure to give a crude, which was dissolved in DMF (1 1 mL), acidified with AcOH (1.5 mL), and treated with NaCNBH3 (6.3 g) and the reaction was stirred for 1 nr. The reaction mixture was purified by RP HPLC (2", 0.1 % AcOH in water/ ACN) to yield compound 18 (295 mg). MS: m/z caicd for C22H26N404 410.2, found [M+Hf 41 1.2.
19. (S}~4~{{1-acetyl·3-hydroxyazetϊdin-3-yl)buta-1,3~dίyn-1-yl)~N-(3-amίno~ 1 ~{hydmxya snQ)~3~ ethy!-1-Qxobuian-2-y!)benza sde (19)
Figure imgf000084_0001
teri-buty^ 3-hydroxy-3-{{tnmethy!s^y eihynyl}a-eetidine-1-carboxyiaie (19.2)
Figure imgf000084_0002
To a stirring solution of etbynyltrimethylsslane (3.22 mL, 22.8 mmol) in THF (12 rnL) cooled in a dry ice/acetone bath under a nitrogen atmosphere was added r?~BuLi (3 min) (2.5 M , 9 mL) and the reaction was stirred for 5 min. A solution of lerf-butyl 3-oxoazetidine-1- carboxy!ate (0.9 g, 5.26 mmol) in THF (5 mL) was then added and the reaction was allowed to warm to rt over 2 hr. The reaction was quenched with water (10 mL) and saturated aqueous NH4CI (75 ml) and diluted with Et20 (50 mL). The organic layer was washed with saturated aqueous NH4CI (2 x), dried over Na2S0 and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/0-100% EtOAc/hexanes) to yield compound 19,2 (500 mg, 35.3%). MS: m/z calcd for C13H23N03Si 269.1 , found [M+Na]+ 292.1. terf-buty 3-eihyny ~3~hydroxya^etsdme-1 -carboxy1ate (19.3)
To a stirring solution of compound 19.2 (500 mg, 1 .86 mmoi) in MeOH (14 mL) was added K2C03 (20 mg) and the reaction was stirred for 5 hr. Solvent evaporation under reduced pressure gave a crude, which was purified by flash chromatography (silica gel) to yield compound 19.3 (318 mg, 87%). MS: m/z calcd for C,0H ! 5NO3 197.1 , found [M+Na]+ 220.0.
{S)-ieri-butyi 3- (4-({3-((ieri-bisioxycarbony!)amino)-1 -met hoxy-3-meihyl-1 -oxobutan-2- y^)carbamoyi)pheny!)buta-1 ,3-diyn-1 -yS)-3-hydroxyazeisdine-1 -carboxy ate (19.4)
Figure imgf000085_0001
To a stirring solution of CuCI (10 mg) in 30% r?-butylamine/water (1 : 1 waterTHF, 3 mL) and hydroxylamine (50% aqueous, 18 μί), cooled in an ice/MeOH bath was added a cold solution of compound 19.3 (300 mg, 1.52 mmoi) in 30% n-buty!amine/water (1 : 1 water/THF, 7.5 mL). Next a solution of INT-1 (1 .54 g, 2.28 mmoi) and hydroxylamine (50% aqueous, 18 pL) in 30% n-buty!amine (1 : 1 water: DMF, 7.5 mL) was added dropwise and the reaction was stirred for 15 min, and its progress was monitored by LCMS. The reaction mixture was diluted with EtOAc (100 mL), washed with 1 M citric acid (200 mL), saturated aqueous NaHC03 (100 mL), brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to yield compound 19.4 (500 mg), which was carried through to the next step without further purification. MS: m/z calcd for C3oH39 308 569.3, found [M-s-Naf 592.4.
(S)-methy! 3-amsno-2-{4-C(3 iydroxya£etsdm-3-y!)buta-1 ,3-dsyn-1 -y!)benzamsdo)-3- methy!butarsoate dsacetaie (19,5)
To a stirring solution of compound 19.4 (600 mg, 1.05 mmol) in DCM (1 mL) at 0°C was added TFA (3 mL), and the reaction was stirred for 30 min. The mixture was concentrated under reduced pressure to give a crude, which was purified by RP HPLC to yieid compound 19.5 (145 mg, 56%). MS: m/z calcd for C20H23N3O4 369.2, found [M+Hf 370.1.
(S)-AH3~am!no-1 -(hydroxyam!nQ)~3-met^
yH)buta-1 ,3-diyn-l -yS)benzamide (19,6)
To a stirring solution of compound 19.5 (275 mg, 0.74 mmol) in IPA (3.7 mL) was added hydroxy!amine (50% aq, 931 L) and the reaction was stirred overnight. The reaction mixture was acidified with AcOH and concentrated under reduced pressure to yield compound 19.6. MS: m/z calcd for C19H22N404 370.2, found [M+Hf 371.2.
{S)-4-({1 -acety 3-hydroxyaz:et!dm-3-y!)buia-1,3-dsyn-1 -yi)-i¥-{3-amino-1 -{hydroxyam!no}-3- methyi~1 ~oxobutan~2~y!)benzamsde (19)
Figure imgf000086_0001
Figure imgf000087_0001
To a stirring solution of compound 19.6 (25 mg, 0.058 mmol) in D F (800 μί) was added DIPEA (30 μΙ_), followed by AcOH (0.66 pL) and PyBOP (36.3 mg, 0.07 mmol) and the reaction was stirred for 1 hr. The reaction mixture was diluted with water and purified by RP HPLC to yield compound 19 (1 1 mg, 45.9%). MS: m/z calcd for C21 H24N4O5 412.17, found [M+H]4' 413.2.
20. N-((2Ss3R)-3-amsno~1^ydrQxyamino)-1-oxobutan-2-y!)-4-((1- fonny!azetidin~3-y!)bs ta~1,3"diyn-1-y!)benza ide (20)
{2S,ZR)- et yl 2~(4~(bromoethynyl)benzam!do)-3-((feri~butoxycarbonyi)am!no)butanoate (20.2)
Figure imgf000088_0001
To a stirring solution of 4-(bromoethynyl)benzoic acid (21 .7 g, 96 mmol) in acetonitri!e (321 mL) was added compound 20.1 (synthesized as described in WO 2008/154642 at page 236 ei seq) (25.8g, 96 mmol) followed by TEA (33.6 mL, 241 mmol) and the reaction was cooled to 0°C. HATU (40.3 g, 106 mmol) was added and the reaction was stirred while warming to rt for 1 hr. The reaction was concentrated under reduced pressure to approximately 15 mL and was diluted with EtOAc (75 mL) and washed with 1 M citric acid (25 mL). The organic layer was washed with saturated aqueous NaHC03/water (45 mL/20 mL), brine (40 mL), and concentrated under reduced pressure to yield a crude, which was purified by flash chromatography (silica gel/10-40% EtOAc in hexanes) to yield compound 20.2 (35 g, 83%). MS: m/z calcd for C19H23BrN205 438.07 & 440.07, found [M+H]+ 439.0 & 441 .0.
Figure imgf000089_0001
ierf-butyS 3-C(4-{({2S,3i?)-3-({fer^butoxycarbony ammG)-1 -meihoxy-1 -oxobutan-2- y^)carbamoyi)phenyl!)buta-1 ,3-diyn-1 -yH)azeiidine-1 -carboxy^ate {20,3}
Figure imgf000089_0002
To a stirring solution of CuC! (15mg) in 30% n-buiylamine (1 : 1 H20 THF, 2.6 mL) and hydroxyiamine (50% aqueous, 18 pL) cooled in an ice/MeOH bath, was added a cold solution of ferf-butyl 3-ethyny!azetidine-1 -carboxylate (0.54 g, 2.98 mmol) in 30% n-butylamine (1 :1 H20/THF, 2.6 mL). A solution of (2S,3R)~rnefhyl 2-(4-(bromoethynyl)benzamido)-3-((ierf- butoxycarbonyi)amino)butanoate (131 g, 2.98 mmo!) in 30% n-butylamine (1 : 1 H20/THF, 10.5 mL) and hydroxylamine (50% aqueous, 18 μί) was then added dropwise over 30 min, and the reaction was stirred for 15 min. The reaction mixture was diluted with EtOAc (100 mL), and the organic layer was washed with 1 M citric acid (96 mL), saturated aqueous NaHC03, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to yield compound 20.3 (1.7 g), which was carried through to the next step without further purification. MS: m/z caicd for C29H37N3O7 539.3, found [M+Hf 540.3.
{2S,3f?)~methy! 3-amino~2~(4-(a∑et!din~3~yf uta-1 ,3~diyn~1 ~y!)benzamido)butanoate (20.4)
To a stirring solution of compound 20.3 (1.7 g) in DCM (6 mL) at 0°C was added TFA (6 mL) and the reaction was stirred for 1 hr. The reaction was concentrated under reduced pressure from DCM twice to yieid compound 20.4, which was carried through to the next step without further purification. MS: m/z calcd for C19H21 3O3 339.2, found [M+Hf 340.2.
N-{{2S,3 )-3-aminG-Hhy rGxyamino}-1-oxo
y benzamsde (20.5)
To a stirring solution of compound 20.4 (1.7 g) in I PA (5 mL) at 0°C was added hydroxylamine (50%, 3.13 mL) and the reaction was stirred at 5-10°C overnight. The reaction mixture was acidified with AcOH and purified by RP HPLC (2") to yield compound 20.5 (654 mg, 72,5%). MS: m/z calcd for C18H2o 403 340.15, found [M+Hf 341.2. -C^SjSRI-S-amino-l-Ch ro yamsno)
dsyn-1-y!)ben;zarniide (20)
To a stirring solution of 20.5 (800 mg, 199 mmo!) in NMP (9.9 mL) 0°C was added DIPEA (698 L) followed by 2,2,2-trifluoroeihyl formate (2 x 40 L) and the reaction progress was monitored by LCMS. The reaction mixture was acidified with AcOH (1 mL), diluted with water (10 mL) and purified by RP HPLC (2") to yieid compound 20 (421 mg, 57.2%). MS: m/z calcd for C19H2oN404368,15, found [M+Hf 369.1. 21. {S)~N~{3~a ino~1~(hydmxya ino}-3' ethyM-oxobutan-2^!}'4'((1- { ethy!su!fony!)azetidin~3~y!}buta-1^-diyn~1~y!}benza ide (21)
Figure imgf000091_0001
Figure imgf000091_0002
To a stirring solution of compound 1 (147 mg, 0.41 mmol) in DMF (1.45 mL), cooled in an ice bath, was added DIPEA (0.18 mL, 1.04 mmol) followed by methanesulfony! chloride (32 μί, 0.41 mmol) and the reaction was stirred at -15°C overnight. The reaction mixture was diluted with water (1.5 mL), acidified with AcOH (65 μί) and purified by RP HPLC (2", 0.1 % AcOH in water/ACN) to yield compound 21 (34 mg, 16.6%). MS: m/z calcd for C20H24N4O5S 432.1 , found [M+H]+ 433.0,
22. 4-{(1-formylazeiidin-3-yl}buta- 1, 3-diyn- 1 -yl}-N-{{2S, 3R}-1 - {hydroxyaniino}~3~(methylamino)-1-QXQbutan~2~yl)benzaniide (22)
Figure imgf000092_0001
Reactant MW Eq Moles Sample Vol Molarity Density %
(mmol) Mass (ul) (molar) (g/ml) vt
(mg) (%)
A/-{(2S,3f?)-3-amino-1- 368.387 1.000 0.543 200
(hydroxyamino)-l- oxobutan-2-yl)-4-((1- formy!azetidin-3-y!)buta- 1 ,3-diyn-1-y!)benzamide
TEA 101.190 2 1.086 1 10 151 0.726
Formaldehyde 30,026 1.000 0.543 44.1 40.4 1.09 37
TFA 1 14.023 6 3.26 371 251 1.48
Sodium cyanoborohydride 39.853 3 1.629 102
n-Butylamine 73.137 3 1.629 1 19 161 .74
Ammonium hydroxide 18.038 10 5.43 367 14.8
To a stirring solution of compound 20 (200 mg; 0.54 mmol) in water (3 mL) and DMF (1 mL) and MeOH (1 mL) was added TEA (151 pL) followed by formaldehyde (37% aqueous, 40.4 pL, 0.54 mmol) and the reaction progress was monitored by LCMS. Additional formaldehyde (0.5 eq) was added and again the reaction progress was monitored by LCMS. n- Butyiamine (161 pL) was added and the reaction was stirred for 3 hr. Sodium cyanoborohydride (102 mg; 1.63 mmol) was then added, followed by TFA (251 pL, 3.26 mmol) and the reaction was stirred for 30 min. The reaction was quenched with cone. NH4OH (367 pL, 5.43 mmol) and the mixture was purified by RP HPLC to yield compound 22 (16 mg, 6%). MS: m/z calcd for C2oH22 404 382,2, found [M+H]+ 383, 1.
23. {S)~N~{3~hydmxy-1^ydroxyam!no}~3~methyl-1'Oxobutan'2-y!)~4~{{1- {Qxetan-3-y!}azetidin-3-y!}buta-1,3-d!yn-1-y!)benzamide (23)
Figure imgf000093_0001
Figure imgf000093_0002
To a stirring solution of compound 2b (502 mg, 1.21 mmol) in THF (10 mL) was added oxetan-3-one (87 mg, 1.21 mmol) and AcOH (5 mL) and the reaction was stirred for 30 min. MeOH (10 mL) was added followed by sodium cyanoborohydride (152 mg, 2.41 mmol) and the reaction was stirred for 18 hr. The mixture was concentrated under reduced pressure to give a crude, which was purified by RP HPLC (2", 0.1 % AcOH in water/ACN) to yield compound 23 (10 mg). MS: m/z caicd for C22H25N3O5 41 1.2, found [ +H]+ 412.3.
24. {S)-N-{3-amsno-1 '-{hydrox -amino)-3-methyl-1 -oxobutan-2-yi}-4-(5- (azetidin-3-yl)penta~1,3-diyn~1-yl)benzarnide (24)
Figure imgf000094_0001
terf-butyl! 3~({{(trifkioromethyl)su!fonyf)oxy)methyl)azetidine-1 -carboxy!ate (24.2)
Figure imgf000094_0002
To a stirring solution of the azetidine (1.32 g, 7.05 mmoi) in DCM (35 mL) was added DIPEA (2.46 mL, 14.1 mmol) and the reaction was cooled in a dry-ice/acetone bath. Trifiic anhydride (1.25 mL, 7.40 mmol) was added and the reaction was stirred for 30 rnin. The reaction was quenched with water (20 mL), the organic layer was washed with saturated aqueous NaHC03 (10 mL), brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to an oil, which was purified by flash chromatography (silica gei/0-3% MeOH in DCM) to yield compound 24.2 (1.28 g, 56.9%). MS: m/z caicd for Ο10Η16Ρ3ΝΟ53 319.1 , found [M+Na]+ 342.1. terf-buty 3-fprop-2-yn~1 -yS)az:etidine-1 -carboxy!ate {24.4}
Figure imgf000095_0001
To a stirring solution of ethynyltrimethylsiiane (1.06 g, 10.8 mmol) in THF (10 mL) at 0°C was added r?~BuLi (1.5 M, 8.6 mL, 12.9 mmol) and the reaction was stirred for 30 min. A solution of DMPU (3.1 mL) was then added, followed by a solution of compound 24.2 (0,6 g, 1.88 mmol) in THF (3 mL) and the reaction was stirred for 30 min at -20°C. cone NH4OH (1 mL) and MeOH (1 mL) were then added and the reaction was warmed to rt over 10 min. The mixture was diluted with Et20 (100 mL) and water (100 mL). The organic layer was washed with water (2 x 50 mL), and was then concentrated under reduced pressure to yield compound 24.3 as a thick oil. To compound 24,3 was added TBAF (1 M in THF, 1.88 mL, 1.88 eq) and the reaction was stirred at 5-10°C overnight. The reaction was diluted with Et20 and washed with a solution of water/5 M NH4Ci (100 mL: 50 ml). The organic layer was washed with saturated NH4CI, dried over sodium sulfate, filtered and concentrated under reduced pressure to give a crude, which was purified b flash chromatography (silica gel) to yield compound 24.4 (235 mg). Ή NMR (400 MHz, CDCI3) δ 1.44 (s, 9 H), 1.97 (s, 1 H), 2.44 (d, J = 6.8, 1 H), 2.68-2,74 (m, 1 H), 3.69 (dd, Ja = 8.4 Hz, Jb - 5.2 Hz, 2 H), 4.022 (t, J = 8.4 Hz, 2 H). (S)-fert-butyl 3~C5 4~C{3-((feri~butoxycarbonyi)amino)-1 -methoxy~3~rnethyl~1-oxobutan~2- y^carbamoy!lpheny^penta^^-diyn-l -ylla^etsdine-l-carboxySate (24.5)
Figure imgf000096_0001
To a stirring solution of CuCI (16 mg) in 30% n-butyiamine (1 :1 H20 THF, 0.7 mL) and hydroxylamine (50% aqueous, 48 pL) cooled in an ice/MeOH bath, was added a cold solution of fert-buty! 3-(prop-2-yn-1-y!)azetidine-1-carboxy!ate (150 mg, 0.77 mmol) in 30% n- butylamine (1 : 1 H20/THF, 1.74 mL). A cold solution of (2S,3f?)-methyl 2-(4- (bromoethynyl)benzamido)-3-((ieri-butoxycarbony!)amino)butanoate (348 mg, 0.77 mmol) in 30% n-butyiamine (1 :1 H20 THF, 0.6 mL) and hydroxylamine (50% aqueous, 16 μί) was then added dropwise over 15 min, and the reaction was stirred for 15 min. The reaction mixture was worked as described in procedure 1 to yield compound 24.5 (300 mg), which was carried through to the next step without further purification. MS: m/z calcd for C31 H41 N3O7 567.3, found [M+Na]+ 590.4. (S)-methy! 3~amino~2~{4~(5~{a∑et!d!n~3~yf)penta-1 ,3~diyn~1~yI)ben arnido)-3- methy!butanoate (24.6)
To a stirring solution of compound 24.5 (300 mg, 0.53 mmo!) in DCM (1 mL) cooled in an ice/MeOH bath was added TFA (4 mL) and the reaction was stirred for 30 min. The reaction mixture was concentrated under reduced pressure, azeotroped with EtOAc, then diluted with water and purified by RP HPLC (1 ", 0.1 % AcOH in water/ACN) to yield compound 24.6 (159 mg). MS: m/z caicd for C2i H25 303 367.2, found [M+Hf 368.1.
{S)-/ -(3-am!no-Hhydroxyamin0)-3-met^
diyn-1-y!)benzamide (24)
To a stirring solution of compound 24.6 (69 mg, 0.19 mmol) in I PA (1050 pL) at 0°C was added hydroxylamine (50% aqueous, 750 pL) and the reaction was stirred at rt for 7 hr. AcOH (645 pL) was added and the mixture was purified by RP HPLC (1 ", 0.1 % AcOH in water/ACN) to yield compound 24 (42 mg, 607%). MS: m/z caicd for C20H2 O3 368.2, found [M+H]+ 369.1.
25. {S)-N-{3-amino-1-{hydroxyamino}~3~methyi-1-Qxobutan-2-yl}~4~{5-{1- formy!azetidin-3-yi)penta-1,3-diyn-1-yi)benzam!de (25)
Figure imgf000097_0001
Figure imgf000097_0002
Figure imgf000098_0001
To a stirring solution of compound 24 (12.9 mg, 0.035 mmol) in DMF (140 μΙ_) cooled in ice/MeOH bath was added DIPEA (9.8 μΙ_, 0.056 mmol) followed by 2,2,2-trifluoroethyi formate (3.45 μ!_, 0.035 mmol) and the reaction was stirred for 5 min. The reaction was diluted with water (2 mL), neutralized with AcOH (6 μϋ and purified by RP HPLC (1 ", 0.1 % AcOH in water/ ACN) to yield compound 25 (4.9 mg). MS: m/z calcd for C21 H24N4O4 396,2, found [M+H]+ 397.1.
(S,E}-N-{ 3-amin 0- 1 -{hydroxyami: 3-methyi-1-Qxobuian-2-yl)-4-{4- <zetidin-3~yl)but~3~en~1~yn~ 1 26}
Figure imgf000098_0002
Figure imgf000098_0003
{E)-teii-hutyl 3-{2-iodoviny a etidine-1 -carboxylaie (26.1) Reagent W Eq. mmo! g, mL
Compound 1.3 185, 1 1 .0 10.80 2.0 g
CrC 122.9 5.0 54.0 6.63 g
CHI3 393.7 2.0 21 .6 8.51 g
THF 60 mL
To a stirring solution of CrCI2 (6.63 g, 54.0 mmo!) in THF (40 mL) was added CHi3 (8.51 g, 21.6 mmo!) in THF (15 mL) dropwise at OX. Compound 1.3 (2.0 g, 10.8 mmol) in THF (10 mL) was then added and the reaction was stirred at 0°C for 2 hr then at room temperature for 1 hr. The reaction mixture was added to ice water, and extracted with EtOAc. The organic iayer was washed with aqueous Na2S203, brine, concentrated under reduced pressure to a residue, which was purified by flash chromatography (siiica gel/ PE/EA 20: 1 ) to yield compound 26.1 (2.41 g, 57%) as a yellow oil (2.41 g). H NMR (400 MHz, CDCI3) δ 6.71 (dd, J = 14.5, 8.5 Hz, 1 H), 6.19 (d, J =14.5 Hz, 1 H), 4.08 (i J = 8.5 Hz, 2H), 3.78 (d, J = 6.0 Hz, 1 H), 3,74 (d, J = 4.2 Hz, 1 H), 3.25-3.15 (m, 1 H), 1 .43 (s, 9H).
{S, £}-tert- buiy! 3-{4-{4-(3-(iert-but03 sycarbo nylamino) -1 -meth Dxy-3-!Tiethyi-1 -0 5 obuian-2- yicarbamc >y!)phenyl)but-1 -en~3-yny )a∑etidi ne-1~carb< axy!ate ί 26.2)
Reagent MW Eq. mmol g, mL
Compound 28.1 309 1.0 4.2 1.30 g
Compound I T-1 374.4 1.0 4.2 1.57 g
PdCI2(Ph3)2 701.9 0.1 0.42 0.29 g
Cui 190.5 0.1 0.42 80 mg
Et3N 101 3.0 12.6 1.82 mL
THF 15 mL
To a stirring soiution of compound !NT~1 (1.57 g, 4.2 mmol), PdCI2(Ph3)2 (0.29 g, 0.42 mmol), and Cui (80 mg, 0.42 mmol) in THF (10 mL) was added compound 26.1 (1.30 g, 4.2 mmol) in THF (5 mL), followed by Et3N (1.82 mL, 12.6 mmol) and the reaction mixture was stirred at room temperature overnight. Water was added, and the resulting mixture was extracted with EtOAc. The organic layer was washed with brine, concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gei/PE/EA 2/1 ) to give compound 28.2 (1.20 g, 52%) as a pale yellow oil. MS: m/z calcd for CsoH^ NaGy 555.3, found [M+H]+ 556.
{S,£)~methyi 3-amino~2~C4-{4-Cazet!dsn~3~y!)but^
bss{2,2,2-trifSuoroacetate) (26.3)
Figure imgf000100_0001
To a stirring solution of compound 26.2 (1.1 g, 1.98 mmol) in CH2CI2 (20 mL) at 0°C was added TFA (1.47 mL, 19.8 mmol) dropwise and the reaction mixture was stirred at 0°C for 3 hr. The solvent was evaporated under reduced pressure to give compound 28.3 (0,65 g, 93%) as a yellow solid, MS: /z caicd for C2oH25 3G3 355.2, found [M+H]+ 356; ' H NMR(400 MHz, DMSO-de) δ 8.90 (d, J = 8.8 Hz, 2H), 8,70 (br s, 1 H), 8.16 (s, 3H), 7.94 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 6.50 (dd, J = 15.8, 7.9 Hz, 1 H), 6.03 (d, J = 15.9 Hz, 1 H), 4.94 (d, J = 8.8 Hz, 1 H), 4.12-4.05 (m, 2H), 3.96-3.91 (m ,2H), 3.73 (s, 3H), 3.67-3.62 (m, 2H), 1.39 (s, 3H), 1.37 (s, 3H).
{S,£)- -{3-amsno-1 -{hydroxyammo)-3-m
1 -yn-1 -yl)ben£ami e (26.4)
To a stirring solution of compound 28.3 (2, 18 g, 3.74 mmol) in IPA (8.8 mL) cooled in ice bath was added hydroxy!amine (50% aqueous, 8.8 mL) and the reaction was stirred at 5-10°C overnight. AcOH (9 mL) was added, IPA was removed under reduced pressure and the resulting mixture was purified by RP HPLC (2") to yield 26.4 (1.55 g, 71 %) as the TFA salt. MS: m/z calcd for C19H24N4O3 356.2, found [M+H]+ 357.2,
{S,E -M-{3-amino-1 -(hydroxyamino)-3-methyi-1 -oxobutan-2-y!)-4-{4-{1- ( eihylsulfonyl!)az:eisdin-3-y!)but-3-en-1 -yn-1 -y!)benzamsde (26)
Figure imgf000101_0001
Figure imgf000101_0002
Reactant W Eq Moles Sample Vol Density
(mmol) Mass (ml) (g/rn!)
(mg)
yl)benzamide
ethanesulfonyl chloride 1 14.551 1 0.205 23.52 0.016 1.47
DIPEA 129.243 2 0.41 1 53.1 0.072 0.74
AcOH 60.052 2.1 0.431 25,9 0.025 1.049
To a stirring solution of compound 26,4 (120 mg, 0.20 mmol) in DMF (1 .2 mL) was added DI PEA (72 pL, 0.41 mmol) and the reaction was cooled in an ice bath. Next, methanesulfonyl chloride (4.3 pL, 0.3 equiv) was added and the reaction was stirred for 40 min. Additional methanesulfonyl chloride (1 1 pL, 0.7 eq) was added. Additional DI PEA (1 eq) was added and the reaction was stirred fo 1 .5 hr. Additional methanesulfonyl chloride (1 eq) was added and the reaction was stirred for 30 min. AcOH (70 pL) was added, followed by water (5 mL) and the mixture was purified by RP HPLC (2', 0.1 % TFA in water/ACN) to yield compound 26 (35 mg, 31.1 %). MS: m/z calcd for C20H26 4O5S 434.2, found [M+H]+ 435.2.
27. {S,E}-N-{3-amino-1-{hydroxyamsno}-3-methyi-1-oxobuian-2-yl)-4-{4- (1-formylazetidin-3-y!}biit-3-en-1-yn-1-yl)tenzam!de {27}
Figure imgf000102_0001
Figure imgf000102_0002
Figure imgf000103_0001
To a stirring solution of compound 26.4 (43 mg, 0.12 mmol) in DMF (1 mL) and water (9 drops) was added DIPEA (28 pL, 0.16 mmol) and the reaction was cooled to 0°C. 2,2,2-trif!uoroethy! formate (12 μ!_, 0.12 mmol) was then added and the reaction was stirred for 10 min. The mixture was purified by RP HPLC (1 ", 0.1 % TFA in water/ACN) to yield compound 27 (7,2 mg, 15.4%). MS: m/z calcd for C^H^INL 384.2, found [M+H]1" 385.1.
28. (S,E)-4-(4-(1-acety!azetidin-3-yi}but-3-en-1^n-1-yi)-N-(3-amino-1- (hydroxyamino}-3-methy!-1-oxQtuian-2-y!}benzamide (28)
Figure imgf000103_0002
Figure imgf000103_0003
Figure imgf000104_0001
To a stirring solution of compound 26.4 (0.1 14 g, 0.242 mmol) in DMF (1 mL) was added DIPEA (0.042 mL, 0.242 mmol) and the reaction was cooled to 0°C. Acetic anhydride (7 L) was added and the reaction progress was monitored by LCMS. Additional acetic anhydride (11 μί) was added and the reaction was stirred for 2 hr. The reaction was quenched with n-butylamine (15 pL). TFA (19 pL) was added and the mixture was purified by RP HPLC (1", 0.1 % TFA in water/ACN) to yield compound 28 (67 mg, 69.4%). MS: m/z calcd for C21 H26N404 398.2, found [M+Hf 399.2.
29. N~((S)~3~a ino~1^ydroxyamino)~3-methyM-oxobutan~2~yi)-4-((5~ oxopyrrolidin-3-yl)buta-1,3"diiynyi)benza ide (29)
Figure imgf000105_0001
Figure imgf000105_0002
Figure imgf000105_0003
29.11
1 ,3-dibromo-2,2-dimeihoxypropane (29,2)
Figure imgf000105_0004
To a stirring solution of compound 29.1 (157g , 2.7 mol) in CH3OH (1.6 L) at 0°C was added Br2 (950 g, 5.9 moL) dropwise, and the reaction was stirred with warming to rt for 15 hr. The precipitate was collected by filtration and was washed with cold methanol to yield compound 29.2 (450 g, 60%) as a white solid.
Nisopropy^ 3,3-dimetho) cycyciobutane-1 ,1 -dscarboxyfat 5 ^215-3^
Reagent I MW Eq. mol g, mL Compound 29.2 261.94 1 1.35 mol 360 g
Diisopropyl ma!onate 188.22 2 2.7 mol 507 g
NaH 24.20 2.2 3.0 mol 120 g
DMF 1.0 L
To a suspension of NaH (120 g , 3.0 mol) in DMF (1 L) was added dropwise diisopropyl maionate (507 g, 2.7 mo!) under an Ar atmosphere, and the reaction was stirred. Compound 29.2 (360 g, 1.35 moi) was then added in portions and the mixture was heated to reflux for 48 hr. The reaction mixture was poured into water (2 L), and extracted with PE (6 x 1 L). The combined organic layers were dried, filtered and concentrated under reduced pressure to give a yellow oil, which was purified by distillation under reduced pressure to yield compound 29,3 (150 g, 45%) as a colorless oil.
3~oxocyclobutanecarboxylic acid (29.4)
Figure imgf000106_0001
Compound 29.3 (150 g, 0.52 mol) was added to a solution of 10 M HCi (400 ml), and the reaction mixture was heated to reflux for 60 hr. The reaction mixture was cooled to rt, extracted with Et20 (10 x 1 L) and the combined organic layers were dried, filtered and concentrated under reduced pressure to give compound 29.4 (65 g) as a yellow oil, which was carried through to the next step without further purification.. methyl S-oxocycHobutanecarboxySate (29.5)
Figure imgf000106_0002
S0CI2 1 18.97 65 mL
CH30H 650 mL
To a stirring solution of 29 .4 (65g , 0.57 mo!) in CH3OH { 650 mL) at 0°C was added dropwise SOCI2 (65 mL) and the reaction was stirred with warming to rt for 15 hr. The solvent was removed under reduced pressure, and the residue was diluted with water (200 mL), and extracted with DCM (3 x 200 mL). The combined organic layers were dried, filtered and concentrated under reduced pressure to give a crude, which was purified by flash
chromatography (silica gel/ PE/EA 20: 1 to 50: 1 ) to yield compound 29.5 (50 g, 83%) as a yellow oil.
3-(hy roxymethyi)cydobuian0i (29.6)
Figure imgf000107_0001
To a suspension of LiAIH4 (0.22.8 g , 0.48 mol) in Et20 (500 mL) under an Ar atmosphere was added dropwise a solution of 29.5 (50 g , 0.4 moL) in Et20 (300 mL) and the reaction was stirred at rt for 3 hr. The reaction was quenched with water (44 mL), and the resulting solids were removed by filtration. The filtrate was washed with Et20, and the combined organic Iayers were dried, filtered and concentrated under reduced pressure to yield compound 29.6 (27.8 g, 69%) as a colorless oil.
3-{{tert-buiy1dimethy s!ly!oxy)methy!}cyc!obutanoS (29.7)
Figure imgf000107_0002
TBSCi 150.72 1.1 0.17 mo! 25.0 g
DMAP 122.17 0.1 0.015 mol 1.8 g
NEt3 20 mL
THF 500 mL
To a stirring solution of 29.6 (15.3 g , 0.15 moL) in THF (500 mL) at 0°C was added DMAP (1.80 g, 15 mmoL), followed by TBSCI (25.0g 0.17 mol) and triethy!amine (20 mL) and the mixture was allowed to warm to rt and stirred for 8 hr. The solvent was removed under reduced pressure, and the residue was diluted with water (100 mL), and extracted with DCM (3 x 100 mL). The combined organic layers were dried, filtered and concentrated under reduced pressure to yield compound 29.7 (31 g) as a red oil, which was used in the next step without further purification.
3~((tert-butyldimethyIsilyioxy)methyl)cyciobutyl benzoate (29.8)
Figure imgf000108_0001
To a stirring solution of compound 29.7 (31.0 g , 0.15 moL) in THF (500 mL) at 0°C were added benzoyl chloride (25.2 g, 180 mmoL ) and NEt3 (20 mL) and the reaction mixture was heated to reflux for 15 hr. The solvent was removed under reduced pressure, and the residue was diluted with water (100 mL), and extracted with DCM (3 x 100 mL). The combined organic layers were dried, filtered and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica ge!/PE/Et2G 5: 1 to 1 :1 ) to yield compound 29.8 (25.2 g, 55%). MS: m/z calcd for C18H2803Si 320.2, found [M+Hf 321. 3~{hydroxyrnethyl)cyc!obutyl benzoate (29.9)
Figure imgf000109_0001
To a stirring solution of 29.8 (12.6 g , 39 mmol) in THF (200 mL) was added Bu4NF (10.7 g, 41 mmo!) and the reaction mixture was stirred for 3 hr. The solvent was removed under reduced pressure, and the residue was diluted with water (50 mL), and extracted with DCM (3 x 100 mL). The combined organic layers were dried, filtered and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/PE/EA 5: 1 to1 : 1 ) to yield compound 29.9 (7.2 g, 88%) as a colorless oil.
S-formylcyclobutyf benzoate(29.10)
Figure imgf000109_0002
To a stirring solution of oxalyl chloride (5.04 g , 40 moL) in DCM (40 mL) at -78 °C under an Ar atmosphere was added dropwise a solution of DMSO (6.24 g, 80 mmol) in DCM (20 mL), and the reaction was stirred for 30 min. A solution of compound 29.9 (4.12 g , 20 mmol) in DCM (20 mL) was added dropwise and the reaction was stirred for 30 min. A solution of NEt3 (20.2 g, 200mmo!) in DCM (20 mL) was then added dropwise, and the reaction mixture was allowed to warm to rt over 30 min. The mixture was poured into cold 1 HCI (200 ml), and was extracted with DCM (3 x100 mL). The combined organic layers were dried, filtered and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/PE/EA 5: 1 to1 : 1 ) to yield compound 29.10 (3.8 g, 93%) as a colorless oil.
(1ss3s)-3-(2,2-dibromoviny!}cyctobuty! benzoate(29.11}
Figure imgf000110_0001
To a stirring soiution of CBr,- (9.96 g, 30 moL) in DCM (15 mL) at -20°C under an Ar atmosphere was added dropwise a solution of PPh3 (15.7 g, 60 mmol) in DCM (50 mL) and the reaction was stirred for 30 min. The reaction was cooled to -78°C and a solution of 29.10 (3.06 g, 15 mmol) in DCM (15 mL) was added dropwise, and the reaction was stirred for 30 min. The reaction was allowed to warm to rt over 30 min. The solvent was removed under reduced pressure, and the residue was purified by flash chromatography (silica gel/PEEA 10: 1 to 5: 1 ) to yield compound 29,11 (4.2 g, 79%) as a colorless oil.
Meth l 4-({{1s,3s)-3-{benzoyloxy)cycSobutyl}buta-1 ,3-d5ynyi)benzoate(29.12}
Figure imgf000110_0002
Reagent MVY Eq. Mmol g, mL
NEta 101 .19 3 30 3.04 g
DMF 40 mL
To a stirring solution of 29,11 (3.58 g , 10 mmol), Pd2dba3 ( 91 .6 m g , 0.1 mmo I), TMPP (142 mg ,0.4 mmol), and NEt3 (3.04 g , 30 mmol) in DMF (40 mL) was added INT-1 ,3 (1 .76 g , 1 1 mmol) and the reaction was stirred under an Ar atmosphere at 80 °C for 5 hr. The reaction mixture was diluted with EtOAc (100 mL), washed with water (3 x 50 mL ), dried, filtered and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/ PE/EA 50: 1 to 10: 1 ) to yield compound 29.12 (1 .0 g, 40%) as a yellow solid. MS: m/z calcd for ·0 .Η ·«Ο, 358.1 , found [M+H]+ 359. methyl ^{(flSjSsl-S-h dro yc cSo uty!l uta-l^-d n-l -y!l en^oate (29.13)
Figure imgf000111_0001
Figure imgf000111_0002
To a stirring solution of compound 29.12 (4.2 g, 1 1.78 mmol) in MeOH (150 mL) was added K2C03 (4 g, 29 mmol) and the reaction was stirred overnight. The solvent was removed under reduced pressure, and water and EtOAc were added. The organic layer was washed with brine, dried, filtered and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/EtOAc/PE 1 :10 to 1 :6) to yield compound 29.13 as a solid. MS: m/z calcd for C-BH-,0 254.1 , found [M+H]+ 255. methyl 4-{(3-oxocyc!obuty buta-1,3~dsyn~1~yf)benzoate (29.14)
Figure imgf000112_0001
Figure imgf000112_0003
To a stirring solution of compound 29.13 (4.7 g, 18.48 mmoi) in DCM (80 mL) was added PCC (11.98 g, 55.45 mmoi) and the reaction was stirred overnight. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (silica gel/ EtOAc/PE 1 : 10) to yield compound 29.14. m/z ca!cd for C 6H 203252.1 , found [M+Hf 253. methyl ^{(S-Ch dro ysminolc cSo uiy^ uta-l^-ds n-l-y^ en^oate (29.15)
Figure imgf000112_0002
Figure imgf000112_0004
To a stirring solution of compound 29.14 (3.58 g, 14.19 mmol) in MeOH (50 ml_) was added NH2OH (1.25 g, 17,03 mmoi) and the reaction was stirred overnight. The solvent was removed under reduced pressure to yieid compound 29,15. m/z caicd for C16H13NQ3 267.1 , found [M+H]+ 268. H-NMR (400 MHz, DMSO-d6) δ 10.51 (s, 1 H), 7.95-7.97 (d, 2H), 7.88-7.70 (d, 2H), 3.88 (s, 3H), 3.340-3.48 (m, 1 H), 3.22-3.28 (m, 2H), 2.87-2.99 (m, 2H) methyi 4-{{5-oxopyrrondin-3-y!)buia-1 ,3-diyn-1 -yS)benzoate (29.16)
Figure imgf000113_0001
Figure imgf000113_0002
To a stirring solution of compound 29.15 (3,74 g, 14.03 mmoi) in DCM (50 mL) was added dropwise SOCI2 (3.64 g, 30.87 mmol) and the reaction was stirred for 20 min. The reaction mixture was added to ice-water and the organic Iayer was washed with brine (2 x), dried, filtered and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel/MeOH/DCM) to yield compound 29.16 as a soiid. m/z calcd for C16H13N03 267.1 , found [M+Hf 268. Ή-NMR (400 MHz, DMSO-d6) δ 7.95-7.97 (d, 2H), 7.82 (s, 1 H), 7.68-7.70 (d, 2H), 3.86 (s, 3H), 3.52-3.58 (m, 2H), 3.34 (s, 1 H), 3.22-3.27 (m, 1 H), 2.24- 2.29 (m, 1 H).
4-{{5-oxopyrrondin-3-yS)buta-1 ,3-d!yny!)benz:oic acid (29.17)
Figure imgf000114_0001
Figure imgf000114_0002
To a stirring solution of compound 29.16 (508 mg, 188 mmol) in MeOH (5 mL) and water (5 mL) was added LiOH (134 mg, 5.81 mmol) and the reaction was stirred overnight. MeOH was removed under reduced pressure, and the mixture was acidified to pH 3 with HCI (6 N, 5 mL) and extracted with EtOAc (50 mL). The solids were removed by filtration. The organic layer was concentrated under reduced pressure to yield solsds that were combined to the previously isolated solids to yield compound 29.17 (800 mg), which was carried through to the next step without further purification. MS: m/z caicd for Ci5H, , 03 253.1 , found [M+H]+ 254.1 ,
(2S)-methyl 3-{ieff-butoxycarbonyiam!no}-3-meihy 2-{4-({5-oxopyrroydin-3-yl)buia-1.3- synyf)benzamido)butarsoate (29.18)
Figure imgf000114_0003
To a stirring solution of (S)-methyi 2-amino-3-{ferf-butoxycarbony!amino)-3- methyibutanoate (461 mg, 1.87 mmol) and compound 29.17 (474 mg, 1.87 mmol) in DMF (4 mL) was added DIPEA (0.82 mL, 4.7 mmol) followed by HATU (854 mg, 2,25 mmol) and the reaction was stirred overnight. The reaction mixture was partitioned between 1 M citric acid and ethyl acetate. The organics were washed with semi-saturated sodium chloride, saturated sodium bicarbonate then saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated under reduced pressure to yield compound 29.18, which was carried through to the next step without further purification. MS: m/z calcd for
Figure imgf000115_0002
aOe 481.2, found [M- Boc+H]+ 382.1. ~f(S)~3~amsno-1-(hydroxyamino)~3~^
1 ,3-diyny!)benzarnide (29)
To a stirring solution of compound 29.18 (1.87 mmoi) in MeOH (2 mL) was added HCI (4 M in dioxane, 4 mL) and the reaction was stirred for 3 hr. The reaction was concentrated under reduced pressure at 0°C to yield compound 29.19, which was dissolved in IPA (2 mL) and treated with hydroxylamine (50% aqueous, 2 mL) at 5-10°C overnight. The reaction mixture was concentrated under reduced pressure, diluted with water (4 mL) and ACN (1 mL), acidified at 0°C with TFA (4 mL), and purified by RP HPLC (2" column, 0.1 % TFA in water/ACN) to yield compound 29 (445 mg, 47.7%). MS: m/z calcd for C20H22 4O4 382.2, found [M+H]4' 383.1. 30. N-{(S)~3~8m!no~1~{hydmMyamino}-3~methyM-oxobutan-2^ meihy!~5~oxopyrrQ!sdin-3-y!)buta-1,3~diyny1)benza sde (30) methyf 4~{{1 ~methyf-5-oxopyrro d!n~3~yl)buta~1 ,3-dsyn~1 ~yl)benzoate (30.1)
Figure imgf000116_0001
Figure imgf000116_0003
To a suspension of NaH (18.71 mg, 0.47mmoi) in DMF (2mL) at 0°C were added a solution of compound 29.16 (50 mg, 0.188mmo!) and Me! (53.105mg , 0.376mmol) in DMF (3mL) and the reaction was stirred for 2hr at room temperature, ice-water (10 mL) was slowly added and the reaction mixture was extracted with EA, dried, filtered and concentrated under reduced pressure to give a crude, which was purified by RP HPLC to yieid compound 30.1. MS: m/z ca!cd for C 7H1 SN03 281 .1 , found [M+H]+ 282.
4-{(1 -methy!~S~oxopyrro din-3-y!)buta-1 ,3~diyn-1 -y!)benzosc acid (30.2)
Figure imgf000116_0002
Figure imgf000117_0001
To a stirring solution of compound 30.1 (265 mg, 0.943mmol) in THF (35 mL) was added a solution of LiOH.H20 (158.3mg, 3.772mmo!) in water (15 mL) and the reaction was stirred for 3 hr. The reaction mixture was acidified to pH 1 -2 with HCI (3 M), and was extracted with EA. The organic layer was dried, filtered and concentrated under reduced pressure to yield compound 30.2 as yellow solid. MS: m/z calcd for Ci6Hi3N03 267.1 , found [M+Hf 268.
{2S)-rnethyl 3~C{tert-butoxycarbonyI)amino)~3~methyI-2-(4-((1~rnethyl-S-oxopyrrolidin-3~ yH)buta-1 ,3-diyn~1 ~yl)ben;za!T!!do)butanQate (30.3)
Figure imgf000117_0002
Figure imgf000117_0003
To a stirring solution of compound 30.2 (251 mg, 0.94 mmoi) in DMF (40 mL) were added I T-1.6 (231 mg, 0.94 mmoi), HATU (393 mg, 1.034 mmoi) and DIPEA (364 mg, 2.82 mmoi) and the reaction was stirred overnight. The reaction mixture was diluted with H20, and extracted with EA. The organic layer was washed with brine, dried, filtered and concentrated under reduced pressure to give a crude, which was purified by flash chromatography (silica gel MeOH/DCM) to yield compound 30.3 as a yei!ow solid. MS: m/z calcd for 495.2, found [M+H]+ 496.
(2S)-meihyl 3-amsno-3-meihyi-2-{4-({1-methy!-S-oxopyrro!idin-3-y buta-1,3-d!yn-1 - yl!)benzamido)buianoate (30.4)
Figure imgf000118_0001
Figure imgf000118_0003
HCI(g) was bubbled through a solution of compound 30.3 (372 mg, 0.75 mmol) in MeOH (10 mL) for 2 hr. The solvent was removed under reduced pressure to give compound 30.4 as a yellow solid. MS: m/z calcd for C22H25N304 395.2, found [M+H]+ 396. 1H-NMR (400 MHz, CD3OD) δ 7.89-7.91 (d, 2H), 7.61 -7.83 (d, 2H), 5.01 (s, 1 H), 3.84 (s, 3H), 3.73-3.79 (m, 1 H), 3.45-3.51 (m, 2H), 3.38 (s, 1 H), 2.87 (s, 3H), 2.74-2.80 (m, 1 H), 2.45-2.52 (m, 1 H), 148-149 (d, 8H)
^-C{S)-3-amino-1"(hydroxyam!no)-3-methy^
3-y!)buta-1 s3-diyn-1 -y^benzamide (30)
Figure imgf000118_0002
To a stirring solution of compound 30.4 (45 mg, 0.104 mmol) in IPA (1 mL) was added hydroxyiamine (50% aqueous, 1 mL) and the reaction was stirred overnight. The reaction mixture was cooled to 0°C and acidified with TFA (2 mL), diluted with water (1 mL) and ACN (0.5 mL) and purified by RP HPLC (1 " column, 0.1 % TFA in water/ACN) to yield compound 30 (22.5 mg, 42.2%). MS: m/z ca!cd for C2! H24 404 396.2, found [M+H]+ 397.1 ,
31. N~{(S)-3-amino-1-{hydroxyamino}-3~methyi-1-Qxobutan-2-yl}-4~{(1-(2- (hydroxymethyi}cyciopropanecarbonyl)azetidin-3-yl}ethynyi)benzamide (31)
Figure imgf000119_0001
(S)-methy! 2-{4-(azetidin-3-ySethynyi)ben.:am!do)-3-{(ieri-bi!ioxycarbony!)am!no)-3- methy!butarsoate (31.2)
Figure imgf000119_0002
Figure imgf000120_0001
The reaction was conducted according to procedure 1 to yield compound 31.2.
(2S)-methy! 3~{f ferf-butoxycarbony!)amino)~2~{4-f (1 -{2- (hydroxymeihyl}cyctopropanecarbony!)az:etidm-3-y!)eihyr!y!)benzamido)-3- methyibutanoate (31.3)
Figure imgf000120_0002
The reaction was carried out as described for compound IMT~% to yield compound 31.3 MS: m/z ca!cd for C28H37N3O7 527.3, found [M-Boc+H]+ 428.2. Compound 31.3 was Boc-deprotected according to procedure 2 to yield compound 31.4. ^-{(SJ-S-amino-l -fh drox aminol-S-meth l -o obuian^- ^^-CCI^- {hydroxyrnethy!)cydopropanecarbony1)a2:etsdsn-3-y!)ethynyS)ben2:arnide (31)
To a stirring solution of compound 31 ,4 (6.82 g, 15.95 mmoi) in IPA (20 mL) was added hydroxylamine (50% aqueous, 20 mL) and the reaction was stirred for 28 hr. The reaction was concentrated under reduced pressure and purified by RP HPLC to yield compound 31 (34 mg). MS: /z calcd for C22H28N4Os 428.2, found [M-Boc+H]1" 429.2.
N-((S)-3-hydrQxyaminQ)-3-methyi-1-QXQbutan-2-yl)-4-({1-{Q.
(32)
Figure imgf000121_0001
{S)~ferf~buty! 3-ethyny!pyrralidine-l -carboxylate (32.2)
Figure imgf000121_0002
Figure imgf000122_0001
To a stirring solution of (R)-ferf-butyl 3-formylpyrro!idine-1-carboxyiate (2.4 g, 12.05 mmol) in ACN (25 mL) was added Bestmann reagent (2.33 g, 12.05 mmol), followed by K2C03 (3.33 g, 24.09 mmol) and the reaction mixture was stirred for 24 hr. Solvent evaporation under reduced pressure gave a crude, which was purified by flash chromatography (silica gel, 2- 60% EA in DC ) to yield compound 32.2 (980 mg).
(S)-f erf-butyl 3~{(4-({{S)-3-hydroxy~1 -methoxy-S-methyl!-l -oxobutan-2- yS)carbamoyl}pheny buta-1 ,3-diyn-1-y pyrro!idine-1-carboxyiaie (32.3)
Figure imgf000122_0002
To a stirring solution of hydroxyiamine hydrochloride (8,33 mg, 0, 120 mmol) and copper chloride (3.95 mg) in 30% n-butylamine (aqueous, 5 mL) was added (S)-fert-buty! 3- ethynylpyrrolidine-1-carboxylate (0.78 g, 1 ,997 mmol) and the reaction was stirred for 20 min. A solution of (S)-methyi 2-(4-(bromoethynyl)benzamido)-3-hydroxy-3-methylbutanoate (0.707 g, 1997 mmol) in 30% n-butyiarnine (aqueous, 5 mL) and THF (10 mL) was then added and the reaction was stirred for 30min. Excess solvent was removed under reduced pressure, and the reaction mixture was extracted with EA (3 x 100 mL). Solvent evaporation under reduced pressure gave compound 32,3, which was carried through to the next step without further purification. MS: m/z calcd for CseHas sOe 468.2, found [M+H 469.2.
{2S)-methy 3-hydroxy-3-methy 2-{4-{pyrrondin-3-ySbuia-1 ,3-diyn-1 - y benxamidoJbutanoate (32.4)
Boc deprotection was carried out according to procedure 2 to yield compound 32,4. MS: m/z calcd for C21 H24N2O4 368.2, found [M+Hf 369.1.
A^((S)-3 iydroxyamino)-3 nethyl-1 ^>xobutan^
1 ,3-diyn-1 -yl)benzamide (32)
Figure imgf000123_0001
To a stirring solution of compound 32.4 (360 mg, 0.977 mmol) in THF (2 mL) was added AcOH (0.2 mL), oxetan-3-one (141 mg, 1.95 mmol) and sodium cyanoborohydride and the reaction was stirred for 3 nr. The reaction was concentrated under reduced pressure to yield compound 32. S, which was dissolved in I PA (3 mL) and treated with hydroxyiamine (50% aqueous, 3 mL) for 2 days. The reaction mixture was concentrated under reduced pressure and purified by RP HPLC to yield compound 32. MS: m/z calcd for C23H27N3G5 425.2, found [!VHH]4 426.3.
33. N-((S)'3~hydrQxy"1-(hydroxya inQ)-3' ethyl~1-Qxobutan-2-y!)'4~({(S)-- 1-(2-hydroxyethy!}pyrrolidin-3-y!}buta-1,3-dsyn-1-yl}benzamide β3)
Figure imgf000124_0001
(S)-methy! 3-hydroxy-2-(4-{{{S)-1 -{2-hydroxyethy!)pyrro din-3-y buta-1 ,3-diyn-1■ y ben2amido)-3-methy!buianoate (33,2)
Figure imgf000124_0002
To a stirring solution of compound 32.3 (360 mg, 0.98 rnmoi) in MeOH (5 mL) was added 2-((ienf-butyldimethylsilyl)oxy)aceta!dehyde (170 mg, 0.98 rnmoi) and sodium cyanotrihydroborate (61.4 mg, 0.98 mmol) and the reaction was stirred for 2 hr. The mixture was concentrated under reduced pressure to yield compound 33.1 , which was dissolved in TFA (4 mL) and stirred for 18 hr. The reaction was concentrated under reduced pressure to yield a residue, which was neutralized with saturated aqueous K2C03 and extracted with EA (3 x 100 mL). The combined organic layers were dried, and concentrated under reduced pressure to yield compound 33,2, which was carried through to the next step without further purification.
^-{{S)-3-h droxy~1 ~{hydroxyamino)-3-rr8eih l-1 -oxobutan-2-y!)-4-{{{S)-1 -(2- hydroxyethy pyrro!idin«3-yJ)buia-1 ,3-diyn-1 -y^benzamide {33}
To a stirring solution of compound 33.2 in IPA (5 mL) was added hydroxylamine (50% aqueous, 4 mL) and the reaction was stirred for 2 days. IPA was removed under reduced pressure, and the residue was acidified with AcOH (5 mL), filtered and purified by RP HPLC (0.1 % TFA in water/ACN) to yield compound 33. MS: m/z calcd for C22H27N3O5 413.2, found [M+H]+ 414.2.
Figure imgf000125_0001
4-[4-{Azetidin-3-yi)buta-1 l3-diynyl]-N-[(1 S)-2-hydlroxy-1 -(hydroxy carbamoyi)-2- methyi-propyi]benzamide acetate (2b, 50 mg, 0.12 mmol) was dissolved in methanol (1 mL) and cooled in an ice bath. N,N"-diisopropy!ethy!amine (0.02 mL, 0.1 1 mmol) and THF (0.50 mL) were added followed by 1-fluoropropan-2-one (0.03 mL, 0.36 mmoi). Sodium triacetoxyborohydride (127.54 mg, 0.60 mmoi) was added and the reaction was stirred at ambient temperature for 45 minutes. The reaction was concentrated under reduced pressure and redissolved in D F. It was purified by RP HPLC (0.1 % TFA in water/ACN, 5-10-30%) to give 34 as a white solid as the TFA salt (31.5 mg, 0.060 mmoi, 49% yield). MS: m/z calcd for C22H26FN3O4 415.2, found [M+Hf 416.1.
Figure imgf000126_0001
4-[4-(3-Hydroxycyc!obuty!)buta-1,3~diyny!]benzo!C acid (35.1)
Methyl 4-[4-(3~hydroxycyciobutyi)buta- 3-diynyl]benzoaie (29,13, 5,09 g, 20.02 mmol) was dissolved in THF (60 mL) and 1.0 M sodium hydroxide (60.05 mL, 60.05 mmol) was added. After 4 h, the reaction was concentrated under reduced pressure to remove most of the THF. The solution was cooled in an ice bath and acidified with 6 mL of cone HCI. A purple- white solid was filtered off and rinsed with EtOAc and then dried further under vacuum to yield compound 35.1 (4.5 g, 94%). MS: m/z caicd for C15H1203 240.1 , found [M+H]+ 241.1.
Methy {2S)-3-hydroxy-2-[[4-[4-(3-hydroxycyciobuty!)buia-1^-dsynyi]ben2:oy am!no]-3- methyl-butanoate (35.2)
4-[4-(3-Hydroxycyc!obuty!)buta-1 ,3-diynyl]benzoic acid (35.1 , 500 mg, 2.08 mmol) was dissolved in DMF (4 mL) to give a clear solution containing a small amount of purple solid. The solution was cooled in an ice bath and N,N"-diisopropyiethy!amine (0.8 mL, 4.58 mmol), methyl (2S)-2-amino-3-hydroxy-3-methy!-butanoate hydrochloride (382.2 mg, 2.08 mmol) and HATU (830,8 mg, 2.19 mmol) were added. The reaction was stirred at rt for 2 h and then it was diluted with EtOAc and washed with 1 M citric acid (2X), water, sat bicarb and brine, then dried with sodium sulfate, filtered and concentrated under reduced pressure to yield compound 35.2 (755 mg, 98%). MS: m/z calcd for C21 H23N05 369.2, found [M+Hf 370.0. Methyl (2S)-3-hydroxy~3-methy!-2-[[4-[4-{3-oxocyc!obutyS)buta-1 ,3- diynynbenzoynaminojbutanoaie (35.3)
Methyl (2S)-3-hydroxy-2-[[4-[4-(3-hydroxycyclobutyl)buta-1 ,3-diynyl3benzoyl]amino]-3- methy!-butanoate (35,2, 755 mg, 2.04 mmol) was dissolved in DCM (10 mL), triethyl amine (1 .42 mL, 10.22 mmol) and dimethy!sulfoxide (1 .6 mL, 22.48 mmol). Sulfur trioxide pyridine complex (1.3 g, 8.18 mmol) was added and the reaction was stirred at rt for 17h, The reaction was concentrated under reduced pressure and redissoived in EtOAc. The solution was washed with 1 M citric acid (2x), water, sat bicarb and brine, then dried with sodium sulfate, filtered and concentrated under reduced pressure to yield compound 35.3 (627 mg, 84%). MS: m/z calcd for C21 H21 NO5 367, 1 , found [M+Hf 368.1 .
Methy {2S)-3-hydroxy-2-[[4-[4-[3-{3-hydroxya2eisdin-1 -y!)cyciobuiy buta-1 ,3- dsynyf]benzoyi]amsno]-3-methyi~buianoate (35.4)
Azetidin-3-ol hydrochloride (89.45 mg, 0.82 mmoi) was dissolved in MeOH (2 mL) and dipotassium carbonate (0.41 mL, 0.82 mmol) was added. The reaction was stirred at rt for 10 min. The reaction was cooled in an ice bath and then acetic acid (0.12 mL, 2.18 mmol), methyi-(2S)-3-hydroxy-3-methyi-2-[[4-[4-(3-oxocyclobuty!)buta-1 ,3- diyny!]benzoy!]amino]butanoate (35.3, 100 mg, 0.27 mmol) and sodium cyanoborohydride (34.21 mg, 0.54 mmol) were added and the reaction was stirred at rt. After 0.75 h, the reaction was diluted with EtOAc and washed with sat bicarb and brine, then dried with sodium sulfate, filtered and concentrated under reduced pressure to yield methyl {2S)-3-hydroxy-2-[[4-[4-[3-(3- hydroxyazetidin-1 -yl)cyclobutyi]buta-1 ,3-diynyi]benzoy!]amino]-3-methyi-butanoate (72.5 mg, 0.17 mmol, 62.7% yield). MS: m/z calcd for C24H28 205 424.2, found [M+Hf 425.1. i¥- 3-hydroxy-1 -(hydroxya!Tiino -3-methy!-1 -oxobutan-2-yS)-4-((3-(3-hydroxya-eetidin-1 - y cyc!obuiy bisia-1 ,3-diyn-1 -yl)benza!Tiide (35)
Methy!-(2S)-3-hydroxy-2-[[4-[4-[3-(3-hydroxyazetidin-1 -yl)cyc!obutyl]buta-1 l3- diyny!]benzoy!]amino]-3-methyi-butanoate (35.4, 72.5 mg, 0.17 mmol) was treated according to Procedure 3 to yield compound 35 (21.7 mg, 0.040 mmol, 23.2 % yield). MS: m/z calcd for Cy,H;¾F3 30/ 425.2, found [M+Hf 426.1.
36. N-({S)-3-hydtQxy-1-(hydmxya !nQ)-3- ethy!-1-oxobutan-2-y!)-4-{(3- ((S)-3-hydroxypyrfoiidin-1-yi}cy obutyl}buta-1,3-diyn-1-yl)benzamide (36)
Figure imgf000128_0001
ethyl! (S)-3^ droxy~2~{4-(f3-{{S)-3^ droxypyrro dm-1-y1)cyc!obuty!)buta-1,3~diyn-1 - yS)benzamido)-3-methy!butanoate (36.1)
(3S)-Pyrroiidin-3-ol hydrochloride (67.27 mg, 0.54 mmol) and N,N"- diisopropy!ethy!amine (0.09 mL, 0.52 mmol) were combined in MeOH (2 mL). The reaction was cooled in an ice bath and then methyl (2S)-3-hydroxy-3-methyl-2-[[4-[4-(3- oxocyclobutyi)buta-1 ,3-diynyl]benzoyl3amino]butanoate (35.3, 100 mg, 0.27 mmol) and sodium triacetoxyborohydride (230.75 mg, 1.09 mmol) were added and the reaction was stirred at rt. After 0.75 h, the reaction was diluted with EtOAc and washed with sat bicarb and brine, then dried with sodium sulfate, filtered and concentrated under reduced pressure to yield 36.1 (97 mg, 0.221 mmol, 81.3 % yield) MS: m/z calcd for C2sH3oN2G5 438.2, found [M+Hf 439.2.
N-((S}-3- ydmxy-1-(hydrQxyamh )-3-met yi-1-QXQbutan-2-yl}-4-((3-((S^
hydrQxypyrrolld -l-yljcycSobutyljbuta-l^-diyn-l-yljbenza sde (38)
Compound 36.1 (97 mg, 0.22 mmol) was treated according to Procedure 3 to yield 36 (37 mg, 30%). MS: m/z calcd for CssHaoFa aO? 439.2, found [M+H]+ 440.1. 37. N-((S)~3~hydroxy~1~(hydroxyamino)~3~methyi-1-oxobutan-2-yl)~4~{(3~ {{R)-3-hydroxypyrro!idin~1~y!}cyc!obuty!)bista-1,3-diyn~1^!)benzai ide (37)
Figure imgf000129_0001
Methyl (S)-3-hydr0xy~2~{4~(f3-{(/?)~3~hy^^
y ben amido)-3-methy!butanoaie (37,1)
(3 ?)-Pyrrolidin-3-ol hydrochloride (67,27 mg, 0.54 mmol) and N,N"~ diisopropy!ethyiamine (0.09 mL, 0.52 mmoi) were combined in MeOH (2 mL). The reaction was cooled in an ice bath and then methyi-(2S)-3-hydroxy-3-methyi-2-[[4-[4-(3- oxocycIobuty!)buta-1 ,3-diynyl]benzoyI]amino]butanoate (35,3, 100 mg, 0.27 rnmol) and sodium triacetoxyborohydride (230.75 mg, 1.09 mmoi) were added and the reaction was stirred at rt. After 0.75 h, the reaction was diluted with EtOAc and washed with sat bicarb and brine, then dried with sodium sulfate, fiitered and concentrated under reduced pressure to yield compound 37,1 (105 mg, 88%). MS: m/z calcd for C25H3oN205 438.2, found [ +Hf 439.2.
N-((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4^^
hydrox pyrroHdm-1-yl}cyclobuiyl)buta-1,3-dlyri-1-yf)berizamlde (37)
Compound 37.1 {105.mg, 0.24 mmol) was treated according to Procedure 3 to yield compound 37 (35 mg, 26%). MS: m/z calcd for C26H30F3N3O7 439.2, found [M+Hf 440.1 . 38. 4-({3-{3-H uoroa£etidin-1 ~y!)cydobutyf)buia-1 ,3-diyn-1 -yf)-N-(3- hydroxy-1 -{hydroxyamino}-3-methy 1 -oxobutan-2-yl}benzamide (38)
Figure imgf000130_0001
Meth HS)-2-f4-({3 3-fiuGroazet!d!n-1 ^
hydroxy-3-meihyibutanoate (38.1)
3-Fiuoroazetidine hydrochloride (57.69 mg, 0.52 mmoi) and Λ/,Λ -diisopropy!ethylamirie (0.09 mL, 0.49 mmoi) were combined in MeOH (2 mL) . The reaciion was cooled in an ice bath and then methy!-(2S)-3-hydroxy-3-methy!-2-[[4-[4-(3-oxocyclobuty!)buta-1 ,3- diyny!]benzoyi]amino]butanoate (35,3, 95 mg, 0.26 mmoi) and sodium triacetoxyborohydride (219.21 mg, 1.03 mmoi) were added and the reaction was stirred at rt. After 0.75 h, the reaction was diluted with EtOAc and washed with sat bicarb and brine, then dried with sodium sulfate, filtered and concentrated under reduced pressure to yield compound 38.1 (94 mg, 85%). MS: m/z calcd for C24H27FN2O4 426,2, found [M+H]+ 427.2.
4-{{3-(3-Fiuoroazetidin-1-yl)cyctobuty!)buta-1 ,3-dsyn-1 -yi)-N^3-hydroxy-1 -(hydroxyamino)- 3-methyM ~oxobutan~2~yi)benzamide (38)
Compound 38.1 (93 mg, 0.22 mmmol) was dissolved in I PA (0.45 mL) and cooled in an ice bath. Hydroxylamine (0.58 mL, 8.72 mmoi) was added and the reaction was stirred at 4° C for 4 days. The reaction was concentrated under reduced pressure to remove the I PA and then acidified with acetic acid, diluted with D F and purified by RP HPLC (1", 0.1 % TFA in water/ACN) to yield compound 38 (32 mg, 26%). MS: m/z calcd for C25H27F4 306 427.2, found [M+H]+ 428.1. 39. 4-f{1-{2-Cyanoethy!)a∞tidin-3-y1)buta-1!3-diyn-1 -y )~N-(3-hydroxy-1 - (hydroxyamino)-3- eihyM -oxobutan-2-y!)benzamide (39)
Figure imgf000131_0001
To a stirring solution of compound 2b (35 mg, 0.08 mmoi) in ACN (0.3 mL) and water (0.12 mL) was added prop-2-enenitri!e (0.01 mL, 0.10 mmoi) followed by potassium carbonate (5 mg) and the reaction became biphasic. The reaction was stirred vigorously at rt. After an hour, another portion of potassium carbonate (5 mg) was added and the reaction was stirred for 24 hours. The reaction was acidified with acetic acid and purified by RP HPLC (1 ", 0,1 % TFA in water/ACN) to yield compound 39 (16 mg, 36%). MS: m/z. calcd for C24H25F3 4O6 408.2, found [M+H]+ 409.0,
The following compounds of the invention may be prepared according to the synthetic procedures described above:
Figure imgf000131_0002
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
H 3-methyl-1 -oxobuiars-2-yl)berszamide
Figure imgf000137_0001
yi)buta-1,3-diyn-1-y!)berizamide
Figure imgf000138_0001
y!)benzamide
Figure imgf000139_0001
Figure imgf000140_0001
y!)benzamide
Figure imgf000141_0001
Figure imgf000142_0001
B, Antimicrobial! Activity
1. Bacteria! Screens and Cultures
Bacterial isolates were cultivated from -70° C. frozen stocks by overnight passages at 35 C in ambient air on Mue!!er-Hinton agar (Beckton Dickinson, Franklin Lakes, NJ). Clinical isolates tested were obtained from various geographically diverse hospitals in the US and abroad (Focus Diagnostics, Herndon, VA and JMl, North Liberty, IA). Quality control strains were from the American Type Culture Collection (ATCC: Rockviile, Md.).
2, Susceptibility Testing
Minimum inhibitory Concentrations (MICs) were determined by the broth microdilution method in accordance with the Clinical and Laboratory Standards Institute (CLSl) guidelines. In brief, organism suspensions were adjusted to a 0.5 McFarland standard to yield a final inoculum between 3x 105 and 7x 10b colony-forming units (CFU)/mL. Drug dilutions and inocu!a were made in sterile, cation adjusted Mue!ier-Hinton Broth (Beckton Dickinson). An inoculum volume of 100 \iL was added to wells containing 100 uL of broth with 2-fold serial dilutions of drug. All inoculated microdilution trays were incubated in ambient air at 35° C for 18-24 h. Following incubation, the lowest concentration of the drug that prevented visible growth (OD600 nm < 0.05) was recorded as the MIC. Performance of the assay was monitored by the use of laboratory quality-control strains and levofloxacin, a compound with a defined MIC spectrum, in accordance with CL8I guidelines. Typically, compounds of the present invention have MIC values of 0.03 - 16 ng/mL. To this end, data for certain representative compounds is shown in Table I below.
Table I: Minimum Inhibitory Concentrations (MICs)
Figure imgf000143_0001
Figure imgf000144_0001
MIC Key:
A = MlC's of 1.0 Mg/mL or less
B = MlC's of greaier than 1.0 g/mL to 8.0 Mg/mL
C = MlC's of greater than 8.0 Mg/mL to 16.0 Mg/mL
D = MlC's of greater than 16.0 Mg/mL
*AEC001 is E, Coii is ATCC 25922; APAE001 is Pseudomonas aeruginosa ATCC27853; It should be understood that the organic compounds according to the invention may exhibit the phenomenon of tautomerism. As the chemical structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the invention encompasses any tautomeric form of the drawn structure.
Furthermore, while particular embodiments of the present invention have been shown and described herein for purposes of illustration, it will be understood, of course, that the invention is not limited thereto since modifications may be made by persons skilled in the art, particularly in light of the foregoing teachings, without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
Ail of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification are incorporated herein by reference, in their entirety to the extent not inconsistent with the present description.

Claims

WHAT IS CLAIMED IS:
1 , A compound of formula I:
Figure imgf000146_0001
or a stereoisomer, pharmaceutically acceptable salt or ester thereof, wherein
A is azetidinyl or pyrrolidinyi, wherein said azetidinyl or pyrrolidiny! is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted d-C3 alky!, halogen, cyano, -C(0)R4, oxo, hydroxyl, -S(0)2R4, substituted or unsubstituted C3-C6 heterocyclyl and substituted or unsubstituted C4-C7 heterocyciyialkyl;
B is absent, a CrC2 aikylene or C3~C6 cycloalkyi wherein said d-C2 aikyiene or C3-C6 cyc!oaikyl is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted C C3 alkyi, halogen, cyano, -C(0)R4, oxo, hydroxyl, -S(0)2R4, substituted or unsubstituted C3-C6 heterocyclyl and substituted or unsubstituted C4-C7 heterocyciyiaikyl;
or A and B together form a fused 5-9 membered bicyc!ic ring system, wherein A is azetidinyl or pyrrolidinyi and B is a C3-C3 cycloaikyl and wherein each of A and B is unsubstituted or substituted with 1 or 2 groups selected from substituted or unsubstituted Ci-C3 alkyi, halogen, cyano, -C(0)R4, oxo, hydroxyl, ---S(0)2R4, substituted or unsubstituted C3-C6 heterocyclyl and substituted or unsubstituted C4-C7 heterocyciyiaikyl;
G is selected from the group consisting of -C≡C-, -CH=CH-C≡C--, -C≡C-CH=CH-, and " 0 ~ ~~C -~ """ .
Q is O or NR, wherein R is hydrogen or an unsubstituted d-C3 alkyi;
Ri and R2 independently are selected from the group consisting of hydrogen, substituted or unsubstituted d-C3 aikyl, substituted or unsubstituted C3-C6 cycloaikyl, substituted or unsubstituted 4-6 membered heterocyclyl, and substituted or unsubstituted heteroaryl, or R-. and R2, together with the carbon atom to which they are attached, form an unsubstituted C3-C6 cycloalkyl group or an unsubstituted 4-8 membered heterocyclic group;
R3 is selected from the group consisting of hydrogen, substituted or unsubstituted Ci-C6 alky!, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloaikylalky!, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyi, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroaryla!ky!;
each R4 is independently hydrogen, substituted or unsubstituted C C3 alkyi, substituted or unsubstituted C3-C6 cycloalkyl or NRSR6; and
each R5 and R6 is independently hydrogen or C C3 alkyl.
2. The compound of claim 1 , wherein R3 is hydrogen or a substituted or unsubstituted C C6 alkyi.
3. A compound according to any one of claims 1-2, wherein G is -C≡C-C≡C-
4. A compound according to any one of claims 1-3, wherein Q is NR,
5. A compound according to claim 4, wherein R is hydrogen.
8. A compound according to any one of claims 1-3, wherein Q is O and R3 is H.
7. A compound according to any one of claims 1-8, wherein R-, is methyl and R2 is methyl.
8. A compound according to any one of claims 1-7, wherein B is absent.
9. A compound according to any one of claims 1-7, wherein B is C C2 alkyiene.
10. A compound according to any one of claims 1-7, wherein B is C3-C6 cycloalkyl.
1 1. A compound according to any one of claims 1-10, wherein A is unsubstituted azetidinyl.
12. A compound according to any one of claims 1-10, wherein A is azetidinyl substituted with 1 or 2 groups selected from substituted or unsubstituted C;~C3 alkyi, -C(0)R4, substituted or unsubstituted C3-C6 heterocyclyl, hydroxy! and -8(0)2R,:.
13. A compound according to claim 12, wherein A is azetidinyl substituted with substituted or unsubstituted C<-C3 alkyl.
14. A compound according to claim 12, wherein A is azetidinyl substituted with -C(0)R .
15. A compound according to claim 14, wherein R4 is hydrogen,
16. A compound according to claim 14, wherein R4 is methyl.
17. A compound according to claim 14, wherein R4 is CrC3 a!kyi substituted with hydroxy!.
18. A compound according to claim 14, wherein R4 is C C3 alky! substituted with amino.
19. A compound according to claim 14, wherein R4 is CrC3 alky! substituted with hydroxy! and amino.
20. A compound according to claim 14, wherein R4 is substituted C3~C6 cyc!oalkyi,
21. A compound according to claim 14, wherein said azetidinyi is further substituted with hydroxy I.
22. A compound according to claim 12, wherein A is azetidinyi substituted with C3-C6 heterocyclyl.
23. A compound according to claim 12, wherein A is azetidinyi substituted with hydroxyl.
24. A compound according to claim 12, wherein A is azetidinyi substituted with -S(0)2R,:.
25. A compound according to claim 24, wherein R4 is methyl.
26. A compound according to claim 14, wherein R4 is NR5R6.
27. A compound according to claim 26, wherein R5 and R6 each is hydrogen.
28. A compound according to claim 26, wherein R5 is Ci-C3 aikyi and R6 is hydrogen.
29. A compound according to claim 28, wherein R5 is methyl.
30. A compound according to any one of claims 1-10, wherein A is unsubstituted pyro!iidinyl.
31. A compound according to any one of claims 1-10, wherein A is pyrroiidinyl substituted with 1 or 2 groups selected from substituted or unsubstituted Ci-C3 alkyl, -C(0)R4, substituted or unsubstituted C3-C6 heterocyclyl, oxo, hydroxy! and -S(0)2R4.
32. A compound according to claim 31 , wherein A is pyrroiidinyl substituted with substituted or unsubstituted C<-C3 alkyl,
33. A compound according to claim 31 , wherein A is pyrroiidinyl substituted with substituted or unsubstituted C3-C6 heterocyclyl.
34. A compound according to claim 31 , wherein A is pyrroiidinyl substituted with oxo.
35. A compound according to claim 31 , wherein A is pyrroiidinyl substituted with hydroxy!.
36. A compound according to claim 1 , wherein G is -CH=CH-C≡C-,
37. A compound according to claim 36, wherein A is azetidiny! substituted with 1 or 2 groups selected from substituted or unsubstituted C C3 alkyi, -C(0)R4, C3-C6 heterocyciyl, hydroxy! and ~S(0)2R4.
38. A compound according to claim 37, wherein A is azetidiny! substituted with -C(0)R4 or -S(0)2R4.
39. A compound according to claim 38, wherein R4 is hydrogen or methyl.
40. A compound according to claim 36, wherein A is pyrrolidinyi substituted with 1 or 2 groups selected from substituted or unsubstituted C C3 alkyi, oxo, C3-C6 heterocyciyl, hydroxy! and -S(0)2R4.
41. The compound of claim 1 , wherein said compound is:
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(azetidin-3-y!buta-1 ,3- diynyl)benzamide (1 );
(SH-((1-acetylazetidin-3-yl)buia-1 ,3-diyn-1-yl)-A -(3-hydroxy-1-(hydroxyamino)-3-methy!-1- oxobutan-2-yl)benzamide (2a);
(S)-4-((azetidin-3-y!)buta-1 ,3-diyn-1-y!)-^
yl)benzamide (2b);
(S)-4-((1-formylazetidin-3-yi)buta-1 ,3-diyn-1-yl)-A -(3-hydroxy-1-(hydiOxyamino)--3-methy!--1-- oxobutan-2-yl)benzamide (3);
(S)-4-((1-(2-aminoacetyi)azetidin-3-yl)buta-1 ,3-diyn-1-yl)-W-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-y!)benzamide (4);
4-((1-(2-amino-3-hydroxypropanoyi)azetidin-3-yl)buta-1 ,3-diyn-1-yi)-W-((S)-3-hydroxy-1- (hydroxyamino)-3-methy!-1-oxobutan-2-y!)benzamide (5);
(S)-A/-(3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yi)-4-((1-(2-hydroxyethyl)azetidin-3- yi)buta-1 ,3-diyn-1-y!)benzamide (6);
(S)-A/-(3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-methy!az.etidin-3-yi)buta- 1 ,3-diyn-1-y!)benzamide (7);
(S)-A -(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-(oxetan-3-yi)azetidin-3- y!)buta-1 ,3-diyn-1-yl)benzamide (8); /V-((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yl)-4-(5-((2/:?,3S)-3- hydroxypyrroiidin-2-yl)penta-1 ,3-diyn-1-y!)benzamide (9);
(S)-4-((1-acetyiazetidin-3-yi)buta-1 ,3-diyny!)-A/-(3-amino-1-(hydroxyamino)-3-methy!-1- oxobutan-2-yl)benzamide 2,2,2-trif!uoroacetate (10);
(S)-3-((4-(3-amino-1-(hydroxyamino)-3-meihyl-1-oxobuian-2-ylcarbamoyl)phenyl)buta-1 l3- diyny!)-A/-methylazetidine-1-carboxamide (1 1 );
(S)-3-((4-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-ylcarbamoyl)phenyl)buta-1 !3- diyny!)azetidine-1 -carboxamide (12);
(S)-4-((1-acetyiazetidin-3-yi)buta-1 ,3-diyny!)-^
1-oxobutan-2-y!)benzamide (13);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-(2-hydroxyacetyl)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (14);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobuian-2-yi)-4-((1-{2-hydroxyethy!)azeiidiri-3- yl)buta-1 ,3-diyn-1-y!)benzamide (15);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyI-1-oxobuian-2-y!)-4-((1-formyIazetidin-3-yI)buia-1 ,3- diyn-1-yi)benzamide (16);
(S)-4-((1-formylazetidin-3-yl)buta-1 ,3-diyn-1-yl)-A/-{1-(hydroxyamino)-3-methyi-3-(methyiam^ 1-oxobutan-2-yi)benzatnide (17);
(S)-4-((1-acetyiazetidin-3-yl)buta-1 l3-diyn-1-y!)-A/-(1-(hydroxyamino)-3-methy!-3-(meihylamino)- 1-oxobutan-2-y!)benzamide (18);
(S)-4-((1-acetyi-3-hydroxyazetidin-3-y!)buta-1 ,3-diyn-1-y!)-A/-(3-amino-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yi)benzamide (19);
A/-((2Sl3 ?)-3-amino-1-(hydroxyamino)-1-oxobutan-2-y!)-4-((1-formyiazetidin-3-yi)buta-1 ,3-diyn 1-yl)benzamide (20);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-(methy!suifony!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (21 );
4-({1-formylazetidin-3-yl)buta-1 ,3-diyn-1-yl)-N^^
oxobutan-2-yl)benzamide (22); (S)-A/-(3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((1-(oxetan-3-y!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (23);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-(5-(azetidin-3-yl)penta-1 ,3-diyn- 1-yi)benzamide (24);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methy!-1-oxobuian-2-yi)-4-(5-(1-formylazetidin-3-yl)penta- 1 ,3-diyn-1-yI)benzamide (25);
(S!£)-A -(3-amino-1-(hydroxyamino)-3-methyi-1-oxobutan-2-y!)-4-(4-(1-(methyisulfonyi)azetidi
3- yi)but-3-en-1-yn-1-yl)benzamide (26);
(S!£)-A/-(3-amino-1-(hydroxyamino)-3-meihy!-1-oxobuian-2-yi)-4-(4-{1-formylazeiidin-3-y!)bu en-1-yn-1-y!)benzamide (27);
(S,£)-4-(4-(1-acety!azetidin-3-y!)but-3-en-1-yn-1-yl)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (28);
(S,£)-4-(4-(1-ace1y!azeiidin-3-y!)bui-3-en-1-yn-1-yl)-W-{3-amino-1-(hydroxyamino)-3-methyl-1^ oxobutan-2-yl)benzamide (29);
A/-((S)-3-amino-1-(hydroxyamino)-3-methyI-1-oxobutan-2-y!)-4-((1-methyi-5-oxopyrroIidin-3- yl)buta-1 ,3-diyny!)benzamide (30);
A/-{(S)-3-amino-1-{hydroxyamino)-3-methy!-1-oxobutan-2-y!)-4-{(1-(2- (hydroxymethyi)cyc!opropanecarbonyl)azetidiri-3-yi)ethyny!)benzamide (31 );
W-((S)-3-hydroxyamino)-3-meihy!-1-oxobutan-2-yl)-4-((1-(oxetan-3-yI)pyrrolidin-3-yl)buta-1 ,3- diyn-1-y!)benzamide (32);
A -((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yl)-4-(((S)-1-(2- hydroxyethyl)pyrrolidin-3-yl)buta-1 ,3-diyn-1-y!)benzamide (33);
4- ((1-(1-fluoropropan-2-yl)azetidin-3-yl)buta-1 !3-diyn-1-yl)-N-((S)-3-hydroxy-1-(hydroxyamino)-3- methy!-1-oxobutan-2-yi)benzamide (34);
N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((3-(3-hydroxyazetidin-1- yl)cyciobutyl)buta-1 ,3-diyn-1-yl)benzamide (35);
N-{(S)-3-hydroxy-1-(hydroxyamino)-3-meihy!-1-oxobutan-2-yi)-4-((3-((S)-3-hydroxypyrroiidir!-1- yI)cyc!obutyl)buta-1 ,3-diyn-1-yl)benzamide (36); N-((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((3-((R)-3-hydroxypyrro!idin-1- yl)cyciobutyl)buta-1 ^-diyn-l-yljbenzamide (37);
4-((3-(3-fluoroazetidin-1-yl)cyclobutyl)buta-1 ,3-diyn-1-y!)-N-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yl)benzamide (38);
4-((1-(2-cyanoethyl)azeiidin-3-yi)buta-1 ,3-diyn-1-yi)-N-(3-hydroxy-1-(hydroxyamino)-3-meihyl-1- oxobutan-2-yl)benzamide(39);
4-((1-(2!2-difluoroethyl)azetidin-3-yi)buta-1 ,3-diyn-1-y!)-N-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yl)benzamide (40);
4-((1-(2-amino-2-oxoethy!)azetidin-3-y!)buia-1 ,3-diyn-1-y!)-N-(3-hydroxy-1-{hydroxyamino)-3- methyi-1-oxobutan-2-yI)benzamide (41 );
4-((3-(3-fluoropyrrolidin-1-y!)cyc!obutyl)buta-1 ,3-diyn-1-yl)-N-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yi)benzamide (42);
4-((3-(3l3-difluoroazeiidiri-1-yl)cyclobutyl)buta-1 ,3-diyri-1-yl)-N-{3-hydroxy-1-(hydroxyarnino)-3- methy!-1-oxobutan-2-yi)benzamide (43);
(S)-N-(3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-y!)-4-(6-(3-hydroxyazetidin-1- yl)hexa-1 ,3-diyn-1-y!)benzamide (44);
(S)-4-(6-(3-f!uoroazetidin-1-yl)hexa-1 ,3-diyn-1-yl)-N-{3-hydroxy-1-(hydroxyamino)-3-methy!-1- oxobutan-2-yl)benzamide (45);
(S^-ie-iS.S-difiuoroazetidin-l-y hexa-I .S-diyn-l-ylJ-N-fS-hydroxy-l-ihydroxyaminoJ-S-methyi- 1-oxobutan-2-y!)benzamide (46);
N-((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-(6-(3-hydroxypyrro!idin-1- yl)hexa-1 ,3-diyn-1-yi)benzamide (47);
4-(6-(3-f!uoropyrrolidin-1-yi)hexa-1 ,3-diyn-1-yl)-N-((S)-3-hydroxy-1-{hydroxyarnino)-3-methyl-1- oxobutan-2-yl)benzamide (48);
(S^-ie-CS.S-difluoropyrrolidin-l-yiJhexa-l ^-diyn-l-y -N-iS-hydroxy-l-ihydroxyaminoJ-S-methyi- 1-oxobutan-2-y!)benzamide (49);
(SH-iazeiidin-S-yibuia-I .S-diyn-l-y -N-iS-hydroxy-l-ihydroxyaminoVS-rnethyl-l-oxobuian^- yl)benzamide (50); 4-(azeiidin-3-ylbuta-1 ,3-diyn-1-y!)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2- yl)benzamide (51 );
4-((1-formylazetidin-3-yl)buta-1 ,3-diyn-1-y!)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (52);
4-((1-glycy!azetidin-3-yl)buia-1 ,3-diyn-1-y!)-N-((2S,3R)-3-hydroxy-1-{hydroxyarnino)-1-oxobuian-
2- yl)benzamide (53);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-serylazetidin-3-yl)buta-1 ,3-diyn- 1-yl)benzamide (54);
N-{(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-(2-hydroxyethyi)azetidin-3- y!)buta-1 ,3-diyn-1-y!)benzamide (55);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-methylazetidin-3-yl)buta-1 ,3- diyn-1-yi)benzamide (56);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-{nriethy!sulfony!)azeiidiri-3- yl)buta-1 ,3-diyn-1-y!)benzamide (57);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-(oxetan-3-y!)azetidin-3-y!)buta- 1 ,3-diyn-1-y!)benzamide (58);
N-{(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(5-((2R,3S)-3-hydroxypyrro!idin-2- y!)penta-1 ,3-diyn-1-yl)benzamide (59);
(S)-3-((4-((3-hydroxy-1-(hydroxyamino)-3-meihyl-1-oxobutan-2-yI)carbamoyl)phenyl)buta-1 ,3- diyn-1-y!)-N-methylazetidine-1-carboxamide (60);
3- ((4-(((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)carbamoy!)phenyi)buta-1 !3-diyn-1- yl)-N-methylazetidine-1-carboxamide (61 );
(S)-3-((4-((3-hydroxy-1-(hydroxyamino)-3-meihyl-1-oxobuian-2-yl)carbamoyl)phenyi)buta-1 ,3- diyn-1-yi)azetidine-1-carboxamide (62);
3-((4-(((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)carbamoy!)pheny!)buta-1 ,3-diyn-1- yl)azetidine-1-carboxamide (63);
(S)-N-(3-hydroxy-1-(hydroxyamino)-3-rneihy!-1-oxobutan-2-yi)-4-((1-(2-hydroxyacetyi)azetidin-3- y!)buta-1 ,3-diyn-1-y!)benzamide (64); N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yI)-4-((1-(2-hydroxyacety!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (65);
(S)-N-(3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((1-(2-hydroxyethyl)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (66);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-{2-hydroxyethy!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (67);
(S)-4-((1-acety!-3-hydroxyazetidin-3-yl)buta-1 ,3-diyn-1-yi)-N-(3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yi)benzamide (68);
4-((1-acety!-3-hydroxyazetidin-3-yl)buta-1 ,3-diyn-1-yi)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)- 1-oxobutan-2-y!)benzamide (69);
(S)-N-(3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yl)-4-((1-(methylsu!fony!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (70);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-{nriethy!sulfony!)azeiidiri-3- yl)buta-1 ,3-diyn-1-y!)benzamide (71 );
(S)-4-(5-(azetidin-3-yi)penta-1 ,3-diyn-1-yl)-N-(3-hydroxy-1-(hydroxyamino)-3-methy!-1- oxobutan-2-yl)benzamide (72);
4-(5-(azetidin-3-y!)penta-1 ,3-diyn-1-yi)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2- y!)benzamide (73);
(S)-4-(5-(1-formyIazetidin-3-yI)penta-1 ,3-diyn-1-yi)-N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (74);
4-(5-(1-formylazetidin-3-y!)penta-1 ,3-diyn-1-y!)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (75);
(S,E)-N-{3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-yl)-4-{4-(1- (methylsu!fony!)azetidin-3-yl)but-3-en-1-yn-1-y!)benzamide (76);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yi)-4-((E)-4-(1-(methy!sulfony!)azetidin-3- yl)but-3-en-1-yn-1-y!)benzamide (77);
(S!E)-4-(4-(1-formylazetidin-3-yl)but-3-en-1-yn-1-yi)-N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (78); 4-((E)-4-(1-formyIazetidin-3-yI)but-3-en-1-yn-1-y!)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (79);
N-((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((5-oxopyrrolidin-3-y!)buta-1 ,3- diyn-1-yi)benzamide (80);
N-((2Sl3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((5-oxopyrrolidin-3-yl)buia-1 ,3-diyn- 1-yl)benzamide (81 );
N-((S)-3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-y!)-4-((1-methyl-5-oxopyrroiidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (82);
N-{(2S,3R)-3-hydroxy-1-(hydroxyarnino)-1-oxobutan-2-yl)-4-((1-meihyi-5-oxopyrroiidiri-3-yl)buta- 1 ,3-diyn-1-y!)benzamide (83);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(((S)-1-(oxetan-3-yl)pyrrolidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (84);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(({S)-1-(2-hydroxyethyl)pyrro!idin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (85);
4-((1-(1-fluoropropan-2-yI)azeiidin-3-y!)buta-1 ,3-diyn-1-y!)-N-((2S,3R)-3-hydroxy-1- (hydroxyamino)-1-oxobutan-2-yi)benzamide (86);
4-((1-(2!2-difluoroethyl)azetidin-3-yi)buta-1 !3-diyn-1-y!)-N-((3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (87);
4-((1-(2-cyanoethyI)azeiidin-3-y!)buta-1 ,3-diyn-1-y!)-N-((3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (88);
4-((1-(2-amino-2-oxoethy!)azetidin-3-y!)buta-1 ,3-diyn-1-y!)-N-((3R)-3-hydroxy-1-(hydroxyamino)- 1-oxobutan-2-y!)benzamide (89);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-{(1-meihy!-1 H-imidazol-4- yl)meihyl)azetidin-3-yl)buta-1 ,3-diyn-1-yl)benzamide (90);
N-((3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-y!)-4-((3-(3-hydroxyazetidin-1- yl)cyciobutyl)buta-1 ,3-diyn-1-yl)benzamide (91 );
4-((3-(3-fluoroazeiidin-1-yl)cyclobutyl)buta-1 ,3-diyn-1-y!)-N-((3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (92); N-((3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-y!)-4-((3-(3-hydroxypyrrolidin-1- yl)cyciobutyl)buta-1 ^-diyn-l-yljbenzamide (93);
4-((3-(3-fluoropyrrolidin-1-y!)cyc!obutyl)buta-1 ,3-diyn-1-yl)-N-((3R)-3-hydroxy-1-(hydroxyamino)- 1-oxobutan-2-y!)benzamide (94);
4-((3-(3,3-difluoroazetidin-1-yl)cyclobutyl)buta-1 diyn-1-yl)-N-((3R)-3-hydrox -1-
(hydroxyamino)-1-oxobutan-2-yi)benzamide (95);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(6-(3-hydroxyazetidin-1-yl)hexa-1 ,3- diyn-1-yi)benzamide (96);
4-(6-(3-fiuoroazetidin-1-yl)hexa-1 ,3-diyn-1-yl)-N-((2Sl3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (97);
4-(6-(3,3-difiuoroazetidin-1-yl)hexa-1 ,3-diyn-1-yl)-N-((2S!3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (98);
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(6-(3-hydroxypyrrolidin-1-yi)hexa- 1 ,3-diyn-1-y!)benzamide (99);
4-(6-(3-f!uoropyrrol!din-1-yi)hexa-1 ,3-d!yn-1-y!)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (100);
4-(6-(3,3-d!fiuoropyrrol!din-1-yi)hexa-1 ,3-diyn-1-yi)-N-{(2S,3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (101 );
4-((1-(4:5-dimethy!-4,5-dihydrooxazol-2-yi)azetidin-3-yi)buta-1 >3-diyn-1-yl)-N-((2S,3R)-3- hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide (102);
4-((1-(4!5-dimethyl-4,5-dihydrooxazol-2-yi)azetidin-3-yi)buta-1 !3-diyn-1-y!)-N-((S)-3-hydroxy-1- (hydroxyamino)-3-methy!-1-oxobutan-2-y!)benzamide (103); or
(S)-N-(3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-y!)-4-((1-((1-methyl-1 H-imidazol-4- yl)methyl)azetidin-3-y!)buta-1 ,3-diyn-1-y!)benzamide (104).
42. The compound of claim 41 , wherein said compound is:
(S)-A-(3-amino-1-(hydroxyamino)-3-methyi--1--oxobuian-2-yl)-4-(azeiidin-3-ylbuta--1 !3- diyny!)benzamide (1 );
(S)-4-((1-acetyIazetidin-3-yI)buta-1 ,3-diyn-1-y!)-A/-(3-hydroxy-1-(hydroxyamino)-3-meihyl-1- oxobutan-2-yl)benzamide (2a); (S)-4-((azetidin-3-y!)buta-1 ,3-diyn-1-y!)-A/-(3-^^
yl)benzamide (2b);
(S)-4-((1-formylazetidin-3-yl)buta-1 ,3-diyn-1-yl)-A -(3-hydroxy-1-(hydroxyamino)-3-methy!-1- oxobutan-2-yl)benzamide (3);
(S)-4-((1-(2-aminoacety!)azetidin-3-yl)buta-1 !3-diyn-1-yl)-W-(3-hydroxy-1-(hydroxyamino)-3- methy!-1-oxobutan-2-yi)benzamide (4);
4-((1-(2-amino-3-hydroxypropanoy!)azetidin-3-yl)buta-1 ,3-diyn-1-y!)-W-((S)-3-hydroxy-1- (hydroxyamino)-3-methy!-1-oxobutan-2-y!)benzamide (5);
(S)-W-(3-hydroxy-1-(hydroxyamino)-3-rnethy!-1-oxobutan-2-yi)-4-({1-(2-hydroxyethyl)azetidir!-3- y!)buta-1 ,3-diyn-1-y!)benzamide (6);
(S)-A/-(3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((1-methylazetidin-3-y!)buta- 1 ,3-diyn-1-y!)benzamide (7);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutar!-2-yi)-4-((1-{oxeiari-3-yi)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (8);
A/-((S)-3-hydroxy-1-(hydroxyamino)-3-methyi-1-oxobutan-2-y!)-4-(5-((2/:?,3S)-3- hydroxypyrro!idin-2-yi)penta-1 ,3-diyn-1-y!)benzamide (9);
(S)-4-((1-acetyiazetidin-3-yi)buta-1 ,3-diynyi)-A/-(3-amino-1-(hydroxyamino)-3-methyi-1- oxobutan-2-yl)benzamide 2,2,2-irifluoroacetate (10);
(S)-3-((4-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-ylcarbamoyl)phenyl)buta-1 !3- diyny!)-A/-methylazetidine-1-carboxamide (1 1 );
(S)-3-((4-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobuian-2-ylcarbamoyl)phenyl)buta-1 ,3- diyny!)azetidine-1-carboxamide (12);
(S)-4-((1-acety!azeiidin-3-y!)buia-1 ,3-diynyi)-W-(3-(dimeihyiamino)-1-(hydroxyamino)-3-meth 1-oxobutan-2-y!)benzamide (13);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-(2-hydroxyacetyl)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (14);
(S)-A/-(3-amino-1-{hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-(2-hydroxyethyi)azeiidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (15);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-formylazetidin-3-yl)buta-1 ,3- diyn-1-y!)benzamide (16);
(S)-4-((1-formylazetidin-3-yl)buta-1 ,3-diyn-1-yl)-A -(1-(hydroxyamino)-3-methyi-3-(methyiamino 1-oxobutan-2-y!)benzamide (17);
(S)-4-((1-acetyiazetidin-3-yl)buta-1 ,3-diyn-1-y!)-A/-(1-(hydroxyamino)-3-methy!-3-{methylami 1-oxobutan-2-y!)benzamide (18);
(S)-4-((1-acety!-3-hydroxyazetidin-3-y!)buta-1 l3-diyn-1-yi)-A -(3-amino-1-(hydroxyamino)-3- methy!-1-oxobutan-2-yi)benzamide (19);
A/-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-y!)-4-((1-formy!azetidin-3-y!)buta-1 ,3-diyn- 1-y!)benzamide (20);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-(methy!sulfonyl)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (21 );
4-((1-formylazetidin-3-yl)buta-1 ,3-diyn-1-yl)-A -((2S,3R)-1-{hydroxyamino)-3-(methyiami oxobutan-2-yl)benzamide (22);
(S)-A/-(3-hydroxy-1-(hydroxyamino)-3-meihyi-1-oxobutan-2-y!)-4-((1-(oxetan-3-y!)azetidin-3- yl)buta-1 ,3-diyn-1-y!)benzamide (23);
(S)-A/-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-(5-(azetidin-3-yl)penta-1 ,3-diyn- 1-yi)benzamide (24);
(S)-W-(3-amino-1-(hydroxyamino)-3-methyi-1-oxobutan-2-y!)-4-{5-(1-formylazetidin-3-yl)penta- 1 ,3-diyn-1-yl)benzamide (25);
(S,£)-A/-(3-amino-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-(4-(1-(methy!sulfony!)azetidi 3-y!)but-3-en-1-yn-1-yl)benzamide (26);
(S,E)-A/-(3-amino-1-(hydroxyamino)-3-methyi-1-oxobutan-2-yi)-4-(4-(1-formylazeiidin-3-yi)b en-1-yn-1-y!)benzamide (27);
(S>E)-4-(4-(1-acety!azetidin-3-y!)but-3-en-1-yn-1-yl)-W-(3-amino-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide (28);
(S!£)-4-(4-(1-acety!azetidin-3-y!)but-3-en-1-yn-1-yl)-A -(3-amino-1-(hydroxyamino)-3-met^ oxobutan-2-yl)benzamide (29);
W-((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-y!)-4-((1-methy!-5-oxopyrrolidin-3- yl)buta-1 ,3-diynyi)benzamide (30); W-((S)-3-amino-1-(hydroxyamino)-3-methy!-1-oxobutan-2-y!)-4-((1-(2- (hydroxymethy!)cyc!opropanecarbonyl)azetidin-3-y!)ethyny!)benzarnide (31 );
A -((S)-3-hydroxyamino)-3-methy!-1-oxobutan-2-yl)-4-((1-(oxetan-3-yl)pyrrolidin-3-yl)buta-1 ,3- diyn-1-yi)benzamide (32);
A/-((S)-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((S)-1-(2- hydroxyethyl)pyrrolidin-3-yI)buta-1 ,3-diyn-1-y!)benzamide (33);
4-((1-(1-fluoropropan-2-yl)azetidin-3-yl)buta-1 !3-diyn-1-yl)-N-((S)-3-hydroxy-1-(hydroxyamino)-3- methyi-1-oxobutan-2-yi)benzamide (34);
N-{3-hydroxy-1-{hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((3-(3-hydroxyazetidir!-1- yi)cyciobutyl)buta~1 ,3-diyn-1-yl)benzamide (35);
N-((S)-3-hydroxy-1-(hydroxyamino)-3-methy!-1-oxobutan-2-yi)-4-((3-((S)-3-hydroxypyrroiidin-1- yl)cyciobutyl)buta-1 ,3-diyn-1-yi)benzamide (36);
N-((S)-3-hydroxy-1-(hydroxyamino)-3-meihyi-1-oxobutan-2-y!)-4-((3-((R)-3-hydroxypyrro!idin-1- yl)cyc!obutyl)buta-1 ,3-diyn-1-yI)benzamide (37);
4-((3-(3-fluoroazeiidin-1-yl)cyclobutyI)buta-1 ,3-diyn-1-yi)-N-(3-hydroxy-1-(hydroxyamino)-3- methy!-1-oxobutan-2-yl)benzamide (38); or
4-({1-(2-cyanoethyl)azetidin-3-yi)buta-1 ,3-diyn-1-y!)-N-(3-hydroxy-1-(hydroxyamino)-3-meth oxobutan-2-yl)benzamide{39).
43, A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound according to any one of claims 1-42.
44, A method for treating a patient having a bacterial infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of claims 1-43.
45. A method according to claim 44, wherein said bacterial infection is a gram-negative bacterial infection.
46. A method according to claim 45, wherein said gram-negative bacterial infection is Pseudomonas aeruginosa, Stenotrophomonas maltophiia, Burkhoideria cepacia, Aicaligenes xylosoxidans, Enterobacteriaceae, Haemophilus, Francisce!iaceae or a Neisseria species. 47, Use of a compound of any one of c!aims 1-42 in the preparation of a medicament for treating a gram-negative bacteria! infection.
PCT/US2014/024304 2013-03-12 2014-03-12 Antibacterial agents WO2014165075A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361777547P 2013-03-12 2013-03-12
US61/777,547 2013-03-12

Publications (1)

Publication Number Publication Date
WO2014165075A1 true WO2014165075A1 (en) 2014-10-09

Family

ID=50487149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/024304 WO2014165075A1 (en) 2013-03-12 2014-03-12 Antibacterial agents

Country Status (1)

Country Link
WO (1) WO2014165075A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015056798A1 (en) * 2013-10-18 2015-04-23 大正製薬株式会社 Hydroxamic acid derivative
WO2015056800A1 (en) * 2013-10-18 2015-04-23 大正製薬株式会社 Hydroxamic acid derivative
WO2015056799A1 (en) * 2013-10-18 2015-04-23 大正製薬株式会社 Hydroxamic acid derivative
WO2016079688A1 (en) 2014-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Antibacterial benzothiazole derivatives
CN105777464A (en) * 2014-12-26 2016-07-20 中国科学院上海药物研究所 Hydroxamic acid derivative, and preparation method and application thereof
WO2017037221A1 (en) 2015-09-03 2017-03-09 Actelion Pharmaceuticals Ltd Substituted 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds
WO2017189586A1 (en) * 2016-04-25 2017-11-02 Duke University Benzoylglycine derivatives and methods of making and using same
WO2017223349A1 (en) 2016-06-23 2017-12-28 Achaogen, Inc. Antibacterial agents
WO2018115421A1 (en) * 2016-12-23 2018-06-28 Intervet International B.V. Compounds useful for treating a mannheimia haemolytica or histophilus somni infection
US10106544B2 (en) 2014-03-04 2018-10-23 Idorsia Pharmaceuticals Ltd 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents
CN110300578A (en) * 2016-12-23 2019-10-01 英特维特国际股份有限公司 For treating the compound of ox or porcine respiratory disease
CN110563611A (en) * 2019-09-19 2019-12-13 中国医学科学院医药生物技术研究所 hydroxamic acid derivative and preparation method and application thereof
CN111254091A (en) * 2020-01-20 2020-06-09 浙江工业大学 A Stenotrophomonas maltophilia GYH and its application in degrading chlorinated hydrocarbon pollutants
JP2021513543A (en) * 2018-02-10 2021-05-27 山東亨利醫藥科技有限責任公司 Antibacterial compound
RU2781450C2 (en) * 2016-12-23 2022-10-12 Интервет Интернэшнл Б.В. Compounds used for treatment of pasteurella multocida or mannheimia haemolytica infection

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018754A1 (en) 1996-10-28 1998-05-07 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US5925659A (en) 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
WO2000061134A1 (en) 1999-04-09 2000-10-19 British Biotech Pharmaceuticals Limited Antimicrobial agents
WO2004062601A2 (en) * 2003-01-08 2004-07-29 Chiron Corporation Antibacterial agents
WO2008027466A1 (en) 2006-08-31 2008-03-06 Schering Corporation Hydantoin derivatives useful as antibacterial agents
WO2008105515A1 (en) 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. Novel hydroxamic acid derivative
WO2008154642A2 (en) 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
WO2009158369A1 (en) 2008-06-25 2009-12-30 Schering Corporation Synthesis and use of heterocyclic antibacterial agents
WO2010017060A1 (en) 2008-08-04 2010-02-11 Schering Corporation Urea derivatives as antibacterial agents
WO2010024356A1 (en) 2008-08-27 2010-03-04 大正製薬株式会社 Novel hydroxamic acid derivative having naphthyridine-n-oxide
WO2010031750A1 (en) 2008-09-17 2010-03-25 Novartis Ag Organic compounds for applications in bacterial infections treatment
WO2010032147A2 (en) 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2011045703A2 (en) 2009-10-13 2011-04-21 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
WO2011073845A1 (en) 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
WO2011132712A1 (en) 2010-04-20 2011-10-27 大正製薬株式会社 Novel hydroxamic acid derivative

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925659A (en) 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
WO1998018754A1 (en) 1996-10-28 1998-05-07 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US20010053555A1 (en) 1996-10-28 2001-12-20 Dinesh V. Patel Methods for solid-phase synthesis of hydroxylamine compounds and derivatives and combinatorial libraries thereof
WO2000061134A1 (en) 1999-04-09 2000-10-19 British Biotech Pharmaceuticals Limited Antimicrobial agents
WO2004062601A2 (en) * 2003-01-08 2004-07-29 Chiron Corporation Antibacterial agents
US20040229955A1 (en) 2003-01-08 2004-11-18 Andersen Niels H. Antibacterial agents
WO2008027466A1 (en) 2006-08-31 2008-03-06 Schering Corporation Hydantoin derivatives useful as antibacterial agents
WO2008105515A1 (en) 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. Novel hydroxamic acid derivative
WO2008154642A2 (en) 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
WO2009158369A1 (en) 2008-06-25 2009-12-30 Schering Corporation Synthesis and use of heterocyclic antibacterial agents
WO2010017060A1 (en) 2008-08-04 2010-02-11 Schering Corporation Urea derivatives as antibacterial agents
WO2010024356A1 (en) 2008-08-27 2010-03-04 大正製薬株式会社 Novel hydroxamic acid derivative having naphthyridine-n-oxide
WO2010031750A1 (en) 2008-09-17 2010-03-25 Novartis Ag Organic compounds for applications in bacterial infections treatment
WO2010032147A2 (en) 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2011045703A2 (en) 2009-10-13 2011-04-21 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
WO2011073845A1 (en) 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
WO2011132712A1 (en) 2010-04-20 2011-10-27 大正製薬株式会社 Novel hydroxamic acid derivative

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy ., 19th Edition", 1995, MACK PUBLISHING COMPANY
BERGERON, R. J. ET AL.: "Effects of C-4 Stereochemistry and C-4' Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues", J. MED. CHEM., vol. 42, 1999, pages 2432 - 2440, XP002182656, DOI: doi:10.1021/jm990058s
BOYCE, R. J. ET AL.: "Total Synthesis of Thiangazole, A Novel Naturally Occurring HIV-1 Inhibitor from Polyangium sp", TEFRAHEDRON, vol. 51, 1995, pages 7321 - 7330, XP002128001, DOI: doi:10.1016/0040-4020(95)00356-D
CHARETTE, A. B. ET AL.: "Mild Method for the Synthesis of Thiazolines from Secondary and Tertiary Amides", J. ORG. CHEM., vol. 63, 1998, pages 908 - 909
FEMANDEZ, X. ET AL.: "Novel Synthesis of 2-Thioazolines", TETRAHEDRON LETT., vol. 41, 2000, pages 3381 - 3384
G. ROTH, B. LIEPOLD; S. MÜLLER; H. J. BESTMANN, SYNTHESIS, vol. 1, 2004, pages 59 - 62
GALEOTTI, N. ET AL.: "Synthesis of Peptidyl Aldehydes from Thiazolines", TETRAHEDRON. LETT., vol. 38, 1997, pages 2459 - 2462, XP004056732, DOI: doi:10.1016/S0040-4039(97)00383-3
ITO, Y. ET AL.: "Synthetic Reactions by Complex Catalysts XXXV", SYN. COMMUN., vol. 4, 1974, pages 97 - 103
ITO, Y. ET AL.: "Synthetic Reactions by Complex Catalysts. XXXI, A Novel and Versatile Method of Heterocycle Synthesis", J. AM CHEM. SOC., vol. 95, 1973, pages 4447 - 4448
JACKMAN ET AL., J. BIOL. CHEM., vol. 275, no. 15, 2000, pages 11002 - 11009
KHAN, S. I. ET AL.: "A Facile and Convenient Solid-phase Procedure for Synthesizing Nucleoside Hydroxamic Acids", TERAHEDRON. LETT., vol. 39, 1998, pages 8031 - 8034, XP004138853, DOI: doi:10.1016/S0040-4039(98)01794-8
KLINE, T. ET AL.: "Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC", J. MED CHEM., vol. 45, no. 14, 2002, pages 3112 - 29, XP008045411, DOI: doi:10.1021/jm010579r
MELLOR, S. L. ET AL.: "N-Fmoc-aminoxy-2-chlortrityl Polystyrene Resin: A Facile Solid-phase Methodology for the Synthesis of Hydroxamic Acids", TETRAHEDRON LETT., vol. 38, 1997, pages 3311 - 3314
NHU, K. ET AL.: "A New and Efficient Solid Phase Synthesis of Hydroxamic Acids", J. ORG. CHEM., vol. 62, 1997, pages 7088 - 7089
PATTENDEN, G. ET AL.: "Naturally Occurring Linear Fused Thiazoline-Thiazole Containing Metabolites: Total Synthesis of (-) Didehydromirabazole A, a Cytotoxic Alkaloid from Blue-Green Algae", J. CHEM. SOC. PERKIN TRANS, vol. 1, 1993, pages 1629 - 1636, XP009071913
PIRRUNG, M. C. ET AL.: "A Convenient Procedure for the Preparation of Amino Acid Hydroxamates from Esters", J. ORG. CHEM., vol. 60, 1995, pages 8084 - 8085
RAMAN, P. ET AL.: "Titanium (IV)-mediated Tandem Deprotection-cyclodehydration of Protected Cysteine N-Amides: Biomimetic Synthesis of Thiazoline- and Thiazole-containing Heterocycles", ORG. LETT., vol. 2, 2000, pages 3289 - 3292
WIPF, P. ET AL.: "C. Thiolysis of Oxazolinenes: A New, Selective Method for the Direct Conversion of Peptide Oxazolines into Thiazolines", TETRAHEDRON LETT., vol. 36, 1995, pages 6395 - 6398, XP004027240, DOI: doi:10.1016/0040-4039(95)01322-9
WITTE, H. ET AL.: "Cyclische Imidsaurester aus Nitrilen und Aminoalkoholen", LIEBIGS ANN. CHEM., 1974, pages 996 - 1009
WYCKOFF ET AL., TRENDS IN MICROBIOLOGY, vol. 6, no. 4, 1998, pages 154 - 159
ZHANG, Y. ET AL.: "Design, Combinatorial Chemical Synthesis, and in vitro Characterization of Novel Urea Based Gelatinase Inhibitors", BIOORG. MED. CHEM. LETT., vol. 9, 1999, pages 2823 - 2826, XP004179171, DOI: doi:10.1016/S0960-894X(99)00498-9

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015056800A1 (en) * 2013-10-18 2015-04-23 大正製薬株式会社 Hydroxamic acid derivative
WO2015056799A1 (en) * 2013-10-18 2015-04-23 大正製薬株式会社 Hydroxamic acid derivative
WO2015056798A1 (en) * 2013-10-18 2015-04-23 大正製薬株式会社 Hydroxamic acid derivative
US10106544B2 (en) 2014-03-04 2018-10-23 Idorsia Pharmaceuticals Ltd 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents
WO2016079688A1 (en) 2014-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Antibacterial benzothiazole derivatives
CN105777464A (en) * 2014-12-26 2016-07-20 中国科学院上海药物研究所 Hydroxamic acid derivative, and preparation method and application thereof
CN105777464B (en) * 2014-12-26 2020-09-29 中国科学院上海药物研究所 Hydroxamic acid derivative and preparation method and application thereof
WO2017037221A1 (en) 2015-09-03 2017-03-09 Actelion Pharmaceuticals Ltd Substituted 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds
US10314823B2 (en) 2015-09-03 2019-06-11 Idorsia Pharmaceuticals Ltd Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds
WO2017189586A1 (en) * 2016-04-25 2017-11-02 Duke University Benzoylglycine derivatives and methods of making and using same
US12103904B2 (en) 2016-04-25 2024-10-01 Duke University Benzoylglycine derivatives and methods of making and using same
JP2019520317A (en) * 2016-04-25 2019-07-18 デューク ユニバーシティ Benzoyl glycine derivatives and methods of making and using the same
US10550074B2 (en) 2016-04-25 2020-02-04 Duke University Benzoylglycine derivatives and methods of making and using same
JP7012289B2 (en) 2016-04-25 2022-02-14 デューク ユニバーシティ Benzoylglycine derivatives and methods for their preparation and use
US11034649B2 (en) 2016-04-25 2021-06-15 Duke University Benzoylglycine derivatives and methods of making and using same
WO2017223349A1 (en) 2016-06-23 2017-12-28 Achaogen, Inc. Antibacterial agents
US11406617B2 (en) 2016-12-23 2022-08-09 Intervet Inc. Compounds for the treatment of bovine or swine respiratory disease
CN110072844B (en) * 2016-12-23 2023-06-02 英特维特国际股份有限公司 Compounds for the treatment of infection by Mannheimia haemolytica or histophilus somni
WO2018115421A1 (en) * 2016-12-23 2018-06-28 Intervet International B.V. Compounds useful for treating a mannheimia haemolytica or histophilus somni infection
JP2020502214A (en) * 2016-12-23 2020-01-23 インターベット インターナショナル ベー． フェー． Compounds for treating bovine or porcine respiratory disease
US12077488B2 (en) 2016-12-23 2024-09-03 Intervet Inc. Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection
US11034650B2 (en) 2016-12-23 2021-06-15 Intervet Inc. Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection
JP7471820B2 (en) 2016-12-23 2024-04-22 インターベット インターナショナル ベー． フェー． Compounds useful for treating Mannheimia haemolytica or Histophilus somni infections - Patents.com
CN110300578A (en) * 2016-12-23 2019-10-01 英特维特国际股份有限公司 For treating the compound of ox or porcine respiratory disease
AU2017380070B2 (en) * 2016-12-23 2022-03-10 Intervet International B.V. Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection
AU2017383069B2 (en) * 2016-12-23 2023-07-13 Intervet International B.V. Compounds for the treatment of Bovine or Swine Respiratory disease
JP7082445B2 (en) 2016-12-23 2022-06-08 インターベット インターナショナル ベー． フェー． Compounds for treating bovine or porcine respiratory disease
CN110072844A (en) * 2016-12-23 2019-07-30 英特维特国际股份有限公司 For treating the compound of haemolysis Mannheim bacterium or Histophilus's infection of sleeping
JP2022141920A (en) * 2016-12-23 2022-09-29 インターベット インターナショナル ベー． フェー． Compounds useful for treating mannheimia haemolytica or histophilus somni infection
RU2781450C2 (en) * 2016-12-23 2022-10-12 Интервет Интернэшнл Б.В. Compounds used for treatment of pasteurella multocida or mannheimia haemolytica infection
CN110300578B (en) * 2016-12-23 2022-12-13 英特维特国际股份有限公司 Compounds for the treatment of respiratory diseases in cattle or pigs
JP2020514270A (en) * 2016-12-23 2020-05-21 インターベット インターナショナル ベー． フェー． Compounds useful for treating Manhemia haemolytica or Histophilus somni infections
JP7412004B2 (en) 2018-02-10 2024-01-12 山東亨利醫藥科技有限責任公司 antimicrobial compound
JP2021513543A (en) * 2018-02-10 2021-05-27 山東亨利醫藥科技有限責任公司 Antibacterial compound
EP4071134A4 (en) * 2019-09-19 2022-12-21 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences HYDROXAMIC ACID DERIVATIVE, METHOD OF PRODUCTION THEREOF AND USE THEREOF
CN110563611A (en) * 2019-09-19 2019-12-13 中国医学科学院医药生物技术研究所 hydroxamic acid derivative and preparation method and application thereof
CN111254091B (en) * 2020-01-20 2022-04-19 浙江工业大学 A Stenotrophomonas maltophilia GYH and its application in degrading chlorinated hydrocarbon pollutants
CN111254091A (en) * 2020-01-20 2020-06-09 浙江工业大学 A Stenotrophomonas maltophilia GYH and its application in degrading chlorinated hydrocarbon pollutants

Similar Documents

Publication Publication Date Title
WO2014165075A1 (en) Antibacterial agents
US9701622B2 (en) Antibacterial agents
US12005047B2 (en) Riluzole prodrugs and their use
US12247011B2 (en) Selective inhibitors of NLRP3 inflammasome
CA2691987C (en) Antibacterial agents
CA2512582C (en) Antibacterial agents
SG190243A1 (en) Hydroxamic acid derivatives and their use in the treatment of bacterial infections
US20150175530A1 (en) Antibacterial agents
HUP0102901A2 (en) Use of n-formyl hydroxylamines as antibacterial agents
US20210269440A1 (en) Immunomodulators, compositions and methods thereof
TW201204717A (en) Cyclohexyl-azetidinyl antagonists of CCR2
US10138255B2 (en) Piperazine derivatives as HIV protease inhibitors
EP1694647A1 (en) Cathepsin cysteine protease inhibitors
NO323969B1 (en) Pharmaceutically active pyrrolidine derivatives
JP2017513892A (en) Isoxazoline hydroxamic acid derivatives as LpxC inhibitors
WO2013039947A1 (en) Polymorphs of n-((s)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((1r,2r)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide
CA3191410A1 (en) Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof
CA2558249A1 (en) Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
WO2005035528A2 (en) Triazole derivatives as antibacterial agents
JP2024508924A (en) Diazepine derivatives useful in the treatment of Clostridium difficile
RU2246941C2 (en) Antibacterial agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14717577

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14717577

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载